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ABSTRACT 
Introduction 
Oesophageal cancer has a poor prognosis. Early diagnosis and the use of chemotherapy and 
surgery for local disease are key to improving survival. This study was designed to see if 
plasma and tissue metabolic profiles could be used to identify oesophago-gastric malignancy, 
indicate the presence of unstable pre-malignant (Barrett’s) epithelium or predict response to 
chemotherapy. 
 
Methods 
Patients were recruited from University Hospitals Birmingham between May 2009 and 
March 2010. Nuclear Magnetic Resonance (NMR) metabolomics was performed on filtered 
plasma and extracted tissue samples.  
 
Results 
Some 258 participants were recruited. NMR metabolomics discriminated between normal, 
Barrett’s and neoplastic epithelium. Tissue levels of hypoxanthine were highest in 
oesophageal adenocarcinoma compared to adjacent normal mucosa. Levels in Barrett’s 
mucosa in the presence of cancer fell between normal and neoplastic mucosa. 3-
hydroxybutyrate levels were elevated both in cancer tissues and plasma compared to controls. 
Plasma levels of 3-hydroxybutyrate were higher in patients with node positive and full 
thickness tumours compared to those who were node negative with early local disease. 
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Conclusion 
NMR metabolomics identified metabolic profiles that characterized different histologic tissue 
types. Metabolites involved in oesophageal carcinogenesis might influence diagnostic and 
management strategies in these patients. 
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INTRODUCTION 
1.1 Epidemiology 
Oesophageal cancer is the sixth most common cause of cancer-related death worldwide [1]. It 
is a highly aggressive malignancy with approximately 8,000 new cases diagnosed in United 
Kingdom every year [2]. It is the ninth  leading cause of cancer and fifth leading cause of 
death due to cancer in the United Kingdom [2].  
 
Oesophageal cancer was first described in the ancient Chinese medical literature. It was said 
to be caused by 'heavy indulgence in heated liquors' and was considered to be 'commonly 
seen in the elderly and rarely developing in young people' [3]. Squamous cell carcinoma 
(SCC) and adenocarcinoma (AC) are the most common type of oesophageal cancer. Rare 
histologic types of oesophageal cancer include leiomyosarcoma, malignant melanoma, 
rhabdomyosarcoma and lymphoma. 
 
1.1.1 Squamous cell carcinoma 
Squamous cell cancer of the oesophagus has particularly high incidences in the Transkei 
region of South Africa [4] and across the Central Asian 'cancer belt' that extends from the 
shores of the Caspian Sea in northern Iran to China. The highest incidence areas in the world 
are  in Linxian in Henan province in China [5], where it is the most common single cause of 
death, with more than 100 cases per 100,000 of population per annum and in Iran on the 
south-eastern shores of the Caspian Sea [6]. In Europe, the Normandy region of France has 
been identified as an area of high incidence of oesophageal SCC. Considerable research in 
these high incidence areas has focused on environmental and particularly dietary factors as 
causal agents. In Normandy, for instance, high incidence has been attributed to the 
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consumption of alcohol and tobacco [7] although  a recent study has shown a high frequency 
of biallelic p53 mutations in this population [8]. 
 
1.1.2 Adenocarcinoma 
In most western countries, the incidence of squamous cell cancer has fallen or remained 
relatively static, while the incidence of adenocarcinoma has increased dramatically since the 
mid-1970s by 5-10% per annum [9]. This change is greater than that of any other neoplasm in 
this time. In the United States, the average yearly increase in incidence is approximately 
20%. However, amongst white men, the incidence has increased >800% since the mid 1970s 
in some areas [10]. Europe has the highest incidence of AC compared to the other continents 
and the country with the highest incidence in Europe is the United Kingdom [11]. 
 
The male European age-standardised incidence rate of oesophageal carcinoma in the UK has 
risen from 8.8 per 100,000 population in 1975-1977 to 14.5 in 2006-2008 (Figure 1). This 
was accompanied with a relatively lower increase in female rates, rising from 4.8 to 5.6 [12].  
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Figure 1 Oesophageal Cancer (C15), European Age-Standardised Incidence Rates, Great 
Britain, 1975-2008 [12] 
Prepared by Cancer Research UK 
Original data sources:           
1. Office for National Statistics. Cancer Statistics: Registrations Series MB1. 
http://www.statistics.gov.uk/statbase/Product.asp?vlnk=8843.     
2.  Welsh Cancer Intelligence and Surveillance Unit. http://www.wcisu.wales.nhs.uk.  
3. Information Services Division Scotland. Cancer Information Programme. 
www.isdscotland.org/cancer.   
4.  N. Ireland Cancer Registry. www.qub.ac.uk/nicr.     
       
Adenocarcinoma now accounts for 60-75% of all oesophageal cancers in most western 
countries. It is strongly linked to the rising incidence of gastro-oesophageal reflux disease 
(GORD) and specifically within that condition, to the development of Barrett’s oesophagus 
which is considered the precursor lesion for most oesophageal adenocarcinomas. Barrett’s 
oesophagus was first described in 1950 as a condition in which the lower oesophagus is lined 
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by columnar epithelium [13]. Barrett originally believed that this situation resulted from a 
congenitally short oesophagus that pulled the proximal stomach upwards, but later accepted 
that it was an acquired condition secondary to gastro-oesophageal reflux. The association of 
adenocarcinoma of the oesophagus with Barrett’s oesophagus was first described by Carrie 
[14]. Since then, this association has become well established. 
 
1.2 Pathogenesis of oesophageal adenocarcinoma  
The  progression from  Barrett’s metaplasia through  dysplasia to carcinoma  has been 
extensively investigated, although the key genetic events are less well understood compared 
to the polyp-cancer sequence in colorectal cancer [15]. In the oesophagus, the first step is 
damage to the squamous epithelium secondary to gastro-oesophageal reflux. The increased 
cell loss leads to an increase of the proliferative zone height to maintain or increase epithelial 
thickness by trophic stimulation of locally produced epidermal growth factor [16]. During 
this process the functional stem cells in the basal zone at the tip of the papillae remain in a 
relatively superficial position making them more accessible and susceptible to refluxed or 
ingested chemical mutagens [17]. This leads to a mucosal adaptive response to the chronic 
inflammation secondary to reflux. When this initial increase in cell proliferation fails to 
compensate for the cell loss, these mucosal breaches in the absence of treatment of reflux 
become replaced by de novo Barrett’s metaplasia [18]; a composite glandular epithelium 
characterised by incomplete intestinal metaplasia that includes mucus secreting goblet cells 
[19]. The degree of differentiation within this metaplastic epithelium varies considerably 
although most researchers see this as an adaptive response to severe reflux [20].The 
protective effect of a mucus layer may account for the relative paucity of symptoms among 
these patients even when 24h pH testing confirms prolonged oesophageal acidification. In 
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turn, this is thought to explain why so many patients present when they have symptoms from 
their cancer (usually dysphagia) rather than those from reflux (heartburn, regurgitation and 
epigastric pain). 
 
There are numerous features that are histologically specific to Barrett’s oesophagus. One of 
the main findings is the heterogeneous nature of the metaplastic columnar mucosa. A single 
type of epithelium is present in less than half of the patients, but the presence of an intestinal 
rather than simple columnar epithelium seems important in carcinogenesis [21]. There are, 
however, a number of definitions for Barrett’s oesophagus that in turn lead to different 
concepts of its frequency and cancer risk. Classic long segment Barrett’s is essentially an 
endoscopic diagnosis where the red Barrett’s lining is visibly different from the paler 
oesophageal squamous mucosa. Biopsy showing columnar epithelium is considered 
confirmatory. Short segment Barrett’s refers to visible lengths of Barrett’s oesophagus of less 
than 2cm. In order not to confuse these with the columnar mucosa of the stomach and in 
particular a  small tubular hiatus hernia, confirmatory biopsy is generally considered essential 
to make a diagnosis of short segment Barrett’s oesophagus. The problem is complicated 
though by having variable histopathologic features that are considered confirmatory. Some 
groups have accepted this as a simple columnar epithelium while others have accepted the 
diagnosis only when there are features of intestinalisation. Other confounders, such as the 
number of biopsies taken and consequent risks of sampling error undoubtedly contribute to 
variations in both incidence of Barrett’s oesophagus and the risk of progression.  Some of 
these points are expanded upon below. 
 
To quantify the risk of developing cancer, the various stages of this sequence have been 
graded histologically. Theisen et al. defined low-grade dysplasia (LGD) as the presence of 
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nuclear enlargement, hyperchromasia and spare mitotic figures. High-grade dysplasia (HGD) 
was defined by the presence of marked nuclear enlargement, pleomorphism, hyperchromasia 
and the presence of mitosis including atypical mitotic figures [20]. Progressive loss of normal 
architecture with distorted glands and an irregular surface epithelium as proper maturation 
fails, also characterise this change.   
 
Numerous attempts have been made to identify the cohort of patients who are at risk of 
progression to adenocarcinoma. It is known that p53 protein expression localised to low-
grade dysplasia confers an increased risk of progression to multifocal high-grade dysplasia or 
adenocarcinoma [5, 22]. Cyclin D1 polymorphism has also been associated with an increased 
risk of progression to adenocarcinoma [23]. Aneuploid DNA content as detected by flow 
cytometry has also been described as a tissue biomarker associated with progression to 
dysplasia [24, 25]. None of these markers, however, have yet become firmly established in 
routine clinical practice  
 
Although it is known that patients with Barrett’s oesophagus have severe GORD as judged by 
duration of oesophageal acidification [26], it is still not clear why some patients develop this 
condition and others do not. Thus it is imperative to identify the cohort of patients who are 
more likely to develop this condition. The risk that this epithelium will become dysplastic 
and the speed with which this can progress to HGD and on to carcinoma also show wide 
variations between series. Many of these differences are probably due to methodologic 
limitations and imprecise definitions, and further work is required to accurately quantify 
these risks.  
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Only a minority of patients with gastroesophageal reflux disease go on to develop the 
histological changes of Barrett's oesophagus. It has been estimated that about 15% of patients 
with GORD will eventually develop a classic long segment Barrett’s [27], although the 
number of patients with Barrett’s who will develop dysplasia and further progression  is not 
accurately known. Sontag et al. in a 19-year prospective study of 848 patients with LGD, 
found that 3.9% of patients progressed to HGD and 2.1% of all patients progressed 
oesophageal adenocarcinoma [28]. 
 
Hameeteman et al. concluded that it took between one and a half and four years for patients 
to progress from low grade dysplasia to cancer. They also concluded that high grade 
dysplasia could be present for as long as three and a half years before it progressed to cancer 
[29]. Theisen et al. in their study concluded that in the subset of patients with Barrett’s 
oesophagus who developed cancer, the time between diagnosis of Barrett’s oesophagus and 
that of oesophageal adenocarcinoma was within three years [20]. Schnell et al. found a mean 
7.3-year surveillance period before cancer was detected. However, when they considered 
patients with early visible lesions, this time decreased to about four years for the development 
of cancer [30]. 
 
According to the guidelines for the diagnosis and management of Barrett’s columnar-lined 
oesophagus published by the British Society of Gastroenterology based on pooled data from 
many studies, it is estimated that dysplasia develops in around 5% of patients with columnar-
lined oesophagus. In those developing low-grade dysplasia, 10–50% may progress to high-
grade dysplasia and adenocarcinoma over 2–5 years [31]. These figures were prepared by a 
close examination of the data pooled from various studies and may as such differ from 
individual studies even if they included large numbers. 
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Endoscopic surveillance programmes with quadrantic biopsies (i.e. one biopsy per quadrant) 
every 2 cm in the columnar segment every two years can detect HGD and oesophageal 
adenocarcinoma at an early stage when the depth of the tumour is limited to the muscularis 
mucosa [31]. Current evidence suggests that a metaplasia/dysplasia/ carcinoma sequence 
occurs in 0.5% of patients with Barrett’s oesophagus / annum [32]. A UK wide study is 
currently being conducted to examine the role of endoscopic surveillance in these patients. 
The BOSS study (Barrett's Oesophagus Surveillance Study) compares endoscopic 
surveillance vs. no endoscopic surveillance for the prevention of early mortality in patients 
diagnosed with Barrett’s oesophagus. In this study patients have been randomized to receive 
endoscopy with biopsy every two years for 10 years or endoscopy at the time of need. 
Furthermore, all of these patients receive a bi-annual postal questionnaire to record their 
symptoms and other health related data. 
 
1.3 Adenocarcinoma at the oesophago-gastric junction 
The increasing incidence of adenocarcinoma of the oesophagus has been accompanied with a 
similar increase in the incidence of carcinoma of the cardia of the stomach. This suggests that 
they may share a common aetiology or may be the same disease [33]. One of the problems is 
that distal oesophageal tumours may grow downward and involve the cardia, and, vice versa. 
To clarify this situation, Siewert et al. divided adencarcinomas in this region into three types 
based on the anatomical location of the tumour centre [34] and  concluded that there were 
marked differences in sex distribution, associated intestinal metaplasia in the oesophagus, 
tumour grading, tumour growth pattern, and stage distribution between the three tumour 
types.  
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Figure 2 Siewert classification of adenocarcinomas of the oesophago-gastric junction (AEG) 
[35] 
 
The Siewert classification is widely used (Figure 2). Type I tumours are considered to arise 
from areas of intestinal metaplasia in the distal oesophagus. Type III tumours are similar to 
proximal gastric cancers and are treated according to gastric cancer guidelines. Type II 
tumours straddle the oesophago-gastric junction. They tend to resemble proximal gastric 
cancer more closely than distal oesophageal adenocarcinoma. The authors found a 
significantly higher proportion of an intestinal-type growth pattern in type I tumours 
compared to type II and III tumours. Due to a difference in the anatomical location of the 
tumours, the pattern of lymph nodal metastasis was also different. Lymphographic studies 
have confirmed that the main lymphatic pathways originating from the lower oesophagus 
advance both up into the mediastinum and down towards the coeliac axis, whereas those from 
the gastric cardia and subcardial region preferentially make their way to the coeliac axis [36]. 
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In practice, tumour location using this system influences the choice of operation. Type I 
tumours clearly require oesophagectomy and Type III tumours a gastrectomy. The debate 
centres around the appropriate operation for Type II tumours where both stomach and 
oesophagus are involved, albeit in variable proportions.  Patients with Type I and Type II 
tumours whose samples were analysed in the current thesis, were both treated by 
oesophagectomy. This last term is often used interchangeably with oesophago-gastrectomy to 
denote that most of the intra-thoracic oesophagus is removed along with the lesser curvature 
of the upper stomach. 
 
1.3.1 Pattern of spread of oesophageal carcinoma 
The pattern of local spread of oesophageal carcinoma depends on the site of the tumour. The 
predominant site for both the tumour types i.e. SCC and AC is different. SCC is usually 
found in the upper one third or upper half of the oesophagus, whereas AC is more common in 
the lower half or close to the OG junction, strengthening the hypothesis that this cancer arises 
from Barrett’s oesophagus.  
 
SCC usually begins as a flat tumour with central ulceration. Extensive submucosal infiltration 
is common, with satellite tumours appearing at some distance from the main lesion. Proximal 
extension is more common than distal, and these tumours rarely extend downwards into the 
stomach.  
 
AC usually begins in an area of intestinal metaplasia (Barrett’s oesophagus) of the 
oesophagus. Tumours at the oesophago-gastric junction frequently spread upwards into the 
oesophagus. 
29 
 
Both cancer types exhibit similar behaviour with local invasion through the wall into adjacent 
structures along with lymph node spread, vascular invasion and haematogenous metastasis.  
Trans-peritoneal and trans-pleural metastases also occur depending on tumour site. 
Submucosal lymphatics of the oesophagus run for considerable distances before penetrating 
the oesophageal wall to connect with paraoesophageal lymphatics and adjacent lymph nodes. 
Thus, deep cervical nodes, peri-gastric and splenic artery nodes are easily involved by a  
lesion in the mid oesophagus [3]. Obstruction of lymphatics by tumour cells may alter 
lymphatic flow and produce skip metastases in apparently remote lymph nodes [37].  
 
Since only a minority of patients with oesophageal carcinoma present with potentially 
resectable disease, the five- year survival for these patients is quite poor. The last population-
based five-year relative survival rates for all patients diagnosed with oesophageal cancer in 
2000-01 in England and Wales were 8% for both men and women (30% for men and 27% for 
women at one year after diagnosis) [38]. 
 
1.4 Staging for oesophageal cancer 
Both the  American Joint Committee on Cancer [39] (AJCC)  and Union for International  
Cancer Control[40] (UICC) use systems based on staging the primary tumour (T), nodal 
spread (N) and distant organ involvement (M) to staging oesophageal cancer. At the time of 
the present study, both organisations considered SCC and AC together.  It is this 
classification that has been used in the current work. 
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T stage Description 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour invades lamina propria or submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4 Tumour invades adjacent structures 
 
N stage Description 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
 
M stage Description 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
Table 1 TNM staging for oesophageal carcinoma.  
 
This classification is linked to prognosis and overall survival. Survival of patients with T1 
disease is better than for other T stages and similarly for patients with N0 disease compared 
to those with N1 disease (Figure 3, Figure 4) [41].  
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Figure 3 Stage II TNM subgroup survival [41] 
 
 
 
Figure 4 Survival by nodal status. Forty-four node-negative (N0) and 67 node-positive (N1) 
patients [42] 
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1.5 Treatments for oesophageal cancer 
Treatment options for oesophageal cancer can be considered attempted curative or palliative. 
Patients with haematogenous or peritoneal metastases are considered incurable. Small 
proportions of patients have early mucosal disease and can be cured by endoscopic mucosal 
resection. For the remainder, careful pre-operative staging is used to identify patients with 
unresectable disease such as airway involvement and those with lymphatic dissemination 
outside the proposed field of surgery that makes most of these patients incurable. The 
mainstays of curative treatment are oesophagectomy alone, neo-adjuvant chemotherapy or 
chemoradiotherapy followed by oesophagectomy or definitive chemoradiotherapy. Neo-
adjuvant radiotherapy before surgery has been abandoned. A small proportion of patients 
deemed incurable on their initial staging can go on to surgery after ‘successful’ neo-adjuvant 
treatment and similarly there are ‘non-responders’ whose disease progresses and become 
candidates for palliative treatment.  Because AC characteristically affects the lower 
oesophagus and oesophago-gastric junction, with downward nodal spread, definitive 
chemoradiotherapy is used much more extensively for SCC, where a smaller volume field 
can be successfully irradiated.  
 
Oesophagectomy with lymphadenectomy via the abdomen and right chest is the most widely 
used operation for AC. The more proximal location of SCC in the oesophagus may 
necessitate an additional incision in the neck to obtain an adequate proximal resection 
margin. The primary aim of surgery is to achieve a complete resection of the tumour (R0) and 
surrounding lymph nodes to maximise the opportunity for cure, obtain the maximum amount 
of information for prognostic purposes and minimise the risk of local recurrence. Complete 
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surgical resection is the most important prerequisite for long-term survival in patients with 
localised oesophageal cancer [34, 42-44].  
 
1.5.1. Neo adjuvant treatments for oesophageal cancer  
 
Neo adjuvant chemotherapy followed by surgery 
A Cochrane review in 2006 analysed the role of preoperative chemotherapy in oesophageal 
cancer [45]. This review was based on 11 randomised trials out of 18 randomised controlled 
trials and two meta-analyses that were potentially eligible for the review. The authors found 
some evidence to suggest that preoperative chemotherapy improved survival (HR 0.88; 95% 
CI 0.75 to 1.04). The largest trial on this subject was from the UK (the OE02 trial). This 
compared two cycles of pre-operative chemotherapy with cisplatin and 5-fluorouracil 
followed by surgery against surgery alone [46]. OE02 demonstrated a significant benefit in 
survival for the chemotherapy arm (hazard ratio of 0.79; 95% CI 0.67-0.93; p = 0.004). The 
survival rate at 2 years was 43% (chemotherapy + surgery) compared with 34% (surgery 
alone).  
 
Similar results were also obtained for resectable gastro-oesophageal cancer in the MAGIC 
trial [47]. MAGIC randomised 503 patients with adenocarcinoma of the stomach and lower 
third oesophagus to receive peri-operative ECF (epirubicin, cisplatin, 5-fluorouracil) 
chemotherapy and surgery or surgery alone. In the ECF arm, 3 cycles were given pre-
operatively and 3 post-operatively. The final analysis demonstrated smaller tumours and 
increased resection rates in the patients treated with chemotherapy, as well as significantly 
improved progression-free and overall survival (hazard ratio of 0.66 (95%CI: 0.53 - 0.81), 
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p=0.0001 for progression-free survival and hazard ratio of 0.75 (95% CI: 0.60 - 0.93), 
p=0.009 for overall survival both in favour of the combined arm).  
 
Neo adjuvant radiotherapy followed by surgery 
A meta-analysis of all trials on neoadjuvant radiotherapy concluded that neo adjuvant 
radiotherapy did not improve survival and was not recommended [48]. This quantitative 
meta-analysis included updated individual patient data (1147 patients) from five randomized 
trials. The authors concluded that there was no clear evidence that preoperative radiotherapy 
improved the survival of patients with potentially resectable oesophageal cancer. They 
postulated that if radiotherapy regimens did improve survival, then the effect was likely to be 
modest with an absolute improvement in survival no more than 3 to 4%.  
 
Neo adjuvant chemoradiotherapy followed by surgery 
Of all the trials published on neo adjuvant chemoradiotherapy, only a few have reported 
survival benefit. The first study to show a survival advantage  was published in 1996 [49]. 
Fiorica et al. subsequently performed a meta-analysis of the published randomised trials [50]. 
They concluded in favour of neo adjuvant chemoradiotherapy followed by surgery for overall 
survival, but they conceded that exclusion of the single study above led to a loss of a 
statistically  significance survival advantage. 
  
The largest single study to date to look at the effects of preoperative chemoradiotherapy in 
locally advanced oesophageal cancer, involved 364 patients in the Netherlands in a phase III 
multicentre (CROSS) trial. This study found that a combination of chemotherapy and 
radiation before resection was superior to surgery alone. Median survival of patients who 
35 
 
received chemoradiation (CRT) and surgery was 49 months, compared to 26 months for those 
who received surgery alone [51].  
 
1.5.2. Adjuvant therapy for oesophageal cancer 
Randomized trials comparing surgery alone against surgery with adjuvant chemotherapy, 
radiotherapy, or chemoradiotherapy, have not found any survival differences [52-56]. 
 
1.5.3 Current neo adjuvant trials in the UK 
There are two trials that are currently being conducted in the United Kingdom to compare the 
efficacy of various chemotherapeutic regimes. OE05 is a randomised controlled trial 
comparing standard chemotherapy (OE02) followed by resection versus ECX (epirubicin, 
cisplatin, capecitabine) chemotherapy followed by resection in patients with resectable 
adenocarcinoma of the oesophagus. This trial has now completed recruitment and the results 
are expected in the near future. ST03 is a randomised Phase II/III study of peri-operative 
chemotherapy (using ECX) with or without bevacizumab in operable adenocarcinoma of the 
stomach and gastro-oesophageal Junction. Patients included in this thesis were offered access 
to these trials as appropriate. 
 
1.6 Prediction of response to neoadjuvant chemotherapy 
The findings from these trials tend to obscure the observation that pathological responders to 
neoadjuvant treatment have a significantly better survival than both pathological non-
responders and patients treated by primary surgery alone [57]. Several analyses suggest that it 
is the response to preoperative therapy (particularly the absence of residual disease in the 
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surgical specimen) that best predicts disease-free and overall survival [58]. Distinguishing 
between responders and non responders would therefore seem highly desirable either before, 
or at least at any early stage during, treatment. For non-responders, avoidance of potential 
severe side effects from chemotherapy and the risk of progression to an incurable stage while 
awaiting surgery are also important considerations.  
 
Factors that can influence tumour response to neoadjuvant chemotherapy include age, sex, 
ethnicity, comorbid conditions, drug interactions, and genetic factors [59]. Numerous studies 
have attempted to predict the response to neoadjuvant chemotherapy based on molecular 
techniques or functional and non-functional imaging. 
 
1.6.1 Molecular techniques: 
To understand the molecular techniques in the prediction of response to neoadjuvant 
chemotherapy, it is important to understand the mechanism of action for the main drugs (5-
FU, Cisplatin) used in the treatment of oesophageal adenocarcinoma. 
 
1.6.1.1 5-Fluorouracil 
5-fluorouracil (5-FU) was designed, synthesized and patented by Charles Heidelberger in 
1957 [60]. It is an analogue of uracil with a fluorine atom in place of hydrogen. 5-FU is an 
antimetabolite that exerts its anticancer effects through inhibition of thymidylate synthase 
(TS) and incorporation of its metabolites into RNA and DNA. It utilises the same cellular 
mechanisms as uracil and rapidly enters the cell where it is converted into several active 
metabolites – fluorodeoxyuridinemonophosphate (FdUMP), fluorodeoxyuridine triphosphate 
(FdUTP) and fluorouridine triphosphate (FUTP). These metabolites disrupt RNA synthesis 
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and the action of TS. Thymidylate synthase methylates deoxyuridine monophosphate 
(dUMP) into thymidine monophosphate (dTMP). Following scarcity of dTMP, rapidly 
dividing cancerous cells undergo cell death via ‘thymineless’ death.  
 
Capecitabine (Xeloda) is an antimetabolite belonging to the fluoroprimidine class of drugs. It 
is an orally administered precursor of 5-FU and is converted to 5-FU by carboxyesterase, 
cytidine deaminase and thymidine phosphorylase. 
 
Molecular techniques for response prediction to the fluoropyrimidine class of drugs can be 
further subdivided into the following: 
 
Genomics: Numerous studies have concentrated on the influence of genetic factors on the 
drug action pathways [61], that may contribute to resistance. Work has been performed on the 
genetic polymorphisms of the enzyme systems involved in folate metabolism and thus 
potentially in sensitivity to 5-FU-based chemotherapy to improve understanding of the 
variation in response to chemotherapy [62]. The methodology of these studies has been based 
on genomic typing utilising tumour tissue samples [61-63], peripheral blood samples [64] or 
immunohistochemical staining [65, 66] of paraffin embedded tumour tissue blocks. 
 
Thymidylate synthase (TS) methylates dUMP into dTMP which is subsequently 
phosphorylated to thymidine triphosphate for use in DNA synthesis and repair. Genetic 
polymorphisms that alter the activity of TS could impact on the therapeutic activity of 5-FU. 
Liao et al. reported a study on 146 Caucasian patients with oesophageal adenocarcinoma 
treated with preoperative 5-fluorouracil-based chemoradiation [67]. They focussed on the 3’ 
untranslated region of the TS gene. There was a trend of association between 6bp/6bp 
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genotype and a decreased risk of local regional recurrence and a higher three year probability 
of locoregional control compared to patients with other genotypes. Similar studies focusing 
on these genetic polymorphisms in patients with gastric cancer have been published [68, 69]. 
None of these studies have been able to adequately differentiate between responders and non 
responders with sufficient accuracy to influence management. 
 
Transcriptomics: Studies of mRNA expression levels of TS have been published both for 
oesophageal adenocarcinoma and gastric carcinoma. Langer et al. examined expression of 
genes associated with metabolism of chemotherapeutic drugs in 21 patients with locally 
advanced oesophageal adenocarcinomas [70]. They noted a significant post-therapeutic 
reduction in the expression levels of TS and multidrug resistance-associated protein 1 
(MRP1) and thus concluded that downregulation of TS and MRP1 mRNA expression levels 
after chemotherapy was associated with tumour response. Amplification of thymidylate 
synthetase has been proposed as a mechanism for poor response to 5- Fluorouracil [63]. 
Similar studies reporting the association of high TS mRNA expression and poor response to 
chemotherapy have been published for gastric carcinoma [71-73]. High TS protein expression 
considered indicative of resistance to 5-FU has also been associated with poorer survival in 
gastric cancers [74]. Conversely, low expression levels of DPD, ERCC1, GSTPi, ERB2/neu 
and EGFR have been reported to be associated with tumour response to chemotherapy [74].  
 
1.6.1.2 Cisplatin  
Cisplatin or cis-diamminedichloroplatinum [75] was first described by Peyrone in 1844 [76] 
and approved for use in testicular and ovarian cancers by the U.S. Food and Drug 
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Administration in 1978.  The therapeutic effects of cisplatin are due to its ability to bind to 
DNA and produce cross-linkages [77]  along with the generation of free radicals [78].  
 
The nucleotide excision repair (NER) pathway is a DNA repair mechanism. It is an important 
method by which the cell can prevent unwanted mutations by removing the vast majority of 
damaged DNA; for instance damaged DNA in skin cells as a result of UV light exposure. 
Several human diseases can result from in-born genetic mutations of NER proteins including 
Xeroderma pigmentosum and Cockayne's syndrome. NER is the predominant DNA repair 
pathway involved in the repair of bulky DNA-damaging lesions caused by platinating agents 
[79, 80]. 
 
The base excision repair machinery (BER) is involved in the repair of oxidative DNA base 
damage that is a result of free radical generation by platinating agents. XRCC1 is a DNA 
repair protein. The protein encoded by this gene is involved in the repair of DNA breaks and 
forms one of the main mechanisms for base excision repair pathway [81, 82]. Glutathione S-
transferases are enzymes involved in the detoxification of platinating agents. 
 
Molecular techniques for response prediction to platinating agents can be further subdivided 
into the following: 
 
Genomics: In a study by Wu et al. on 210 oesophageal carcinoma patients, polymorphisms of 
XRCC1 Arg399Gln were significantly associated with the absence of pathologic complete 
response [61]. The role of ERCC2 in response prediction to chemotherapy with platinating 
agents has also been evaluated [83]. 
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Transcriptomics: The role of mRNA expression of ERCC1 has been investigated for 
prediction of response to platinum based chemotherapy. Although the mRNA expression 
levels of ERCC1 in oesophageal carcinoma are not so convincing [84, 85], the results for 
advanced gastric cancer indicated that the survival in patients with low ERCC1 levels was 
significantly longer that in patients with high levels [86]. 
  
1.6.1.3 Other molecular markers for prediction of response 
Survivin: Survivin is a member of the inhibitor of apoptosis family. Survivin protein inhibits 
caspase activation, thereby leading to negative regulation of apoptosis or programmed cell 
death. In one study, nuclear expression of survivin was also detected in 80% of SCC [87]. 
Expression of this protein has also been documented in gastric cancer [88]. Its role has also 
been explored as a potential biomarker in the development of Barrett's adenocarcinoma [89]. 
High levels of survivin expression have been related to reduced overall survival [75] and lack 
of response or progressive disease [75]. 
 
Bax: The Bcl-2 associated X protein, or Bax is a protein of the Bcl-2 gene family. It promotes 
apoptosis by competing with Bcl-2. Bax protein is found in all cell layers of the normal 
oesophageal squamous epithelium [90]. Kang et al. reported that low expression of Bax was 
significantly associated with the poor survival of patients with locally advanced oesophageal 
cancer [91]. They further recommended that immunohistochemical staining for Bax with a 
pre-treatment biopsy specimen might be useful to select the optimal treatment options for 
these patients 
 
41 
 
Cyclooxegenase-2: Over-expression of cyclooxegenase-2 may be associated with resistance 
to apoptosis [80]. Cyclooxegenase-2 expression has been reported in up to 78% of the AC’s 
[92]. High Cyclooxegenase-2 protein expression levels have been linked with poor prognosis 
and histopathological response [93]. 
 
p53: p53 is a tumour suppressor protein encoded by the TP53 gene. It regulates the cell cycle 
and functions as a tumour suppressor. TP53 is frequently mutated in cancer. Mutant p53 
tends to be resistant to degradation and hence p53 protein expression in tumours is considered 
a surrogate marker of p53 mutation and hence may correlate with tumour resistance.  
p53 negativity has been associated with good tumour response in gastric cancer [53, 93-95]. 
However, the results for oesophageal carcinoma are conflicting [96-98]. Only one study has 
reported  that p53 negativity may correlate with increased tumour responsiveness [96].  
 
Nuclear factor Kappa B: Activated nuclear factor kappa B is a transcriptional factor and has 
been reported to be identifiable in 79% of patients with oesophageal cancers [99]. Activated 
nuclear factor kappa B protein expression is positively associated with aggressive clinical 
biology and poor treatment outcome [99]. It has also been correlated with lack of tumour 
response to neo adjuvant therapy. 
 
Hypoxia inducible transcription factor-1: Hypoxia inducible transcription factor-1 mediated 
pathway is involved in tumour angiogenesis. HIF-1 transcription factors induce the 
expression of several genes that regulate various biological processes critical for tumour 
formation, such as cell proliferation, apoptosis, immortalisation, migration and angiogenesis 
[100]. HIF-1 expression has been negatively associated with response to chemotherapy in 
oesophageal squamous cell carcinomas [101]. However, a recent article investigating HIF-1α 
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expression has observed a positive correlation between expression and initial response to 
chemo radiotherapy [102]. 
 
c-erb-B1 & B2: c-erb-B1 & B2 are proto oncogenes that code for the epidermal growth factor 
receptor. mRNA expression levels of c-erb-B1 & B2 have been examined in patients with 
oesophageal adenocarcinoma receiving neo adjuvant chemotherapy [103]. Levels of 
expression of c-erbB-2, but not c-erbB-1 mRNA, in pre-treatment biopsies were predictive of 
minor histopathologic response to neoadjuvant radiochemotherapy. 
 
Metallothionein: Metallothionein is a family of cysteine-rich low molecular weight proteins. 
Reduced levels of metallothionein, a heavy metal chelator that binds to and inactivates 
cisplatinum have been associated with a significantly increased response rate and importantly 
patient survival [65]. 
 
Caldesmon: Caldesmon is a protein that is encoded by the CALD1 gene. It is a calmodulin 
binding protein and inhibits the ATPase activity of myosin in smooth muscle. Langer et al. 
noted that the expression of caldesmon gene was higher in responders compared to non-
responders to chemotherapy in patients with oesophageal adenocarcinoma [84]. 
 
Glutathione S-transferase: Glutathione S-transferases are enzymes involved in the 
detoxification of platinating agents. Glutathione S-transferase ∏ and P- Glycoprotein were 
associated with a poor response in oesophageal tumour biopsy material from 118 patients 
who were being treated with concurrent cisplatin and 5-FU [66]. 
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1.6.2 Drawback of genomics and transcriptomics   
A significant drawback in most of these studies has been reliance on the genome for accurate 
response prediction. This is because besides expression, transcription and translation would 
always have to follow for genome based data to be fully reliable as a marker of  response to 
chemotherapy [104]. Moreover, genomics and transcriptomics focus on a single marker or a 
set of markers targeting a particular pathway. It is now clear that cancer is a result of a 
multitude of genetic and epigenetic alterations.  Prediction of response to chemotherapy 
would also therefore be dictated by a combination of the changes that these alterations 
produce rather than individual genes or gene products. 
 
The failure to find a clinically useful marker or set of markers based on the genome has led to 
much of the current research being based on proteomics; the study of the proteins finally 
produced by these processes. Although much work has been done on other cancers, studies 
on oesophageal cancer utilising proteomics for response prediction are scant.  
 
One of the first articles utilising proteomics for response prediction in oesophageal cancer 
was based on SELDI (Surface enhanced laser desorption ionisation)[105]. This study 
concluded that there were subtle but definite differences in serum proteomic profile between 
responders and non-responders to chemoradiotherapy. Although initially this technique 
gained momentum, it has recently been criticised due to the lack of identification of proteins 
and high level of peaks produced that are much higher than for known biomarkers. Another 
drawback is the suppression of signals from the low abundance peptides by the high 
abundance peptides due to ion suppression [106]. Other studies have been published since 
utilising proteomics for response prediction [107, 108]. However, as yet no clinically 
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applicable proteomic profile exists that identifies a group of patients who might respond to a 
particular type of treatment in a neo adjuvant setting. 
 
1.6.3 Functional imaging:  
Positron emission tomography (PET) with the glucose analogue 18-fluorodeoxyglucose (18 
FDG), may have a role in the prediction of tumour response during the early phase of 
chemotherapy [109]. The Metabolic response evalUation for Individualisation of neoadjuvant 
Chemotherapy in oesOphageal and oesophago-gastric adeNocarcinoma (MUNICON) study 
evaluated the role of 18 FDG-PET for response prediction in patients with locally advanced 
adenocarcinoma of the oesophagus and oesophago-gastric junction who were receiving 
neoadjuvant chemotherapy [109]. Patients received two weeks of induction platinum and 
fluorouracil-based chemotherapy. A decrease of 35% or more in the tumour glucose 
standardised uptake value (SUV) was defined as metabolic response, a surrogate marker of 
tumour response. The authors concluded that there was a survival benefit in responders 
compared to non responders, predicted by 18 FDG-PET. Moreover, some correlation was 
noted between metabolic and   pathological responders. The authors found major histological 
remissions (<10% residual tumour) in 29 of 50 metabolic responders, but no histological 
response in metabolic non-responders. The median event-free survival was 29.7 months in 
metabolic responders and 14.1 months in non-responders. 
 
The current practice for imaging in oesophago-gastric malignancies includes a CT scan of the 
chest, abdomen and pelvis at the time of diagnosis followed by 18 FDG-PET. Endoscopic 
ultrasound is used specifically to confirm local staging of tumour. 
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1.6.4 Non-Functional imaging:  
Computerised tomography, magnetic resonance imaging, endoscopic ultrasonography and 
upper gastrointestinal endoscopy have all been used for non-functional imaging to predict 
response to neoadjuvant chemotherapy. A recent study by Schneider et al. concluded that 
response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound did not accurately 
predict histopathologic regression after neoadjuvant chemoradiation for oesophageal cancer 
[110]. Similarly, clinical response evaluation using EUS or CT was shown to be highly 
inaccurate in predicting response to neoadjuvant chemotherapy. 
 
1.6.5 Clinicopathological factors:  
A variety of clinicopathological factors have been used to predict response of oesophageal 
cancer to chemoradiotherapy. Kogo et al. concluded that nutritional status, T stage, M stage, 
and alkaline phosphatase were significant factors that contributed to the response of 
oesophageal carcinoma to chemoradiotherapy [111]. On the other hand, a study from Dublin 
concluded that smaller tumour length was predictive of a greater response to chemotherapy 
and radiation therapy [112]. No single item or combination of items has yet been shown to 
have sufficient predictive accuracy to be of value in clinical practice.  
 
1.7 Metabolomics 
Metabolomics is defined as “the measurement of metabolite concentrations and fluxes and 
secretion in cells and tissues in which there is a direct connection between the genetic 
activity, protein activity and the metabolic activity itself” [113]. It is the study of global 
metabolite profiles in cells, tissues, and organisms.  
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It is believed that changes in the metabolome are the ultimate answer of an organism to 
genetic alterations, disease, or environmental influences. Since the small molecule 
composition is studied in metabolomics, it can safely be regarded as the end point of the 
“omics” cascade [114]. Unlike genes and proteins, which are “upstream” entities whose 
expression predicts cell functioning; metabolites reflect actual cellular conditions at the time 
of sampling. The metabolome is therefore most predictive of phenotype [115, 116]. 
 
The focus of metabolomics is on complete metabolite profiles in a sample, rather than one or 
a few metabolites and associated pathways. Consequently, the comprehensive and 
quantitative study of metabolites (metabolomics) is a desirable tool for either diagnosing 
disease or studying treatment response. In the context of oesophageal cancer patients and in 
particular adenocarcinoma, where a precursor lesion exists, this diagnostic potential could 
extend to the identification of the metaplastic and dysplastic states as well as correlations 
with specific stages of disease. It is expected that metabolomics will give even more reliable 
results when combined with specific proteomic signatures involving proteins with known 
functions.  
 
There are two complementary approaches used for metabolomic investigations – metabolic 
profiling and metabolic fingerprinting. In metabolic profiling, quantitative analytical methods 
are developed for metabolites in a pathway or for a class of compounds. This approach 
produces independent information that can be interpreted in terms of known biochemical 
pathways and physiological interactions. In metabolic fingerprinting the intention is not to 
identify each observed compound but to compare patterns or fingerprints of metabolites that 
change in response to disease or toxin exposure [117]. 
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Metabolic profiles are typically generated with high-throughput nuclear magnetic resonance 
(NMR) spectroscopy, direct infusion electrospray mass spectrometry (ESI-MS) and gas 
chromatography mass spectrometry (GC-MS). 
 
1.7.1 Nuclear Magnetic Resonance Spectroscopy 
NMR spectroscopy was discovered independently by Nobel laureates Edward Purcell and 
Felix Bloch. Two independent groups, working in s laboratories on opposite coasts of the 
USA, discovered NMR almost simultaneously (Bloch, Hansen, and Packard at Stanford 
University [118]; Purcell, Torrey, and Pound at Harvard [119]).  
 
Nuclear magnetic resonance is an effect whereby nuclei in a magnetic field absorb and re-
emit electromagnetic energy. Each nucleus has one or more protons and neutrons (except the 
hydrogen nucleus 1H, which only contains a single proton), both of which have the intrinsic 
quantum property of spin. Inside an oriented magnetic field, the spin of the nuclei can either 
be oriented parallel or anti-parallel with the external magnetic field. The energy absorbed or 
emitted by the nuclei is at a specific resonance frequency, specific for each nucleus. In each 
molecule, due to differences in the electronic surroundings, each proton resonates at a slightly 
different frequency, called the chemical shift. This enables the identification of various 
compounds in complex biological mixtures.  
 
The use of NMR spectroscopy to detect metabolites in unmodified biological samples was 
first reported by Seeley et al. in 1974 [120]. Ten years later, Nicholson showed that proton 
NMR spectroscopy could be used to diagnose diabetes mellitus [121]. He subsequently 
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pioneered the application of multivariate pattern recognition methods to NMR spectroscopic 
data that form the foundation of metabolomics analysis in NMR [122].  
 
During the last 10 years one dimensional (1D) -1H-NMR spectroscopy has become a standard 
analytical tool in biomedical metabolomics. However due to the chemical complexity of 
biological samples, the amount of overlap in 1D-1H-NMR spectra is quite substantial. In 
order to unambiguously assign substances in crowded regions of the NMR spectra two 
dimensional (2D) -NMR methods, e.g. 2D J-resolved (J resolved spectroscopy can be used to 
acquire “proton decoupled” 1D NMR spectra to reduce spectral congestion) [123] or 2D  2D-
1H,13C-HSQC (heteronuclear single quantum coherence) spectroscopy, are becoming 
increasingly used for biological samples as better software and spectrometer hardware have 
been developed.  
 
The work for this thesis was carried out at the Henry Wellcome Building for biomolecular 
NMR spectroscopy (HWB-NMR) at the University of Birmingham. The HWB-NMR is a UK 
national NMR facility. It provides academic and industrial users with open access to seven 
NMR spectrometers, most equipped with cryogenic probes, a high throughput autosampler 
and mass spectrometer. The majority of the data for this thesis were acquired on a 600 MHz 
UltraShield plus Bruker magnet with a 4-channel Bruker Avance III console (Figure 5) using 
a low volume cryogenically cooled probe (30 µl sample volume). 
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Figure 5 600 MHz UltraShield plus Bruker magnet 
 
1.7.2 Basics of NMR 
Any rotating object possesses angular momentum. This can be described as the rotational 
analogue of the linear momentum. A spin is a type of angular momentum. It is a fundamental 
property of electron and nucleus. The magnetic moment of a nucleus arises from this integral 
property of spin.  
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When a sample is placed inside a magnetic field, the individual spins precess (precession is 
the rotation of the spins around the main axis (vertical) of the external magnetic field) around 
the magnetic field. Once in a magnetic field, there are only 2 directions in which the 
individual spins can align – parallel or anti parallel to the magnetic field.  It is important to 
note that a nucleus that has it’s spin aligned with the external field will have a lower energy 
than when it has its spin aligned in the opposite direction to the field. However, the difference 
in energy state of these two systems is very small. Thus it is conceivable that only a small 
amount of energy could flip a spin from the parallel to an anti parallel orientation. 
 
The distribution of spins between the parallel and anti-parallel level is given by the 
Boltzmann distribution [124], hence at 0 K, all spins would orient in the parallel direction in 
presence of an oriented external magnetic field. However, at higher temperatures; the energy 
that is generated from Brownian motion is enough to flip these spins into an anti parallel 
orientation. It has to be understood that at equilibrium magnetisation, the energy gap in 
between the two energy levels is very small (eg. at room temperature, only 1 in 10,000 spins 
will be parallel in excess to equal distribution).  The net magnetisation of the sample is 
parallel to the external magnetic field. However, a spectrum cannot be recorded in this state 
of equilibrium. 
 
When radio frequency is applied at 90º to the external magnetic field, the spins start 
precessing around the axis on which the RF field is applied. For a simple 1D NMR 
experiment the radio frequency would be turned off when the angle between the external 
magnetic field and the sample magnetisation reaches 90º. Once in the transverse plane, the 
spins will start precessing (i.e. the macroscopic magnetisation vector rotates around the z axis 
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which coincides with the direction of the external magnetic field) and will relax towards the 
equilibrium magnetisation over time. 
 
These precessing spins produce a time dependent magnetic field that then induces a time 
dependent electric field. This electric field then induces a current in the receiver coil which is 
recorded as a free induction decay (FID). This is then Fourier transformed to produce the 
final spectrum. 
 
1.7.3 Cancer metabolism 
The subject of cancer metabolism has been a topic of much research and debate over the last 
few decades. Although numerous pathways have already been described, key mechanisms are 
yet to be elucidated to complete the understanding of tumour metabolism. Listed below are 
some of the important effects which have improved our understanding of cancer metabolism. 
 
1.7.3.1 The Warburg effect 
Described by Warburg et al. in 1924, ‘the Warburg effect’ continues to be a pivotal theory in 
the understanding of tumour metabolism [125]. This effect described the observation that 
cancer cells predominantly produced energy by non-oxidative breakdown of glucose to 
pyruvate and then to lactate, as compared to healthy cells which primarily produce energy 
from pyruvate through tricarboxylic acid cycle and oxidative phosphorylation (respiration). 
Warburg identified the ratio of glycolysis to respiration as being one of the main differences 
between healthy and cancerous cells. This observation came to be known as ‘the Warburg 
effect’. These mechanisms adapt the cancer cells to hypoxic conditions and thus account for 
their increased tendency for survival inside solid tumours. 
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1.7.3.2 The role of cancer genes in metabolic regulation 
Cells employ a variety of mechanisms to adapt metabolism to specific physiological states. 
“The metabolic requirements of each cell type are determined by their tissue function and 
environment” [126]. Thus metabolic regulation can be described as the process by which 
cells control the chemical processes necessary for life. For example, numerous factors play a 
role in determining the fate of glucose in cancer cells – ‘the Warburg effect’.  
 
One of most studied cancer genes is the p53 oncogene. p53 interjects at many points in both 
glycolysis and oxidative phosphorylation. One of the ways that p53 functions is to slow down 
glycolysis and promote oxidative phosphorylation. It thus provides a mechanism of blocking 
tumorigenesis and ‘the Warburg effect’ [127]. 
 
1.7.3.3 The role of metabolic reprogramming in promoting tumorigenesis 
Broadly speaking, metabolic reprogramming refers to the altered metabolism in cancer cells 
that enables it to meet the increased anabolic requirements of a growing and dividing cell 
[128]. Thus altered metabolism is now considered to be a core hallmark of cancer.  
 
The role of Hypoxia inducible transcription factor-1 is central to the understanding of 
metabolic regulation and metabolic reprogramming. During conditions of hypoxia, HIF-1α 
helps to restore oxygen homeostasis by inducing glycolysis, erythropoiesis and 
angiogenesis[129]. HIF1α activation in different cell types can either promote or repress 
tumorigenesis[130]. 
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1.7.4 The role of metabolomics in the study of tumour metabolism  
One of the main goals within cancer metabolomics is to develop fast and reliable methods for 
characterising disease non-invasively [131]. Metabolomics can be used for diagnosing cancer 
states directly in body fluids, through facilitating fast screening or by applying it to 
histopathological samples in order to classify different tumours using techniques such as 
magic angle spinning (MAS)-NMR [132] (Magic angle spinning NMR spectroscopy is a 
technique that can be used to acquire NMR spectra of  intact tissue samples). Furthermore, it 
can be applied to solid and liquid samples in vivo or in vitro.  
 
There is good evidence to support the use of metabolomics in cancer. Metabolomic strategies 
have been used to detect bladder cancer based  on urinalysis [133]. Metabolomics has also 
been used  to direct treatment plans where profiles reflect  prostate cancer pathologic stage 
and aggressiveness, conventionally determined by histopathology only after prostatectomy 
[134]. More recently, the metabolomic alterations of prostate cancer progression have been 
characterised and sarcosine identified as a potentially important metabolic intermediary of 
cancer cell invasion and aggressive behavior [135]. 
 
Metabolomics has also been used to study drug resistance and metabolic therapeutic targets. 
Merz at al. have reviewed the possible strategies for the use of nuclear magnetic resonance-
based metabolomics in detecting drug resistance in cancer [136]. NMR has been employed to 
study the response to chloroethylnitrosourea in melanoma and pulmonary carcinoma [137]. 
The authors of that study concluded that metabolomics of tumour response to an anticancer 
agent might identify metabolic pathways of drug efficacy and adaptation to treatment. 
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1.7.4.1 Common NMR detectable changes associated with malignancy 
There is a plethora of studies describing the various metabolic alterations noted in blood, 
tissue and urine using NMR metabolomics. Listed below are some of the commonly 
described metabolites. 
 
Alanine: Levels of this metabolite are ioncreased in tissue hypoxia. It has been documented 
in hepatomas, astrocytomas, gliomas, meningiomas and dysembryoplastic neuroepithelial 
tumours. 
 
Choline containing metabolites: These include choline, phosphocholine, phosphatidylcholine 
and glycerophosphocholine. They are key constituents of cell membranes. Their levels 
change during apoptosis and necrosis. They have been widely documented in brain tumours, 
sarcomas, prostate cancer and hepatoma hepatomas [138-141]. 
 
Glycine: Glycine is an amino acid and an essential precursor for de novo purine synthesis. 
The levels of glycine are decreased following the disruption of the HIF-1α signalling pathway 
[142]. 
 
Lactate: Lactate is an end product of glycolysis. It increases during hypoxia and ischaemia. It 
has been associated with a large number of tumours[143]. 
 
Nucleotides: These are used to manufacture DNA and RNA. They are also key metabolic 
intermediates in fatty-acid and glycogen metabolism.  
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Sarcosine:  Although only recently described in prostate cancer, sarcosine is a potentially 
important metabolic intermediary and an important predictor f cancer cell invasion and 
aggressive behavior in this disease[135]. 
 
Taurine: Taurine is important in osmoregulation and volume regulation. It is increased in 
squamous-cell carcinoma[144], prostate cancer and liver metastasis[145]. 
1.7.4.2 NMR in metabolomicsThere are several advantages of using 1H NMR spectroscopy to 
acquire metabolite levels in metabolomics. It is a relatively rapid process with uncomplicated 
sample preparation methods. It is capable of observing all high abundance metabolites that 
contain non-exchangeable protons. It does not require any chromatographic separation or 
ionization of the metabolites prior to data acquisition in the spectrometer. The data obtained 
from 1H NMR spectroscopy can be used for quantitative analysis. Moreover, it is robust and 
reproducible and with high throughput, is well suited to large studies on human samples. 
Finally, although the instrumentation is quite expensive, the costs for consumables and 
materials are low making this an attractive proposition for large biofluid studies. 
 
The main disadvantage of using 1H NMR spectroscopy for metabolomics is poor sensitivity. 
As a result, the observation is limited to approximately 100 metabolites which comprise less 
than 10% of an organisms’s metabolome. Another shortcoming of (1D) 1H NMR 
spectroscopy is that there is lot of overlap of resonances. As a result the ability to identify and 
distinguish these metabolites is limited in the crowded regions of the spectrum. 
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1.7.4.3 Metabolomics in oesophageal cancer 
A few studies that have explored the role of metabolomics in the context of oesophageal 
cancer. Zhang et al. investigated the role of serum metabolic profiles derived from the 
combination of high performance liquid chromatography-mass spectrometry (LC-MS) and 
NMR [146]. This study presented results from 67 patients with AC. They also included a 
small number of patients with Barrett’s oesophagus and high grade dysplasia. The authors 
identified 12 candidate metabolites that differentiated significantly between patients with 
cancer and healthy controls. Similarly tissue metabolomics employing GC-MS has also been 
attempted with the aim to identify candidate biomarkers in oesophageal carcinoma [147]. 
Hasim et al. performed plasma and urine metabolic profiling to identify metabolic signatures 
in 108 patients with SCC [148]. Another study from the same region in China has 
investigated 1H NMR in human plasma to identifiy differences between metabolite 
concentrations between different ethnic groups [149]. A similar approach has also been 
employed in gastric carcinoma. Cai et al. used a combination of metabolomics and 
proteomics to investigate glucose metabolism in 65 patients with gastric cardia cancer [150]. 
 
Researchers at Imperial College London reported the results of MAS-NMR of intact tissue in 
thirty five patients with oesophageal adenocarcinoma and matched controls [151]. Profiles 
identified by these authors support the hypothesis of field change in the oesophagus even in 
the non-Barrett’s segments of patients with AC. 
 
Below is table of some of the recent metabolic studies which have aimed to evaluate various 
metabolites in oesophageal carcinogenesis.  
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Metabolic change Year of 
publication 
Title (reference) 
lactic acid, valine, leucine/isoleucinec, 
methionine, carnitine, tyrosine, tryptophan, 5-
hydroxytryptophan, myristic acid, margaric 
acid, linolenic acid, linoleic acid, 
pyroglutamic acid, glutamine, b-
hydroxybutyrate, citrate, lysine, creatinine, 
glucose, N-acetylated protein, proline, 
histidine, alanine, glutamate 
2012 Esophageal Cancer Metabolite Biomarkers 
Detected by LC-MS and NMR 
Methods[146] 
dimethylamine, a-glucose, b-glucose, citric 
acid, Leucine, alanine, isoleucine, valine, 
glycoprotein, lactate, acetone, acetate, 
choline, isobutyrate, unsaturated lipid, VLDL, 
LDL, 1-methylhistidine, Mannitol, glutamate, 
c-propalanine, phenylalanine, acetate, 
allantoin, pyruvate, tyrosine, b-glucose, 
guinolinate, N-acetylcysteine, valine, 
dihydrothymine, hippurate, methylguanidine, 
1-methylnicotin-amide, Citric acid 
2012 Revealing the metabonomic variation of EC 
using 1H-NMR spectroscopy and its 
association with the clinicopathological 
characteristics[148] 
phosphocholine to glutamate ratio in 
histologically-normal tissue 
2010 Metabolic profiling detects field effects in 
non-dysplastic tissue from esophageal 
cancer patients[151] 
Glutamine, β-hydroxybutyrate, Citrate, 
Lysine, Creatinine, α-glucose 
2010 Metabolomics study of esophageal 
adenocarcinoma[152] 
l-Valine, Naphthalene, 1-Butanamine, l-
Altrose, d-Galactofuranoside, Pyrimidine, 
Aminoquinoline, l-Tyrosine, Isoleucine, 
Purine, Serine, Phosphoric acid, Myo-inositol, 
Arabinose, Arabinofuranoside, l-Asparagine 
, Tetradecanoic acid, l-Alanine, Hexadecanoic 
acid, Bisethane  
2009 Metabolomic study for diagnostic model of 
oesophageal cancer using gas 
chromatography/mass spectrometry[147] 
 
Table 2 Recent metabolic studies in oesophageal carcinoma 
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Although NMR metabolomics continues to grow rapidly, its use to identify metabolites 
characterizing the pre-neoplastic state, different stages of disease or in the prediction of 
response to neoadjuvant chemotherapy in oesophageal adenocarcinomas has not been fully 
elucidated. 
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AIMS  
The aims of this study were to prospectively evaluate the role of plasma and tissue profiles 
as:  
• biomarkers for the identification of oesophago-gastric malignancy  
• indicators of unstable Barrett’s epithelium  
• predictors   of  response to neoadjuvant chemotherapy  
 
These goals would be achieved by using a combination of approaches. 
1. NMR metabolomics of plasma and tissue 
2. MS metabolomics of plasma and tissue 
3. MALDI proteomics of plasma and tissue (manuscript in appendix) 
4. Tissue gene expression profiling 
 
This thesis concentrates on NMR metabolomics in plasma and tissue. Tissue MS 
metabolomics and gene expression profiling were used as confirmatory modalities as 
potentially useful molecules were disclosed. These other techniques are highlighted within 
the relevant sections of the results chapter.  
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METHODS 
2.1 Ethical considerations 
2.1.1 Ethical approval 
Ethical approval was obtained from South Birmingham Research Ethics Committee for this 
study on the 16th May, 2008 (REC reference number - 08/H1207/3). To further perform 
proteomics, immunohistochemistry, genomics and transcriptomics on the collected 
specimens, a substantial amendment to the ethical approval was successfully obtained on 
18th November, 2009.  
 
2.1.2 University Hospital Birmingham sponsorship 
A research project authentication for this project was obtained from University Hospital 
Birmingham on the 28th May, 2008 (Project reference – RRK 3425). 
 
2.2 Patient Recruitment 
2.2.1 Study duration 
• Patients presenting to University Hospitals Birmingham between May 2009 and 
March 2010 as specified below. 
 
61 
 
2.2.2 Inclusion criteria 
• All patients presenting with gastro-oesophageal malignancy or high grade dysplasia in 
Barrett’s oesophagus, discussed by the oesophago-gastric multi-disciplinary team 
(MDT) of the pan-Birmingham Cancer Network.  
• Selected patients undergoing upper GI endoscopy for benign disease (controls). 
• Selected patients with non-dysplatic Barrett’s oesophagus. 
• Healthy volunteers. 
 
2.2.3 Exclusion Criteria 
• Patients unable to give valid consent. 
• Patients refusing to take part in the study. 
• Medically unwell or terminally ill patients where the collection of blood and tissue 
was thought inappropriate. 
 
Sample collection 
Sample collection included blood and tissue samples as specified below. Five healthy 
volunteers provided blood only. 
 
2.3 Sample collection for blood 
2.3.1. Time Intervals 
2.3.1.1. Patients  
Longitudinal blood sampling was carried out for each patient with cancer. Samples were 
collected at five time points. 
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• At diagnosis, immediately before the patient underwent staging laparoscopy. This 
served as the pre-chemotherapy sample. 
• At the completion of chemotherapy before the patient was admitted for resectional 
surgery. 
• After the induction of anaesthesia, but before surgery had commenced. 
• Within six weeks of the surgery either at the time of, or shortly after discharge from 
the hospital. 
• More than six weeks following surgery. 
 
For patients who did not receive chemotherapy, the second blood sample was not collected 
unless the time gap between the first sample and resectional surgery was more than six 
weeks. 
 
Patients undergoing palliative treatment had one sample collected at the time of contact. 
 
2.3.1.2. Controls and patients with non–dysplastic Barrett’s 
These subjects were recruited at the time of endoscopy. One venous sample was collected 
and processed in a similar fashion. 
 
2.3.1.3 Healthy volunteer controls 
Three blood samples were collected from each volunteer. Samples were collected at random 
times of the day on three different days. 
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2.3.2. Pre-processing 
6 ml of blood was collected by venepuncture into lithium heparin tubes. Lithium heparin 
tubes were selected for the 1H-NMR analysis in order to avoid background signals from 
ethylenediaminetetraacetic acid (EDTA) which is used as an anticoagulant in most 
laboratories. These tubes were immediately placed on ice and processed within four hours. 
Times to centrifugation and final storage of samples were noted. Samples were centrifuged at 
4°C at 200 relative centrifugal force (RCF) in a pre-cooled centrifuge. Plasma was then 
collected and divided into five  aliquots; 700 µL x 2, 300 µL x 2 and a final aliquot made up 
of whatever was left, usually between 300 µL to 600 µL. Samples were stored at -80°C until 
analysis. It has been previously published that differences between individuals are far greater 
than variation from any other experimental factor. Moreover, these changes can be reduced 
by placing the specimens on ice[153]. Nonetheless, all attempts were made to process and 
freeze all plasma samples within four hours of collection so as to minimise any changes in the 
metabolic profile. 
 
2.3.3. Processing for NMR analysis 
The aliquots of plasma were removed from -80°C storage and left to thaw at room 
temperature. From preliminary observations it was noticed that the plasma still had some ice 
crystals at 30 minutes but was fully thawed at 90 minutes. Therefore, a thaw time of one hour 
was used in all experiments. 
 
The next step was ultrafiltration of the specimen to remove the proteins from plasma. This 
was achieved using filters (Nanosep 3K OMEGA; Pall Corporation, Ann Arbor, MI). These 
centrifugal filters were washed several times with 0.5 ml water at 4000 RCF at a temperature 
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of 36°C to remove glycerol from the filter membrane until no NMR signal was observed in 
the filtrate. The filters were subsequently kept wet at 4°C to avoid damage to the filter 
membrane.  
 
A series of preliminary experiments were carried out to optimise conditions that could be 
standardised. These experiments and their results are described very briefly here followed by 
a complete description of the final methodology used.  
 
2.3.3.1 Experiments to ascertain wash cycles 
Typically eight washing cycles were required to remove glycerol from the filters. To optimise 
this, multiple Nanosep filters were washed using the technique described and filtrates were 
obtained at the 2nd, 4th, 6th, 7th and 8th wash were stored at -80 °C. These were later thawed 
and NMR spectra obtained to look for signals. The signals thus obtained confirmed that six 
wash cycles removed most traces of glycerol. Increased cycles showed additional impurities 
considered to be likely breakdown products from the membrane. 
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Figure 6 NMR spectra after various wash cycles 
2.3.3.2 Experiments to ascertain filtration times and volumes for plasma 
A number of experiments were conducted so as to optimise the: 
• Sample volume for filtration 
• Duration of filtration 
• RCF of the centrifuge 
All these experiments were conducted in a pre-cooled centrifuge maintained at 4°C. 
 
Experiment 1 
Two 700 µL plasma aliquots were thawed and subjected to ultrafiltration, 10,000 RCF at 4°C. 
After two hours, only 125 µL of ultrafiltate was obtained per specimen. At five hours, just 
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under 200 µL of ultrafiltrate was obtained. After 18 hours, the final volume of the ultrafiltrate 
was 275-315 µL. 
 
Experiment 2  
A 700 µL plasma aliquot was centrifuged at 10,000 RCF at 4°C for 10 minutes, designed to 
precipitate the proteins to the bottom of the Eppendorf vial. 600 µL of supernatant was then 
collected and filtered. At one hour, the volume of ultrafiltrate was 120 µL.  At two hours 150 
µL, at four hours between 190-200 µL and finally, at 6 hours 225-230 µL of ultrafiltrate was 
produced.   
 
Experiment 3  
Since the performance of filters dropped exponentially with time (as seen in the previous 
experiments), the 700 µL aliquot was divided into two equal parts of 350 µL each to expedite 
the process. At one hour, the volume of the ultrafiltrate was 110 µL, at two hours 150 µL, at 
four hours between 170-200 µL and finally at six hours 205-230 µL of ultrafiltrate was 
produced. 
 
Experiment 4  
The 700 µL aliquot of plasma was divided into three parts of 233 µL each and then filtered.  
At two hours, the volume of the ultrafiltrate was between110-125 µL, at four hours, it was 
150 µL and after six hours the volume was between 140-170 µL. 
 
Experiment 5  
To achieve an optimum volume of ultrafiltrate (350 µL from 700 µL plasma) in a reasonable 
time, the 700 µL aliquot of plasma was divided into three parts and filtered at an increased 
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speed of 12000 RCF for 3 hours. The resultant ultrafiltrate volume of each part was between 
100-160 µL. 
 
The final protocol for filtration of plasma consisted of filtration of 300 µL of plasma at 
12,000 RCF for 3 hours. This produced a reliable volume of more than 100 µL ultrafiltrate 
for all samples. During these optimization experiments, it was noticed that the rate of 
filtration were similar for a majority of the samples. However, no attempts were made to 
record filtration times of individual samples or perform any statistics on the rates of filtration. 
No spectra were acquired for unfiltered plasma samples. Due to a background of broad NMR 
peaks from macromolecules, spectra from unfiltered plasma are usually acquired using a 
spectral technique called CPMG spectroscopy which specifically filters out those broad 
signals. However, this would lead to T2 editing of signal intensities. Filtered plasma samples 
don’t contain proteins and therefore NMR spectra can be acquired using NOESY presat. 
However, some metabolites might be non-specifically bound to proteins and as a result get 
retained as part of the filtration process. Proteins together with water form a firm gel so that 
all the soluble particles might not get filtered and are thus lost. Compared to all other 
extraction methods, however, (acetonitrile, methanol chloroform), it is reproducible, protein 
removal is much better and the highest metabolite concentrations are achieved [154]. 
 
2.3.3.3 Experiments to ascertain buffer and TMSP concentration 
Sodium phosphate was used as the buffer to maintain a pH of 7 to minimize inter-sample 
chemical shift variations in the metabolite spectra. Experiments were performed with buffer 
concentrations of 20 mM, 50 mM, 100 mM and no buffer. The most reproducible results 
were obtained using 100 mM sodium phosphate buffer. Reproducibility was assessed by 
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visual inspection of the NMR spectra. No statistical tests were performed to analyse the 
degree of overlap between the individual peaks. TMSP (trimethylsilyl) propionate-2,2,3,3-d4 
; Cambridge Isotope Laboratories) was used to provide a reference for the spectra. Using a 
similar design as was used to optimize the buffer concentration, the optimal concentration for 
the TMSP was determined to be 500 µM. These concentrations were therefore used in all 
experiments. 
 
2.3.3.4 Experiments to ascertain tube diameters  
Plasma ultrafiltrates were mixed with 100 mM sodium phosphate buffer (pH 7), 500 µM 
TMSP and 5% D2O (D2O (99.9% pure; GOSS Scientific Instruments Ltd, Essex, UK) to 
obtain the final solution.  
 
D2O was added as frequency reference to counterbalance short term magnetic field 
disturbances and to compensate for long term magnetic field drift both of which would 
contribute to broader resonance lines and reduce the resolution of the NMR spectra. 0.1% 
sodium azide was added to prevent bacterial growth in the samples. A plasma sample from a 
healthy volunteer was filtered and then mixed with this solution. The resulting sample was 
then divided into multiple aliquots. These samples were analysed in 5 mm and 1.7 mm 
cryogenically cooled probes. The 5mm probe was used for both the 3 mm and 5 mm NMR 
tubes (Figure 7). Since the peak resolution and sensitivity was highest for the 1.7 mm tube, a 
repeat NMR spectrum was obtained the following day for another aliquot to access the 
reproducibility of this experimental setup. This additional acquisition would firstly ascertain 
the stability of the sample if left at room temperature and secondly access the additional 
variability that would be introduced by the sample preparation. 
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The best peak resolution and sensitivity were obtained using the 1.7mm tube in the 1.7mm 
cryoprobe with the Bruker 600 spectrometer as shown below. These spectra were adjusted to 
have a similar signal to noise ratio so that the differences seen were not due to an upscaling 
effect. 
 
Most likely the improved sensitivity comes from the special coil design of the 1.7 mm probe 
which leads to a very high Q factor of the probe. Also, the dynamic range of this probe is 
possibly larger due to the very small volume that needs to be shimmed. The superiority of the 
shim also means that T2’ relaxation (apparent transverse relaxation due to B0 field 
inhomogeneities) is minimised leading to sharper lines hence increasing resolution. 
 
NMR tubes used were ordered from the manufacturer’s webpage in batches of 96 tubes (part 
no. 112272). The probe specification at installation using the standard sucrose sample was 
signal: noise ratio of 234: 1. The resolution was 34% (splitting of the anomeric proton) and 
water hump was 24.0/29.4 Hz. 
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Figure 7 NMR spectra from varying tube diameters and probes 
 
These specifications were used for all the plasma and tissue NMR experiments.  
2.4 Sample collection for tissue 
2.4.1. Time intervals 
2.4.1.1. Patients with oesophago-gastric malignancies 
Two sets of tissue samples were obtained from each patient. 
 
1. The first sample was collected at the time of staging endoscopy carried out under 
general anaesthetic immediately prior to staging laparoscopy. Three to four biopsies 
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were collected both from tumour and normal mucosa. For oesophageal SCC and 
Siewert Types 1 and 2 AC, control normal mucosa was the squamous mucosa at least 
5cm proximal to the beginning of the tumour. For Siewert Type 3 tumours, control 
normal mucosa was mucosa from the body of the stomach at least 5cm distal to the 
distal margin of the tumour. Finally, for distal and body gastric cancers, control 
normal mucosa was the columnar mucosa from the body or upper stomach at least 
5cm proximal to the beginning of the tumour. 
 
2. The second sample was collected immediately after resectional surgery. As soon as 
the specimen was obtained, it was transported fresh to the histopathology department. 
A consultant histopathologist with a special interest in oesophago-gastric cancer was 
pre informed about its arrival to avoid delays in processing the specimen. Sections 
were obtained in a standard way. Four sections of cancer tissue (each weighing 
approximately 60 mg) were taken from the specimen. If any Barrett’s mucosa was 
visualised, four additional sections were taken from this tissue. Four sections of 
control normal mucosa (each weighing approximately 60 mg) were collected from the 
sites as described for the staging endoscopies. 
 
2.4.1.2. Patients with non-dysplastic Barrett’s 
All these patients had three to four biopsies of Barrett’s mucosa collected at the time of 
endoscopy (in addition to quadrantic biopsies within a local Barrett’s surveillance 
programme). These adjacent sections of mucosa were sent for histopathology. At the same 
time three to four biopsies of normal oesophageal squamous mucosa at least 5 cm proximal to 
the Barrett’s mucosa were also collected. 
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2.4.1.3. Patients with known high grade dysplastic Barrett’s   
These patients had three to four biopsies of high grade dysplasia collected at the time of 
endoscopy along with histologically confirmed adjacent sections of mucosa. At the same time 
three to four biopsies of normal oesophageal squamous mucosa at least 5cm proximal to the 
Barrett’s segment were also collected. 
 
2.4.1.4. Other patients  
This group comprised of patients with a diagnosis of Gastro Intestinal Stromal Tumours 
(GIST). All these patients had three to four tumour biopsies collected at the time of 
endoscopy along with control mucosa. The control mucosa was the normal oesophageal 
squamous mucosa in the case on oesophageal or junctional GIST and the gastric mucosa in 
the case of gastric GIST.  
 
2.4.1.5. Controls 
All control patients had three to four biopsies of endoscopically normal oesophageal 
squamous mucosa collected at the time of endoscopy. 
 
2.4.2. Sample aliquots 
Endoscopic biopsies were collected in Eppendorf vials. All biopsies from the cancer tissue 
were placed in a single pot. Normal mucosa was collected in a separate container. If 
additional tissues from a visible Barrett’s segment were collected, these were placed in 
separate Eppendorf vials and labelled by distance of the endoscope from the incisor teeth.  
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Each tissue section collected from the resection specimen was placed in a separate Eppendorf 
vial and labelled appropriately. 
 
2.4.3. Sample transport and storage 
All tissue Eppendorf vials were placed on ice and then transported to a -80°C freezer. This 
strategy of slow freezing was based on general principles regarding tissue viability and less 
formation of intra-cellular ice [155-157] when cooling occurs at around 1oC/min. While this 
can be further minimized by the addition of a cryoprotectant (such as glycerol or  DMSO 
[158]), NMR interference from cryoprotectants meant that they were not used.  
 
2.4.4. Measures to create comparable samples.  
All resectional specimens were obtained by a consultant histopathologist. Transport, 
examination of the specimens, selection of the biopsy sites and specimen procurement took 
up to 40 minutes. Following this, the specimens were transported in ice and stored on a -80°C 
freezer. This additional step took a maximum of 10 minutes. In addition, there was a warm 
ischaemia time that the tissues were likely to have experienced at the time of resection. This 
was estimated to be between 10 and 30 minutes depending on the type of resection. 
 
To minimise bias and maximise comparability between operative and endoscopic biopsies, 
the latter were kept on ice for one hour before they were transferred to a -80°C freezer. 
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2.4.5. Experiments to optimize a protocol for tissue freezing  
Pilot experiments using surplus tissue obtained at the time of resectional surgery were carried 
out to see what differences existed in NMR spectra between slow and rapidly frozen tissues. 
Sections of tissue were halved. One set of samples were snap-frozen (Snap freezing is the 
process by which samples are lowered to temperatures below -70°C very rapidly. We used 
liquid nitrogen to achieve this in our optimisation experiments) and the other placed on ice 
for 10 minutes before both were transferred to a -80°C freezer. They were subsequently 
extracted and analysed. There were no appreciable differences in the spectra obtained from 
these paired tissues. Subsequently, on performing statistical analysis (PCA – principal 
component analysis), these tissues separated according to the clinic-pathologic factors (type 
of tissue) rather than the method of extraction. Subsequently, all resectional tissues were 
therefore immediately placed on ice for transport before being stored at -80oC. 
 
2.4.6. Extraction of tissue 
Methanol chloroform extraction originally described by Bligh and Dwyer was chosen as the 
extraction method to prepare samples for NMR data acquisition [159]. This was preferred 
over using tissue samples directly (magic angle spinning - MAS) on the basis that:  
1. Methanol chloroform extraction results in 3 fractions from each tissue –a top polar 
phase that contains the metabolites, a middle protein phase and a bottom non polar 
phase where most of the lipids accumulate. As a result, each of these parts can be used 
separately to perform various analyses on the same tissue biopsy. On the contrary, 
although MAS does not result in destruction of the tissue, repeated freeze-thaw cycles 
coupled with high spinning speeds (4kHz) damage the structural integrity of the 
tissues, making them unsuitable for further analysis. 
75 
 
2. Methanol/chloroform/water extraction performs better than single organic solvent 
extractions as far as yield and reproducibility of the hydrophilic metabolites as well as 
recovery of the hydrophobic metabolites is concerned [160]. 
 
The technique of methanol chloroform tissue extraction for use in nuclear magnetic 
resonance (NMR) spectroscopy- and mass spectrometry (MS)-based metabolomics has been 
previously optimised by Wu et al. [160]. Tissues were first prepared for homogenisation with 
a Precellys®-24 ceramic bead-based homogeniser (Stretton Scientific Ltd., UK). All solvents 
(methanol, chloroform and water) were kept on ice at 4ºC. 8 µl/mg of methanol and 2.5 
µl/mg of water was added to each Precellys tube (larger volumes of solvents were used for 
tissue masses more than 15 mg. This was subsequently compensated for at the time of 
reconstitution of the sample for analysis). Tubes were placed in the Precellys 24 homogeniser 
for two 10s bursts at 6400 rpm. The homogenised mixture was pippeted into a clean 1.8ml 
glass vial using a Pasteur pipette. 8µl/mg of chloroform and 4 µl/mg of water were 
subsequently added to each vial. The vials were vortexed at full power for 30s each and left 
on ice for 10 mins. They were then centrifuged at 1800 g (3000 rpm) at 4ºC for 10 mins. 
 
This resulted in the formation of three separate layers. The polar fraction was divided into 3 
aliquots (25 µL x 2 and 400 µL) and dried in a centrifugal evaporator (SpeedVac®) along 
with the protein fraction and stored at -80°C. The non-polar extracts were collected in glass 
vials, left in solution and frozen on the basis that that long term storage of dried lipids can 
result in denaturation [161]. 
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2.4.7 Reconstitution of the polar extracts for NMR analysis  
Dried polar extracts were reconstituted using a solution of 100mM sodium phosphate buffer 
(pH 7), 500 µM TMSP, 5% D2O and 0.1% sodium azide. The adjusted weight of each tissue 
in the polar aliquots was calculated (adjusted weight = original weight * polar aliquot 
volume/ total volume of polar extract). This weight was then diluted by a factor of five to 
produce a minimum volume of 40 µL to suffice for preparation of the sample for NMR. For 
very small volumes, a higher dilution factor was used. The additional dilution was 
compensated for during the acquisition of the NMR spectra by increasing the number of 
acquired transients. Thus a minimum of 512 transients and a maximum for 8192 transients 
were acquired for the tissue to accommodate for discrepancies in weights.    
 
2.5 NMR data acquisition 
The majority of the data were acquired on a 600 MHz UltraShield plus Bruker magnet with a 
4-channel Bruker Avance III console using a low volume cryogenically cooled probe (30 µl 
sample volume). This spectrometer was also equipped with a sampleJet autosampler thus 
enabling high throughput for large studies. During storage in the sample changer, samples 
were maintained at 6°C prior to analysis. Before the samples were inserted into the magnet 
they were equilibrated for 2 minutes at a temperature of 15°C. The probe was then 
automatically tuned and matched for each sample, followed by automatic shimming 
(shimming is a procedure to make the magnetic field as homogenous as possible across the 
sample) and automated pulse calibration (pulse calibration is the determination of the length 
of the 90º pulse for a given RF field strength) for each sample [162]. Plasma samples were 
acquired using 256 transients.  Prior to acquisition, 16 steady state scans were acquired for 
each spectrum. The spectral width was set to 7288 Hz for all spectra. The water resonance 
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was suppressed using the NOESY presat [163] pulse program which employs saturation 
during the 4 second interscan relaxation delay as well as during a 10 ms NOESY mixing 
time. A total of 32768 data points was acquired leading to an acquisition time of 2.25s.  
 
Hadamard 2D-TOCSY experiments were performed on a 800 MHz Oxford Instruments 
magnet equipped with a 4-channel Varian INOVA console. This spectrometer is equipped 
with a HCN 5mm z-PFG cryogenic probe with enhanced 13C and 1H sensitivity. Hadamard 
spectroscopy is a fast method for the acquisition of multidimensional NMR spectra where the 
indirect dimensions are acquired in the frequency domain rather than the time domain in 
conventional multidimensional NMR spectroscopy by using polychromatic selective pulses. 
All desired frequencies are irradiated at the same time, but the phases of the different 
frequencies are encoded in a Hadamard matrix. As a consequence each frequency in the 
indirect dimension contributes to every NMR acquisition and is deconvoluted by multiplying 
the 1D-NMR spectra with a Hadamard matrix [164]. 
 
2.6 Data processing 
Nuclear magnetic resonance data were processed using NMRLab [165] and MetaboLab [166] 
in the MATLAB (The Math Works, Inc., Natick, MA) programming environment.  
 
FIDs were apodised using an exponential window function with 0.3 Hz line broadening and 
zero filled to 32768 data points prior to Fourier transformation. NMR spectra were 
automatically phase corrected using baseline properties close to the TMSP signal and outer 
baseline regions [166]. All spectra were automatically referenced to the TMSP resonance (0.0 
ppm) of the first spectrum.  
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NMR spectra were then aligned to the TMSP signal and spline baseline correction was 
performed. Water and TMSP signals were then excluded. Total spectral area scaling was 
performed after exclusion of water and TMSP signals to remove differences due to sample 
concentration. The NMR spectra were then realigned using a cross correlation algorithm as 
implemented in NMRLab software. A generalised log transformation was applied to enhance 
small signals in the spectrum [80]. This glog transformation was performed using the 
following equation: 
 
The parameters used were: λ=10-7 , x0=0.005 and α=1. 
The spectra were bucketed to a bin width of 0.003ppm 41.465 x 10-3ppm (8 data points per 
bin).   Data were subsequently exported as a PLS dataset. 
 
2.7 Statistical analysis 
Multivariable statistical analyses were performed in PLS-Toolbox (Version 5.2; Eigenvector 
Research, Manson, WA). This software takes its name from the Partial Least Squares (PLS) 
regression method; a supervised multivariate analysis that is used in many regression 
applications [71]. Further statistics were performed on the data set using the statistics toolbox 
in MATLAB. These included the Mann Whitney U test (non-parametric equivalent of 
unpaired t test), Chi square test and Spearman correlation to examine the relationships 
between variables. 
 
Unsupervised principal component analysis (PCA) and supervised Partial least squares 
discriminant analysis (PLS-DA) were performed for each of the models. The loadings were 
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further improved by performing an orthogonal PLS-DA. Once the data had been imported 
into PLS toolbox, the x block variables (spectra) were pre-processed using mean centring. No 
pre-processing was performed for the y block variables (class vector). The Venetian blind 
algorithm was used for cross validation unless specified otherwise. 
 
2.7.1 PCA 
PCA (Principal Component Analysis) reduces the dimensionality of the data to just a few 
principal components that account for a large amount of the total variance between all of the 
NMR spectra. The results are presented in terms of scores and loadings plots. A scores plot 
summarises the similarities and differences between each of the NMR spectra. Each data 
point on the scores plot represents one sample. Thus the distance between any two data points 
indicates the degree of similarity or dissimilarity between those two samples.  
 
To perform a principal component analysis, the data has to be mean centred. This means, that 
for each value of the x axis (ppm value of the bucketed data in case of NMR spectra) the 
mean value is determined from all samples and is then removed from all samples. This 
procedure is then repeated for each binned data point in the data set. This produces a data set 
whose mean is zero. The covariance matrix is then calculated. Since the covariance matrix is 
square, it can be diagonalised and the eigenvectors and eigenvalues for this matrix are then 
calculated. An eigenvector can be defined as a non-zero vector that, after being multiplied by 
the matrix, remains parallel to the original vector. The eigenvalue is the factor by which the 
eigenvector is scaled when multiplied by the matrix. During a principal component analysis, 
the eigenvectors are ordered with respect to their eigenvalues in descending order, so that the 
first principal component belongs to the eigenvector with the largest eigenvalue. Each 
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principal component is a weighted linear combination of all signal intensities at their 
respective chemical shifts. This information can be visualized in a loadings plot. Thus if two 
groups of samples are separated by the first principal component, then the loadings plot for 
this principal component is an expression of the signals that are producing this metabolic 
difference [167]. The final data is then prepared by keeping only the eigenvectors of interest. 
The eigenvectors describing the separation between different groups don't need to belong to 
the first principal component as the first principal component can contain variations coming 
from biological noise (e.g. blood plasma samples from a heterogenous patient group with 
differences in their fasting status). 
 
2.7.2 PLS-DA 
Partial Least Squares Discriminant Analysis (PLS-DA) is a supervised method used to 
improve the separation between groups of observations. For this analysis, the data analysis 
algorithm is provided with information on which sample belongs to which class. It then 
rotates the principal component in a way that a maximum separation between the classes is 
obtained. However, because of this additional information fed into the computer algorithm, 
the resulting model has to be verified by a cross validation procedure (e.g. venetian blinds 
(2.7.4.1) or leave one out (2.7.4.2)  
 
At the end a discriminant analysis is performed which gives an estimate how much the 
different groups overlap and which can be used when using the established model to analyse 
unknown samples to ascertain the group of the unknown sample. In general the separation 
between the classes is better when using PLS-DA compared to PCA, however one needs to 
be cautious to not over-fitting the data and not introducing a bias by wrong class assignments. 
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Quite often the first two latent variables (LV, the equivalents to principal components of 
PCA) contribute to the maximum class separation. As a result the loading vectors can be 
unclear and it can be complicated to extract metabolites which separate the different classes 
from them. 
 
2.7.3 OPLS-DA 
Orthogonal Partial Least Squares Discriminant Analysis overcomes this problem by rotating 
the LV's of PLS-DA in a way that the sample separation becomes orthogonal and the first 
latent variable is sufficient to produce the separation seen on two latent variables in PLS-DA. 
In this way OPLS-DA is an extension combining the strengths of PLS-DA and Soft 
independent modeling of class analogy classification [168]. In terms of results prediction, 
OPLS-DA is identical to PLS-DA modeling. The primary beneﬁt of OPLS-DA lies in the 
ease of interpretation, especially in the multi-class case. This is achieved by the separate 
modeling of predictive and class-related variation in the x-matrix through the identiﬁcation of 
y-orthogonal variation. Although there no predictive performance advantage of OPLS-DA 
over PLS-DA, its interpretation is much more superior. 
 
2.7.4 Cross Validation 
Cross validation is a technique to access the generalisability of the results generated as a 
result of the analysis. An ideal cross validation would consist of a training set where the 
results are obtained and multiple validation sets to validate those results. This can be 
performed statistically by employing various algorithms. The aim of all of these techniques is 
to use part of the dataset for training and other data points for validation. Cross-validation 
was performed by applying the “Venetian blind” algorithm when the total sample size for the 
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model was greater than 20. For smaller samples sizes, the “leave one out” algorithm was 
used.  
 
2.7.4.1 Venetian Blind algorithm 
For the venetian blind algorithm, each test set is determined by selecting every ‘n’th object in 
the data set, starting at objects numbered 1 through n. The number of splits/ datasets is equal 
to the square root of the total number of objects [169].  
 
2.7.4.2 Leave one out algorithm 
Leave one out algorithm is more conservative than the Venetian blind algorithm and as a 
result reserved for datasets with a sample size of less than 20. Here, each single object in the 
data set is used as a test set [169]. Thus the process is repeated n times till all of the 
observations have been used once as the validation set. 
 
2.7.5 ROC curve 
A ROC (Receiver Operating Characteristic) curve is a graphical plot of the sensitivity vs. 1-
specificity. The best possible prediction method yields a point in the upper left corner of the 
ROC space, representing 100% sensitivity and 100% specificity. A completely random guess 
creates a point along a diagonal line (the so-called line of no-discrimination from the left 
bottom to the top right corner).  Visual inspection of the scores plot and the area under the 
ROC curve was used to determine the strength of a model. 
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ROC curves were calculated using plsdaroc matlab function provided by the pls toolbox. 
These were generated using internal cross validation (2.7.4.1, 2.7.4.2). 
 
Once a good model had been obtained (a ROC score of more than 0.7 if possible), peaks 
contributing significantly to the loadings were integrated. This was performed by centering 
each of the peaks in question individually and then integrating the points. Univariate analysis 
was then performed. 
 
2.8 Assignment of peaks 
The loadings obtained from the various models were exported as a Bruker format file to 
enable viewing in Chenomx for the purposes of peak assignment. Chenomx NMR Suite 
software (Professional edition, version 5, Chenomx, Edmonton, AB, Canada) is a software 
package capable of identifying and quantifying individual compounds based on their 
respective signature spectra. Once a provisional assignment had been made for the peaks with 
the largest contribution in the loadings, these peaks were assigned for the NMR spectra using 
Chenomx.  
 
Once a list of the identifiable peaks for all the models had been prepared, the spectra were 
interrogated for those peaks. Differences in loadings that were not visually recognised as 
spectral differences were discarded. Metabolites that behaved in a consistent fashion across 
most models were selected for further analysis. The resultant metabolites from tissue and 
plasma were then cross referenced to obtain a list of metabolites that were synchronously 
elevated or reduced is tissue or plasma. Selection of metabolites of interest has been further 
explained in section 3.6. 
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An HSQC (Heteronuclear single-quantum correlation spectroscopy) 2D spectrum was 
obtained for a pooled tissue sample to enable assignment of metabolites in two dimensions 
using Amix (v. 3.7, Bruker Biospin). Similar to Chenomx, Amix is a software package 
capable of identifying and quantifying individual compounds based on their respective 
signature spectra. We used the Amix software to characterise the metabolites visualised in the 
HSQC spectra. Subsequently, more HSQC spectra were acquired to correctly characterise the 
metabolites of interest. The advantage of an HSQC spectrum is that it adds additional 
information by combining the 1H and 13C chemical shifts. 
 
In a 2D-HSQC spectrum every proton bound 13C nucleus gives rise to one signal in the 
spectrum. But instead of one chemical shift axis due to the multidimensional nature of the 
spectrum, there are now two chemical shift axes, one showing the chemical shift of the 
proton (typically between 0 and 10 ppm at the proton frequency of 600MHz) and the indirect 
axis showing the chemical shift of the directly bound 13C nucleus (typically recorded to cover 
between 0 and 160ppm at the carbon frequency of 150MHz). Due to the independence of the 
proton and 13C chemical shifts overlapping peaks in the 1D-NMR spectrum can often be 
resolved when spread over two dimensions. 
 
2.9 Statistical total correlation spectroscopy (STOCSY) 
STOCSY identifies highly correlated peak intensities in a series of spectra. This can lead to 
identification of peaks from the same molecule and hence aid molecule identification [170]. 
Although correlations are usually large within the same molecule, STOCSY aids correlation 
to other molecules. More importantly it can help to identify functionally correlated 
metabolites and thus aid in a pathway based approach. Identification of lower or even 
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negative correlations can lead to identification of substances in the same metabolic pathway 
whose concentrations are interdependent or under some common regulatory mechanism.  
 
2.10 Assessment of response to chemotherapy 
Assessment of response was made using two different techniques depending on whether the 
patients were receiving neoadjuvant chemotherapy followed by a potentially curative 
resection or only palliative chemotherapy. 
 
For patients undergoing neoadjuvant chemotherapy, assessment of response was made after 
histopathological assessment of the resected specimen using Mandard criteria [171]. For 
palliative patients, this was assessed using radiological RECIST criteria [172].  
 
2.10.1 Histopathological assessment 
This was made by assessment of the Tumour Regression Grade (TRG) in the resected 
histopathological specimen as described by Mandard et al. [171].  
 
Grade 1 (complete regression) – complete absence of histologically identifiable residual cancer 
and fibrosis extending through the different layers of the oesophageal wall, with or without 
granuloma.  
Grade 2 – presence of rare residual cancer cells scattered through the fibrosis.  
Grade 3 – increase in the number of residual cancer cells, but fibrosis still predominating.  
Grade 4 – residual cancer outgrowing fibrosis.  
Grade 5 – absence of regressive changes. 
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2.10.2 Radiological assessment 
This was performed using a combination of contrast enhanced CT (CECT) and with additional 
CT-PET or MRI as deemed necessary on clinical grounds. RECIST (Response Evaluation 
Criteria In Solid Tumours) criteria described by the task force formulated by European 
Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute 
[172] of the United States, and the National Cancer Institute of Canada Clinical Trials Group 
were used. 
 
Patients selected for palliative chemotherapy by the MDT underwent spiral/multi-slice CT, 
with oral contrast or water including chest, abdomen (pelvis optional) at baseline and within 
two weeks of completion of chemotherapy (Maximum slice width 5mm, IV contrast/venous 
phase). Baseline lesions were categorized as measurable (lesions that can be accurately 
measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with spiral 
CT scan or non-measureable (all other lesions, including small lesions <10 mm with spiral CT 
scan]). Serial measurements of target lesions were made following the detailed RECIST 
recommendations. 
 
Thus all patients whose response was classified according to the RECIST criteria in this study 
underwent a CT scan of the chest, abdomen and pelvis at the time of diagnosis and within two 
weeks of completion of chemotherapy 
 
Evaluation of target lesions.  
Complete response – the disappearance of all target lesions. 
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Partial response – at least a 30% decrease in the sum of the longest diameter of target lesions, 
taking as reference the baseline sum longest diameter. 
Progressive disease – at least a 20% increase in the sum of the longest diameter of target 
lesions, taking as reference the smallest sum longest diameter recorded since the treatment 
started or the appearance of one or more new lesions. 
Stable disease – neither sufficient shrinkage to qualify for partial response nor sufficient 
increase to qualify for progressive disease, taking as reference the smallest sum longest 
diameter since the treatment started. 
 
Evaluation of non target lesions.  
Complete response – the disappearance of all nontarget lesions 
Incomplete response/stable disease – the persistence of one or more non target lesion(s) 
Progressive disease – the appearance of one or more new lesions and/or unequivocal 
progression of existing nontarget lesions. 
 
2.10.3 Calculation of overall response 
In both Mandard and RECIST, the various response grades were collapsed into two  categories 
to increase the numbers of samples in each group and  identify major differences that 
characterised any degree of response 
 
Mandard stage was therefore classified as responders and non responders, where responders 
consisted of patients with TRG 1,2,3 and non responders consisted of patients with TRG 4,5. 
For RECIST staging,  patients were classified as complete responders, partial responders and 
non responders. Complete and parital responders were then grouped together as responders. 
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2.11 Statistical modelling 
Samples were divided into different comparator groups to address the various aims of the 
study. These are described below. 
 
2.11.1 Plasma modelling 
1. Controls vs. gastro-oesophageal adenocarcinoma 
Plasma samples from control patients were compared with pre-treatment (samples from 
patients undergoing neo adjuvant treatment) samples, pre-surgery (patients only 
undergoing resection) samples from patients with resectable gastro-oesophageal 
adenocarcinoma and pre-treatment plasma samples from patients with advanced gastro-
oesophageal adenocarcinoma undergoing palliative chemotherapy. 
 
The aim of this model was to see if it was possible to discriminate between plasma of 
patients with cancer and those without and evaluate profiles in the plasma of cancer 
patients which could be potentially used as biomarkers.  
 
2. Non-dysplastic Barrett’s vs. oesophageal adenocarcinoma types 1,2 
Plasma samples from patients with non dysplastic Barrett’s oesophagus were compared 
with pre-treatment (for patients undergoing neo adjuvant treatment) samples, pre surgery 
(patients only undergoing resection) samples and pre-treatment plasma samples from 
patients with advanced oesophageal adenocarcinoma (types 1,2) undergoing palliative 
chemotherapy. 
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The aim of this model was specifically examine the differences between plasma profiles 
of patients with pre neoplastic disease i.e. non-dysplastic Barrett’s vs. patients with frank 
malignancy. Success of this model could enable us to develop plasma markers of 
neoplastic progression. 
 
 
3. Overall response 
Pre chemotherapy plasma from responders (patients with TRG 1-3 or response on 
RECIST) was compared with non responders (patients with TRG 4-5 or no response on 
RECIST). Only patients with oesophageal adenocarcinoma types 1,2 were included in 
this analysis. 
 
The aim of this model was to identify profiles in plasma that would enable prediction of a 
sub-group of patients who were more likely to respond to chemotherapy. 
 
4. Stage on N (Table 1) 
For this model, only plasma samples from patients not receiving chemotherapy were 
considered. Pre-surgery plasma samples and samples from patients undergoing palliative 
treatment without chemotherapy were thus included in the analysis. Patients with 
adenocarcinoma (oesophageal, gastric, distal gastric) were included. In the operated 
patients, N stage was determined from histopathology of the resected specimen. For 
patients undergoing palliative treatment, the highest N stage recorded for any 
investigation was considered. Patients were classified as node negative (N0) or node 
positive (N1). 
 
90 
 
The aim of this model was to enable identification of profiles in plasma that could 
diagnose locally advanced disease. It would also serve as a validation for any potential 
biomarkers that are identified for cancer since the candidate biomarker should increase 
with increasing burden of disease. 
 
 
5. Stage on T (Table 1) 
For this model, only plasma samples from patients not receiving chemotherapy were 
considered. Pre-surgery plasma samples and samples from patients undergoing palliative 
treatment without chemotherapy in patients with adenocarcinoma (oesophageal, gastric, 
distal gastric) were included. 
 
T stage was determined from histopathology of the resected specimen or in patients 
undergoing palliative treatment, the highest T stage recorded for any investigation was 
considered. Patients were then classified as having T1 or T2 disease; or T3 or T4 disease 
to separate tumours confined within the wall of the organ from those with full-thickness 
involvement. 
 
The aim of this model was to enable identification of profiles in plasma that could 
diagnose locally advanced disease. It would also serve as a validation for any potential 
biomarkers that are identified for cancer since the candidate biomarker should increase 
with increasing burden of disease. 
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6. ‘Bacon and egg’ model 
Plasma samples at 3 time points from the 5 healthy volunteer controls were divided into 5 
groups (one group per individual) to access the intra individual variation versus the inter-
individual variation between subjects. This model was named ‘bacon and egg’ since the 
metabolomic profile of an individual changes due to various environmental influences 
like fasting, type of food, or medications. The aim of this was to provide proof of 
principle that NMR analysis could distinguish between any two healthy individuals and 
that metabolomic changes in blood during chemotherapy in a patient were not merely 
experimental variations.  
 
2.11.2 Tissue modelling 
 
1. Normal squamous mucosa vs. normal gastric columnar mucosa 
Tissue biopsies of normal oesophageal squamous mucosa from control patients and from 
the normal squamous mucosa of patients with oesophageal SCC or Oesophageal AC 
(types 1,2) were compared with normal columnar tissue biopsies of gastric mucosa from 
patients with junctional AC (type 3) and patients with body or distal gastric 
adenocarcinoma. The aim of this model was to demonstrate the ability of NMR in 
differentiating between two normal tissue types before attempts were made in 
differentiating between normal and cancer mucosa. 
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2. Normal squamous mucosa vs. oesophageal adenocarcinoma type 1,2 
Paired normal oesophageal squamous mucosa biopsies were compared with biopsies from 
adenocarcinoma in patients with Oesophageal AC (types 1,2) (both pre- and post- 
treatment). 
The aim of this model was to identify profiles in cancer mucosa that were different from 
normal mucosa and thus evaluate their role as a potential biomarker. Differing metabolite 
profiles would also help gaining an insight into the differing metabolism in these tissues. 
  
3. Normal squamous mucosa vs. Barrett’s mucosa in the presence of a cancer  vs. 
oesophageal adenocarcinoma types 1,2 
Samples from those patients with oesophageal adenocarcinoma (types 1,2) who also had 
morphologically identified Barrett’s were included in this analysis. Three comparative 
groups were therefore created. This included patients both pre and post treatment. 
The aim of this model was to validate the differences that were seen in model 2 and 
evaluate if there were sequential differences in the candidate biomarkers in these three 
tissues. 
 
4. Non dysplastic Barrett’s vs. Barrett’s mucosa in the presence of a cancer   
Tissue samples of Barrett’s mucosa from patients who were undergoing surveillance with 
no histologic evidence of dysplasia were compared with Barrett’s mucosa from patients 
with evidence of oesophageal adenocarcinoma type 1,2 adjacent to the Barrett’s mucosa. 
 
The aim of this model was identify tissue profiles that would be altered in dysplasia and 
thus enable development of biomarkers that could potentially identify a group of patients 
with non-dysplastic Barrett’s who were more likely to progress to dysplasia or carcinoma. 
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5. Overall response 
Pre-chemotherapy cancer tissue biopsies from responders (patients with TRG 1-3 or 
response on RECIST) were compared with non responders (patients with TRG 4-5 or no 
response on RECIST). Only patients with oesophageal adenocarcinoma type 1,2 were 
included in this analysis. 
 
The aim of this model was to identify profiles in cancer tissue that would enable 
prediction of a sub-group of patients who were more likely to respond to chemotherapy. 
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RESULTS 
3.1 Demographics 
258 participants were recruited. The breakdown was as follows. 
 
Name of Group Number of participants 
Oesophago-gastric malignancy 137 
Benign non dysplastic Barrett’s oesophagus 9 
High grade dysplasia of the oesophagus 4 
Gastro intestinal stromal tumours 2 
Controls patients with symptomatic GORD or dyspepsia 101 
Healthy volunteer controls 5 
 
Table 3 Distribution of participants recruited for the study 
 
3.1.1 Patients with oesophago-gastric malignancy 
137 patients had oesophago-gastric malignancy. The mean age of these patients was 66 years 
(range 31-87 years). 123 of these patients were Caucasian, seven were Asian and seven were 
Afro-Carribean. More than 75% were males (105 vs. 32). 103 of these patients were deemed 
fit for curative treatment and had a curable stage while 34 were treated with a palliative intent 
(these patients were either unfit or had a stage that was deemed incurable). Further 
breakdown of these patients is as follows. 
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Oesophago-gastric malignancy 
Oesophageal AC (type 1,2) 71 
Oesophageal AC (type 3) 12 
Body/ distal gastric AC 33 
Oesophageal SCC 21 
Total 137 
 
Table 4 Distribution of patients according to type of cancer 
 
 
The stage specific breakdown of these patients is as follows (this radiologic stage and 
represents the stage at the completion of their pre-op tests) 
 
Stage Number of patients 
Tx N0 M0 3 
T1/2 N0 M0 14 
T1/2 N1 M0 7 
T3/4 Any N M0 89 
Any T Any N M1 23 
Staging not available 1 
 
Table 5 Stage specific breakdown of patients 
 
Of the 137 patients, 48 did not receive chemo/ radiotherapy; 3 patients received radiotherapy 
only and 86 patients received chemotherapy. 
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The breakdown of the various chemotherapeutic agents used is as follows: 
Chemotherapy regime Number of patients 
CF 35 
ECF 3 
ECX 35 
ECX (with bevacizumab/ oxiplatin/ radiotherapy) 4 
EOX 5 
MIC 2 
Agent not known 2 
 
Table 6 Breakdown of patients according to type of chemotherapy received 
 
 
CF – Cisplatinum, 5-Fluorouracil 
ECF – Epirubicin, Cisplatinum, 5-Fluorouracil 
ECX – Epirubicin, Cisplatinum, Xeloda (Capecitabine)  
EOX – Epirubicin, Oxaliplatin, Xeloda (Capecitabine)  
MIC – Mitomycin, Ifosfamide and Cisplatinum 
 
3.1.2 Patients with Non dysplastic Barrett’s oesophagus  
Nine patients had non dysplastic Barrett’s oesophagus and were recruited from a surveillance 
endoscopy programme. Their mean age was 57 years (range 39-69 years). There were eight 
males, all were Caucasian. 
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3.1.3 Patients with high grade dysplasia of the oesophagus 
Three patients with high grade dysplasia had columnar HGD and one patient had squamous 
HGD. Their mean age was 67 years (range 58-80 years). Three were males and all were 
Caucasian. 
 
3.1.4 Controls patients with GORD symtoms or dyspepsia 
101 control patients were recruited from endoscopy clinics. These patients had presented with 
symptoms suggestive of GORD or dyspepsia, had not taken a proton pump inhibitor for two 
weeks and had endoscopically normal appearances. Their mean age was 60 years (range 23-
94 years). Nearly half of these patients were males (n=48), 89% were Caucasians, 7% Asian, 
3% Afro-Caribbean and one patient was mixed race. 
 
3.1.5 Comparison of patients with oesophago-gastric malignancy vs. controls 
There was a statistically significant difference in the age distribution between the two groups 
(p=0.001; Mann Whitney U test). There was also a statistically significant difference in the 
distribution of sex between the two groups (p<0.001; Chi square test). There was no 
difference in the distribution of ethnicity between the two groups (p=0.77; df = 2; Chi square 
test). 
 
24 patients of 137 patients with cancer did not have any pre existing co morbidities compared 
with 29 of 101 patients in the Control group. 13 patients with cancer were not taking any 
regular medications compared with 20 patients in the Control group.  
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The mean co morbid conditions in the cancer group were 1.93 ± 1.12 (range 1 – 6). The mean 
number of medications was 3.96 ± 2.26 (range 1 – 9). The commonest co morbid condition 
was hypertension (n=35) followed by diabetes (n=14). The most common medication in this 
group was proton pump inhibitors.  
 
The mean co morbid conditions in the control group were 2.24 ± 1.74 (range 1 – 10). The 
mean number of medications was 3.26 ± 2.9 (range 1 – 15). Similar to the oesophago-gastric 
group, the commonest co morbid condition was hypertension (n=24) followed by diabetes 
(n=10). The most common medication again was proton pump inhibitors. 
 
There was no statistically significant difference between the number of co morbid conditions 
in between the two groups (p= 0.597; Mann Whitney U test). However, not surprisingly, the 
oesophago-gastric group were taking more medications (p= 0.008; Mann Whitney U test). 
 
3.2 Quality control 
3.2.1 Plasma samples 
The blood samples were placed on ice immediately following collection. The mean time for 
transfer of blood samples on ice from patient to centrifuge was 98.4 ± 55 (range 9 – 249) 
minutes. 67.1% of the samples were processed within 2 hours of obtaining them. The total 
mean time including transfer, preparation of plasma to storage in a -80°C freezer was 118.4 ± 
56.7 (range 26 – 271) minutes.  
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3.2.2 Endoscopic biopsies 
All endoscopic biopsies were collected in Eppendorf vials and immediately placed on ice. 
The mean time from taking the biopsy to be placed on ice was 1.1 ± 11 (range 0 – 130) 
minutes. The mean time from taking the biopsy to a definitive storage in a -80°C freezer was 
65.9 ± 47.4 (range 5 – 233) minutes. 72.5% of the samples reached definitive storage within 
90 minutes. The mean weight of the endoscopic biopsies was 13.5 mg (range 5.1 – 18 mg). 
 
3.2.3 Resectional tissue 
The mean time from obtaining the tissue in theatre, transport to the histopathology laboratory, 
obtaining and placing the specimens on ice was 22.1 ± 11.4 (range 6 – 62) minutes. The mean 
total time from obtaining the specimen to storage in a -80°C freezer was 34.1 ± 11.7 (range 
17 – 76) minutes. The mean weight of the resectional biopsies was 45.3 mg (range 14.2 – 53 
mg). 
 
No attempts were made to elucidate any metabolic differences between the endoscopic and 
resectional biopsies. All attempts were made to equilibrate for differences in time to freezing 
(section 2.4.4) and the sample sizes (section 2.4.7). Based on the various analyses performed 
in this study, it is unlikely that there were any systematic differences in resectional and 
endoscopic biopsies. 
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 3.3 NMR plasma results 
Spectra were obtained for all 391 plasma samples. 9 spectra were excluded from the analysis 
due to a poor quality of the spectrum. As a result, the final tissue analysis was performed on 
383 spectra. 
  
Model 1. Controls vs. gastro-oesophageal adenocarcinoma 
A total of 165 samples were entered into this model. Of these, 97 were from control patients 
and 68 were from patients with gastro-oesophageal adenocarcinoma.  
11.09% of the variability was explained by the first latent variable. Latent variables are 
variables that are not observed but are mathematically calculated from the data (Page 79). 
The use of two first latent variables was suggested by the cross validation, accounting for 
21.85% of the variability. To reduce the number of latent variables and to align the scores 
along the latent variables, orthogonal PLS-DA was then performed (Figure 9). Good 
discrimination was obtained using the first one latent variable with an area under the curve of 
0.8008 on performing a ROC analysis. 
 
Loadings obtained on the first latent variable were then exported to a Bruker format to enable 
display on the Chenomx software. A list of peaks was thus produced which were 
discriminatory on the first latent variable (Figure 10). 
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Figure 8 PLS-DA Model 1 plasma 
 
Crosses indicate patients with gastro-oesophageal adenocarcinoma and squares indicate 
control patients (patients with GORD symptoms or dyspepsia). 
102 
 
 
 
Figure 9 OPLS-DA Model 1 Plasma 
 
Crosses indicate patients with gastro-oesophageal adenocarcinoma and squares indicate 
control patients (patients with GORD symptoms or dyspepsia). 
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Figure 10 Loadings plot for LV1 Model 1 Plasma obtained from OPLS-DA 
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Model 2. Non-dysplastic Barrett’s vs. oesophageal adenocarcinoma type 1,2 
A total of 49 samples were entered into this model. Of these, 10 were from patients with non 
dysplastic Barrett’s oesophagus and 39 were from patients with oesophageal adenocarcinoma 
type 1,2. 
 
8.22% of the variability was explained by the first latent variable. The use of two first latent 
variables was suggested by the cross validation, accounting for 13.4% of the variability. To 
reduce the number of latent variables and to align the scores along the latent variables, 
orthogonal PLS-DA was then performed (Figure 11). Use of two latent variables accounting 
for a total of 13.4% of the variability was suggested by the cross validation. Poor 
discrimination was obtained using the first latent variable with an area under the curve of 
0.5051 on performing a ROC analysis. 
105 
 
 
Figure 11 OPLS-DA Model 2 Plasma 
 
Crosses indicate patients with oesophageal adenocarcinoma type 1,2 and squares indicate 
patients with non dysplastic Barrett’s oesophagus. 
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Model 3. Overall response  
A total of 24 samples were entered into this model. Of these, 8 were plasma samples from 
responders and the remainder from non responders. As explained earlier, this model 
compared pre chemotherapy plasma from responders (patients with TRG 1-3 or response on 
RECIST) against non responders (patients with TRG 4-5 or no response on RECIST). There 
was very good concordance between response evaluation on Mandard criteria and RECIST 
staging. Only one patient differed with regards to response using the two approaches. In that 
case, the Mandard grade was used to classify the patient was used since it is regarded as the 
gold standard for accessing response.  
 
16.44% of the variability was explained by the first latent variable. The use of only the first 
latent variable was suggested by the cross validation (Figure 12). Good discrimination was 
obtained using the first one latent variable with an area under the curve of 0.7031 on 
performing a ROC analysis. 
 
The loadings obtained on the first latent variable were then exported to a Bruker format to 
enable display on the Chenomx software. A list of peaks was thus produced which were 
discriminatory on the first latent variable (Figure 13). 
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Figure 12 PLS-DA Model 3 Plasma 
 
Crosses indicate non responders (patients with TRG 4-5 or no response on RECIST) and 
squares indicate responders (patients with TRG 1-3 or response on RECIST). 
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Figure 13 Loadings plot for LV1 Model 3 Plasma 
 
Model 4. Stage on N 
A total of 23 samples were entered into this model. Of these, 9 were plasma samples from 
patients who had nodal stage of N0 and remainder had nodal status N1. 
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26.01% of the variability was explained by the first latent variable. The use of only the first 
latent variable was suggested by the cross validation (Figure 14). Good discrimination was 
obtained using the first latent variable with an area under the curve of 0.8413 on performing a 
ROC analysis. 
 
The loadings obtained on the first latent variable were then exported to a Bruker format to 
enable display on the Chenomx software. A list of peaks was thus produced which were 
discriminatory on the first latent variable (Figure 15). 
 
 
 
110 
 
 
Figure 14 PLS-DA Model 4 Plasma 
 
Crosses indicate patients with nodal stage N0 (node negative) and squares indicate patients 
with nodal stage N1 (node positive). 
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Figure 15 Loadings plot for LV1 Model 4 Plasma 
 
Model 5. Stage on T 
A total of 23 samples were entered into this model. Of these, 11 were plasma samples from 
patients who had T1 or T2 tumours and remainder had nodal status T3 or T4 tumours. 
 
30.53% of the variability was explained by the first latent variable. The use of only the first 
latent variable was suggested by the cross validation (Figure 16). Good discrimination was 
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obtained using the first latent variable with an area under the curve of 0.8182 on performing a 
ROC analysis. 
 
The loadings obtained on the first latent variable were then exported to a Bruker format to 
enable display on the Chenomx software. A list of peaks was thus produced which were 
discriminatory on the first latent variable (Figure 17). 
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Figure 16 PLS-DA Model 5 Plasma 
 
Crosses indicate patients with T stage 1 or 2 and squares indicate patients with T stage 3 or 4. 
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Figure 17 Loadings plot for LV1 Model 5 Plasma 
 
Model 6. ‘Bacon and egg’ model 
14 samples were entered into the model (one sample was excluded due to sub standard 
quality of spectrum).  
 
The ‘leave one out’ algorithm was used for cross validation. 12.37% of the variability was 
explained by the first latent variable. The use of first four latent variables was suggested by 
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the cross validation, accounting for 69.5% of the variability. However, visually, good 
separation was obtained the first three latent variables was achieved (Figure 18). Area under 
the curve for the five groups was 0.6364, 0.9697, 0.9091, 1 and 0.7273. 
 
Figure 18 PLS-DA Model 6 Plasma (LV1 vs. LV2 vs. LV3).  
The sample cluster for each volunteer has been highlighted with a solid circle.  
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3.4 NMR tissue results 
Spectra were obtained for all 333 tissues. 4 spectra were excluded from the analysis due to a 
poor quality of the spectrum. As a result, the final tissue analysis was performed on 329 
spectra. 
 
Model 1. Normal squamous mucosa vs. normal gastric columnar mucosa 
A total of 174 samples were entered into this model. Of these, 136 were tissue biopsies from 
normal squamous mucosa and the remainder were normal columnar mucosa biopsies. 
 
21.32% of the variability was explained by the first latent variable. The use of two first latent 
variable was suggested by the cross validation, accounting for 24.22% of the variability 
(Figure 19). To reduce the number of latent variables and to align the scores along the latent 
variables, orthogonal PLS-DA was then performed (Figure 20). Use of 2 latent variables 
accounting for a total of 24.54% of the variability was suggested by the cross validation. 
Good discrimination was obtained using the first one latent variable with an area under the 
curve of 0.9478 on performing a ROC analysis. 
 
A number of metabolites were noticed to be significantly different in between the two classes 
on the loadings. On comparison of the spectra at the chemical shift for those metabolites, 
these differences were visually confirmed in the processed spectra without glog 
transformation (Figure 21, Figure 22). 
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Figure 19 PLS-DA Model 1 Tissue (LV1 vs. LV2) 
Crosses indicate tissue biopsies from normal columnar mucosa and squares indicate biopsies 
from normal squamous mucosa. 
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Figure 20 OPLS-DA Model 1 Tissue 
Crosses indicate tissue biopsies from normal columnar mucosa and squares indicate biopsies 
from normal squamous mucosa. 
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Figure 21 Levels of alanine in normal squamous tissue and normal columnar tissue on Model 
1 Tissue  
 
Figure 22 Level of lactate in normal squamous tissue and normal columnar tissue on Model 1 
Tissue  
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(These were figures were for illustration purposes only and as such no attempts were made to 
draw out any inferences from the differing levels of these metabolites). 
Model 2. Normal squamous mucosa vs. oesophageal adenocarcinoma type 1,2 
A total of 116 samples were entered into this model. Of these, 59 were tissue biopsies from 
normal squamous mucosa and the remainder were biopsies from the cancer mucosa. 
 
29.75% of the variability was explained by the first latent variable. The use of only the first 
latent variable was suggested by the cross validation (Figure 23). Good discrimination was 
obtained on the scores plot with an area under the curve of 0.9176 on performing a ROC 
analysis. 
 
The loadings obtained on the first latent variable were then exported to a Bruker format to 
enable display on the Chenomx software. A list of peaks was thus produced which were 
discriminatory on the first latent variable (Figure 24). 
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Figure 23 PLS-DA Model 2 Tissue 
Crosses indicate tissue biopsies from normal squamous mucosa and squares indicate biopsies 
from cancer mucosa in patients with oesophageal adenocarcinoma type 1,2. 
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Figure 24 Loadings plot for LV1 Model 2 Tissue 
 
Model 3. Normal squamous mucosa vs. Barrett’s mucosa in the presence of a cancer vs. 
oesophageal adenocarcinoma type 1,2 
A total of 32 samples were entered into this model. Of these, 11 were tissue biopsies from 
normal squamous mucosa, 11 were tissue biopsies from morphologically identified Barrett’s 
mucosa and the remaining 10 spectra were from biopsies of the cancer mucosa. Only 10 
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samples were available for the third class as one spectrum had been excluded in the 
beginning due to substandard spectral quality. 
 
PLS-DA was performed in the PLS toolbox. 28.44% of the variability was explained by the 
first latent variable. The use of three latent variables was suggested by the cross validation, 
predicting a total variability of 51.39%. On examination of the scores plot, only lv1 and lv2 
were important in discriminating between the 3 classes. As a result, only 2 latent variables 
accounting for a total of 49.07% of the variability were used for this model (Figure 25). The 
scores plot thus obtained differentiated between normal squamous mucosa and Barrett’s/ 
cancer mucosa on lv1 and between Barrett’s mucosa and cancerous mucosa on lv2. The ROC 
value for the prediction of normal squamous mucosa was 1. The ROC values for the 
prediction of Barrett’s mucosa and cancerous mucosa were 0.7013 and 0.6955 respectively.  
 
For the identification of metabolites discriminating in between these three classes, two sub-
models were created comparing normal squamous mucosa vs. Barrett’s mucosa and Barrett’s 
mucosa vs. cancerous mucosa. The comparison between normal squamous mucosa and 
cancerous mucosa has already been made in model 2. 
 
For the submodel comparing normal squamous mucosa vs. Barrett’s mucosa, cross validated 
PLS-DA suggested the use of two latent variables accounting for a total variability of 
45.18%. To reduce the number of latent variables and to align the scores along the latent 
variables, orthogonal PLS-DA was then performed. Use of 2 latent variables accounting for a 
total of 45.18% of the variability was suggested by the cross validation. Good discrimination 
was obtained using the first one latent variable with an area under the curve of 1 on 
performing a ROC analysis. 
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For the submodel comparing Barrett’s mucosa vs. cancerous mucosa, cross validated PLS-
DA suggested the use of two latent variables accounting for a total variability of 37.08%. To 
reduce the number of latent variables and to align the scores along the latent variables, 
orthogonal PLS-DA was then performed. Use of 2 latent variables accounting for a total of 
37.08% of the variability was suggested by the cross validation. Good discrimination was 
obtained using the first one latent variable with an area under the curve of 0.7636 on 
performing a ROC analysis. 
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Figure 25 PLS-DA Model 3 Tissue (LV1 vs. LV2) 
Crosses indicate tissue biopsies from normal squamous mucosa, triangles indicate biopsies 
from Barrett’s mucosa and squares indicate biopsies from cancer mucosa in patients with 
oesophageal adenocarcinoma type 1,2. 
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Model 4. Non dysplastic Barrett’s vs. Barrett’s mucosa in the presence of a cancer   
A total of 20 samples were entered into this model. Of these, 7 were tissue biopsies from non 
dysplastic Barrett’s mucosa and 13 biopsies were of the Barrett’s mucosa from patients who 
had oesophageal adenocarcinoma type 1,2. 
 
The ‘leave one out’ algorithm was used for cross validation. 29.21% of the variability was 
explained by the first latent variable. The use of only the three latent variables was suggested 
by the cross validation accounting for a total variability of 43.09% (Figure 26). To reduce the 
number of latent variables and to align the scores along the latent variables, orthogonal PLS-
DA was then performed. Good discrimination was obtained on the scores plot on lv1 with an 
area under the curve of 0.9121 on performing a ROC analysis. 
 
The loadings obtained on the first latent variable were then exported to a Bruker format to 
enable display on the Chenomx software. A list of peaks was thus produced which were 
discriminatory on the first latent variable (Figure 27). 
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Figure 26 PLS-DA Model 4 Tissue (LV1 vs. LV2) 
Crosses indicate tissue biopsies from non dysplastic Barrett’s mucosa in patients undergoing 
surveillance endoscopy for Barrett’s oesophagus and squares indicate biopsies Barrett’s 
mucosa in patients with oesophageal adenocarcinoma type 1,2. 
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The following peaks were considered discriminatory for the two classes. 
 
 
Figure 27 Loadings plot for LV1 Model 4 Tissue 
 
Model 5. Overall response 
A total of 25 samples were entered into this model. Of these, 12 were tissue biopsies from 
cancerous mucosa in patients who eventually responded to neo-adjuvant chemotherapy and 
13 tissue biopsies were from cancerous mucosa in patients who did not respond to neo-
adjuvant chemotherapy. 
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22.01% of the variability was explained by the first latent variable. The use of only the first 
latent variable was suggested by the cross validation (Figure 28). Good discrimination was 
obtained on the scores plot with an area under the curve of 0.6987 on performing a ROC 
analysis. 
 
The loadings obtained on the first latent variable were then exported to a Bruker format to 
enable display on the Chenomx software. A list of peaks was thus produced which were 
discriminatory on the first latent variable (Figure 29). 
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Figure 28 PLS-DA Model 5 Tissue 
Crosses indicate non responders (patients with TRG 4-5 or no response on RECIST) and 
squares indicate responders (patients with TRG 1-3 or response on RECIST). 
 
The following peaks were considered discriminatory for the two classes. 
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Figure 29 Loadings plot for LV1 Model 5 Tissue 
 
3.5 Univariate analysis of metabolites 
Univariate analysis was performed for all metabolites that were identified using the Chenomx 
software. Univariate analysis was performed using non-parametric tests (Mann Whitney U 
test) on the integrals of the individual metabolites. The first step before performing the 
integration for any peak was to align that individual peak. Following this the limit of 
integration was defined to include the entire peak except if there was overlap with a 
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neighbouring signal in which case the minimum between the two peaks was used as a 
boundary for integration. For metabolites with peaks at several chemical shifts, the resonance 
at the chemical shift with least overlap with other peaks was selected. 
 
3.5.1 Results of univariate analysis in plasma (tabulated results in appendix) 
On univariate analysis of the integration of metabolites, the largest numbers of statistically 
differing metabolites were seen in Model 1. Four metabolites were significant in model 4 
followed by three metabolites each in model 2 and model 3. However there was no 
metabolite that was consistently significant in models 2,3 and 4. Nine metabolites were 
statistically significant in model 5 on univariate analysis. Since model 6 only compared 
plasma samples at 3 time points from the 5 healthy volunteer controls, no attempts were made 
to identify any metabolites for univariate analysis. 
 
3.5.2 Results from tissue (tabulated results in appendix) 
On univariate analysis of the integration of metabolites, the largest numbers of statistically 
differing metabolites were seen in Model 1. Since model 1 had only been constructed to 
demonstrate the ability of NMR in differentiating between two normal tissue types, no 
attempts were made to explore these differences any further.  
 
In model 2 of tissue, again a large number of metabolites were statistically significant.  
Model 3 of tissue compared three different types of tissue and thus a non parametric anaylsis 
was not performed. Five metabolites were statistically significant in model 4 followed by 
only one metabolite in model 5 on univariate analysis. 
133 
 
3.6 Selection of metabolites of interest 
Selection of metabolites for further discussion was made on the basis the results of the 
multivariate analysis (PLS-DA) followed by the statistical significance on univariate anaylsis. 
These differences were then confirmed by visual inspection of overlaid spectra (without g log 
transformation) for the various models.  
 
Inspection of the loadings plots for the various models in plasma analysis revealed that 3-
hydroxybutyrate was elevated in plasma from cancer patients (Model 1 plasma). It was higher 
in non responders (Model 3 plasma), node positive disease (Model 4 plasma) and full 
thickness tumours (Model 5 plasma) compared to responders, node negative and early local 
disease. When cross referenced with the univariate anaylsis, the level of 3-hydroxybutyrate 
was indeed higher in plasma from cancer patients (p<0.05; Mann Whitney U test; Model 1). 
Increased levels of 3-hydroxybutyrate were also noticed in cancer mucosa as compared to 
paired normal control mucosa (Model 2 tissue). These differences were further confirmed on 
visual inspection of the spectra (Figure 43, Figure 44, Figure 45, Figure 46). 
 
No other consistent differences were obtained from plasma based on multivariate analysis. 
Similarly, none of the metabolites were statistically significant in all the models on univariate 
analysis. 
 
Inspection of the loadings plots for tissue revealed that hypoxanthine was higher in cancer 
mucosa as compared to normal mucosa (Model 2 tissue). In model 3 it was noticed that levels 
of hypoxanthine in Barrett’s mucosa associated with cancer were in between those of normal 
mucosa and cancer mucosa. This difference was also noted on univariate analysis for model 2 
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(p<0.0001; Mann Whitney U test). These differences were eventually confirmed on 
inspection of the spectra (Figure 31, Figure 32). 
 
In model 2, both choline containing metabolites and valine were significant on multivariate 
and univariate analysis. Similarly, in model 4 choline containing metabolites were noticed on 
multivariate and univariate analysis. None of the other metabolites were consistently seen 
both on multivariate and univariate analysis and confirmed on inspection of the spectra. 
 
STOCSY was also performed for most of the models in tissue to identify any significant 
correlations or anti-correlations between metabolites. This has been further discussed in 
section 3.7.3. 
 
3.7 Differences in metabolite levels for plasma and tissue 
3.7.1 Hypoxanthine 
Hypoxanthine was elevated in biopsies from adenocarcinoma in patients with oesophageal 
AC (type 1,2) (both pre and post treatment) compared with paired normal oesophageal 
squamous mucosa in Tissue model 2. This difference was first observed on the loadings. On 
comparison of the spectra at the chemical shift for hypoxanthine, these differences could be 
visually appreciated in the processed spectra without glog transformation (Figure 31). To 
confirm this result an NMR spectrum was acquired for a tissue sample which had high levels 
of hypoxanthine before and after it had been spiked to 100 mM exogenous hypoxanthine 
(Figure 30). 
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Figure 30 NMR spectra of a tissue homogenate with and without a hypoxanthine spike (100 
mM) 
 
Figure 31 Level of hypoxanthine in normal squamous tissue and paired cancer mucosa 
(model 2).  
The faded lines indicate individual spectra while the dark line indicates the mean spectrum 
for that class. 
136 
 
These differences were further examined by analysing the difference in the hypoxanthine 
levels in spectra from normal squamous mucosa and Barrett’s mucosa in the presence of the 
spectrum of the cancer mucosa from the same patient. Levels of hypoxanthine in Barrett’s 
mucosa were confirmed to lie in between those for normal squamous mucosa and cancer 
mucosa. 
 
Figure 32 Levels of hypoxanthine in normal squamous tissue, paired Barrett’s and cancer 
mucosa (model 3)  
 
 
Elevated levels of hypoxanthine were observed in pre treatment biopsies of cancer mucosa 
from responders compared to non responders (model 5) on the loadings plot. These 
differences were also seen the spectra (Figure 33), although not as pronounced as the 
previous two models. 
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Figure 33 Level of hypoxanthine in pre chemotherapy cancer mucosa from responders and 
non responders (model 5). 
 
 
The levels of hypoxanthine in plasma were very low. As a result an analysis of the 
differences between the various groups could not be performed. 
 
To confirm the findings seen on NMR, further experiments were performed as described 
below. 
 
3.7.1.1 Hypoxanthine levels in tissue (MS metabolomics) 
Metabolomics Profiling with ESI was carried out using a maXis™ ultra-high resolution Q-
TOF mass spectrometer coupled to HPLC separation.  HPLC was carried out using a Dionex 
UltiMate™ 3000 (Thermo Scientific)  which consists of a capillary pump, binary pump, and 
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autosampler  whereby sample was maintained at 4°C in a thermostated autosampler before 
injection of 2 µl on to a capillary reversed-phase column with dimensions 300- m ID 150-mm 
length. The flow rate was set to 0.4 ml/min with solvent A composed of water: 0.1% formic 
acid and solvent B composed of acetonitrile: 0.1% formic acid in positive ion mode. For 
negative ion mode data, 5 mM ammonium acetate was substituted for the formic acid in 
solvents A and B. The sample was eluted initially with Solvent A for 7 minutes and then with 
a gradient climbing towards 100% B over 4.25 minutes which was then held for a further 
3.75 minutes.  Sodium formate was incorporated was injected as an external calibrant. 
 
To reduce systematic errors associated with instrumental drift, samples were run in a 
randomly selected order. Data were collected in ESI mode in separate runs operated in full 
scan mode with ranges set from 50 to 600 m/z.  Capillary voltage was 4,800 V with a scan 
rate of 0.5 scan per second; the nebulizer pressure was set 0.4 Bar, with a dry gas temperature 
of 4 L/min.  The datasets were automatically recalibrated and all relevant features were 
extracted in the profile analysis 2.0 (Bruker Daltronics) processing software.  Data was 
bucketed to 1 min/0.3 Mz ranges before normalization to total sum of buckets. A Principal 
Component Analysis (PCA) of the processed data was than generated. Putative identification 
of metabolites was possible using accurate HMDB database [173, 174] and subsequently 
confirmed where possible by MS/MS fragmentation. Fragmentation patterns were compared 
not just to HMDB database but also to published fragmentation data as generated by Lu et al. 
[175]. 
 
Hypoxanthine was elevated in biopsies from adenocarcinoma in patients with oesophageal 
ADC (type 1,2) (both pre and post treatment) compared with paired normal oesophageal 
squamous mucosa in Tissue model 2 (Figure 34).  
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Figure 34 Level of hypoxanthine in normal squamous tissue and paired cancer mucosa 
(model 2) on MS metabolomics 
Circles indicate tissue biopsies from normal squamous mucosa and triangles indicate biopsies 
from cancer mucosa in patients with oesophageal adenocarcinoma type 1,2. 
 
 
Much similar to the results from NMR, the level of hypoxanthine in Barrett’s mucosa in the 
presence of a cancer was thus confirmed to be in between those for normal squamous mucosa 
and cancer mucosa (Figure 35). 
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Figure 35 Levels of hypoxanthine in normal squamous tissue, paired Barrett’s and cancer 
mucosa (model 3) on MS metabolomics 
Circles indicate tissue biopsies from normal squamous mucosa, crosses indicate biopsies 
from Barrett’s mucosa and triangles indicate biopsies from cancer mucosa in patients with 
oesophageal adenocarcinoma type 1,2. 
 
3.7.1.2 Hypoxanthine phosphoribosyl transferase activity 
Total cellular RNA was extracted using TRIZOL (Invitrogen). Frozen biopsies were 
homogenised directly in the reagent and further processed following the supplier’s 
instructions. The resulting total RNA was then further purified on RNeasy Mini columns 
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(Qiagen) according to the supplied protocol. RNA quality was checked on an Agilent 
Bioanalyser and only RNA with a RNA integrity number (RIN) of 6.0 or more was used. 
200 ng of this total RNA was worked up following the manufacturers’ procedures using an 
Ambion WT Expression kit then fragmented and labelled using an Affymetrix WT Terminal 
Labelling Kit. 
 
Labelled RNA was hybridised to Affymetrix Human Gene 1.0 ST arrays followed by 
washing and staining on an Affymetrix FS450 fluidics station. Arrays were scanned using an 
Affymetrix Scanner 3000 7G. Affymetrix Command Console was used for instrument control 
and data acquisition. All procedures were according to standard Affymetrix protocols. 
 
 
Figure 36 Hx-PRTase activity as indicated by gene expression analysis (Affymetrix) for 
normal squamous mucosa and paired cancer mucosa. Patient number represents the 
anonimsed biopsy tag. 
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It was seen the hypoxanthine phosphoribosyltransferase activity was higher in cancer mucosa 
compared to the adjacent normal mucosa (Figure 36). This supports the observation of higher 
levels of hypoxanthine in cancer tissues seen in metabolomics. 
 
Furthermore, a similar pattern to that seen in hypoxanthine in tissue was again observed in a   
those patients who had the trio of normal, Barrett’s and cancer mucosa (Figure 37). 
 
Figure 37 Hx-PRTase activity as indicated by gene expression analysis (Affymetrix) for 
normal squamous mucosa, and paired Barrett’s and cancer mucosa 
 
3.7.2 3-hydroxybutyrate 
3-hydroxybutyrate was elevated in biopsies from adenocarcinoma in patients with 
Oesophageal ADC (type 1,2) (both pre and post treatment) compared to paired normal 
oesophageal squamous mucosa biopsies in Tissue model 2. This difference was first observed 
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on the loadings. On comparison of the spectra at the chemical shift for 3-hydroxybutyrate, 
these differences could be visually appreciated in the processed spectra without glog 
transformation (Figure 41).  
 
To confirm the presence of 3-hydroxybutyrate in the samples, a 2D Hadamard 1H,1H-
TOCSY-NMR spectrum was obtained on 3-hydroxybutyrate (chemical shift 1.22 ppm) 
(Figure 38). The selective pulses used had Gaussian shape using a selection bandwidth of 16 
Hz. The spectra used longitudinal encoding and a DIPSI2 mixing sequence of 0, 70 and 120 
ms for the TOCSY transfer [176]. 256 transients were acquired for 7 selected frequencies. 
 
Figure 38 2D Hadamard 1H,1H-TOCSY-NMR spectrum on a tissue homogenate with 
suspected high level of 3-hydroxybutyrate 
The doublet at 1.2ppm was selected for the Hadamard and the magnetisation was transferred 
using TOCSY to the quartet at 2.3ppm amd the doublet at 4.15ppm. 
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Further confirmation of the presence of 3-hydroxybutyrate was obtained by acquiring an 
NMR spectrum for a tissue sample which had high levels of 3-hydroxybutyrate before and 
after it had been spiked to 500 µM exogenous 3-hydroxybutyrate (Figure 39, Figure 40). 
 
Figure 39 NMR spectra of a tissue homogenate with and without a 3-hydroxybutyrate spike 
(500 µM) 
 
 
Figure 40 NMR spectra of a tissue homogenate with and without a 3-hydroxybutyrate spike 
(500 µM) 
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Figure 41 Level of 3-hydroxybutyrate in normal squamous tissue and paired cancer mucosa 
on Model 2 Tissue 
 
The difference in the levels of 3-hydroxybutyrate for tissue models 3, 4 and 5 was not 
visualised on the spectra. 
 
3-hydroxybutyrate was elevated in pre treatment plasma samples from patients with 
oesophageal adenocarcinoma (type 1,2) compared with plasma from control patients in model 
2. This difference was first observed on the loadings. On comparison of the spectra at the 
chemical shift for 3-hydroxybutyrate, these differences could be visually appreciated in the 
processed spectra without glog transformation (Figure 42, Figure 43).  
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Figure 42 Level of 3-hydroxybutyrate in plasma from control patients and pre treatment 
plasma from patients with cancer Model 1 Plasma 
 
 
Figure 43 Level of 3-hydroxybutyrate in plasma from control patients and pre treatment 
plasma from patients with cancer Model 1 Plasma 
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Similarly, elevated levels of 3-hydroxybutyrate were noticed for pre treatment plasma 
samples from non responders versus pre treatment plasma samples from responders (model 3) 
(Figure 44). On analysing the plasma samples longitudinally, the levels for 3-
hydroxybutyrate were higher following treatment for both responders and non responders. 3-
hydroxybutyrate was also elevated in plasma from patients with nodal disease N1 vs. plasma 
from patients with nodal disease N0 (model 4) (Figure 45) and plasma from patients with T 
stage T3, T4 vs. plasma from patients with T stage T1, T2 (model 5) (Figure 46). 
 
Figure 44 Level of 3-hydroxybutyrate in pre treatment plasma samples from responders and 
non-responders Model 3 Plasma 
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Figure 45 Level of 3-hydroxybutyrate in pre surgery plasma samples from patients not 
receiving neoadjuvant chemotherapy and plasma samples from patients undergoing palliative 
treatment without chemotherapy on Model 4 Plasma 
 
Figure 46 Level of 3-hydroxybutyrate in pre surgery plasma samples from patients not 
receiving neoadjuvant chemotherapy and plasma samples from patients undergoing palliative 
treatment without chemotherapy on Model 5 Plasma 
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3.7.3 Succinate and fumarate 
In most tissue models a positive correlation was seen between succinate and fumarate levels. 
However, for model 4 (dysplastic Barrett’s vs. non dysplastic Barrett’s), a reversed 
correlation was noticed between. To further confirm this result an NMR spectrum was 
acquired for a tissue sample before and after it had been spiked to 500 µM exogenous 
succinate and fumarate on two separate occasions (Figure 47, Figure 48).  
 
Figure 47 NMR spectra of a tissue homogenate with and without a fumarate spike (500 µM) 
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Figure 48 NMR spectra of a tissue homogenate with and without a succinate spike (500 µM) 
 
A STOCSY was then performed on each of the classes in this model. It was noticed that 
although for non dysplastic Barrett’s there was a positive correlation between succinate and 
fumarate (0.6615) (Figure 49); this correlation was negative for dysplastic Barrett’s (-0.4594) 
(Figure 50). These results were further confirmed on performing a Spearman correlation on 
the integrals of these metabolites. 
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Figure 49 STOCSY on non dysplastic Barrett’s tissue samples on Model 4 Tissue 
 
 
Figure 50 STOCSY on dysplastic Barrett’s tissue samples on Model 4 Tissue 
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Following this observation, STOCSY was performed on the three subclasses in model 3 for 
tissue (normal squamous mucosa vs. dysplastic Barrett’s mucosa vs. cancer mucosa). Similar 
results were obtained as for model 4. There was no correlation between succinate and 
fumarate for normal squamous mucosa (0.1368) (Figure 51) and cancer mucosa (-0.1325) 
(Figure 53). However, this correlation was stronger and negative for the dysplastic Barrett’s 
mucosa (-0.4678) (Figure 52). 
 
Figure 51 STOCSY on Normal squamous mucosa on Model 3 Tissue 
 
A positive correlation is indicated on the STOCY in red; no correlation in grey and negative 
correlation with blue. 
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Figure 52 STOCSY on dysplastic Barrett’s tissue samples on Model 3 Tissue 
 
 
Figure 53 STOCSY on cancer tissue samples on Model 3 Tissue 
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3.7.4 Resonance at 2.737 ppm (Metabolite X) 
An unassigned resonance at 2.737 ppm was observed to be highly elevated in dysplastic 
Barrett’s mucosa in Tissue model 3. The mean intensity of this peak in the paired normal 
squamous mucosa and cancer mucosa was much lower than for the dysplastic Barrett’s 
mucosa (Figure 54). 
 
Figure 54 Level of Metabolite X in normal squamous tissue, paired Barrett’s and cancer 
mucosa on Model 3 Tissue 
 
Following this observation, this peak was further examined in Tissue model 4, which 
compared Non dysplastic Barrett’s mucosa from patients undergoing Barrett’s surveillance to 
patients with dysplastic Barrett’s mucosa (patients who had Barrett’s mucosa associated with 
an adenocarcinoma). As in model 3, the mean intensity of the peak at 2.737 ppm was much 
higher in dysplastic Barrett’s mucosa compared to non-dysplastic Barrett’s mucosa (Figure 
55). 
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Figure 55 Level of Metabolite X in non dysplastic and dysplastic Barrett’s mucosa on Model 
4 Tissue 
 
The only peak matching the resonance of this peak in Chenomx was sarcosine, but this was 
confirmed not to be the case as the second peak for sarcosine at 3.6 ppm was not present in 
these spectra. This peak could not be assigned to a specific substance from public or 
commercially available databases. 
 
Following this a 2D 13C-HSQC was obtained to ascertain the carbon shift for this metabolite. 
It was confirmed to be 1H 2.737 ppm and 13C as 41.34 ppm (Figure 56).  
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Figure 56 2D 13C-HSQC on a tissue sample with high concentration of Metabolite X 
 
The proton and carbon shifts for this molecule were determined as 1H 2.737 ppm and 13C 
41.34 ppm respectively. 
 
 For further exploration of this molecule a homonuclear 2D-1H,1H-TOCSY NMR spectrum 
was acquired. In a TOCSY pulse sequence magnetisation is transferred between different 
proton nuclei of the same molecule, which will lead to cross peaks in between atoms 
connected by a scalar coupling in the 2D spectrum. By investigating columns or rows of this 
spectrum all proton resonances belonging to one molecule can be identified.  
 
The 2D TOCSY spectrum was acquired at a field strength of 600.13 MHz. 16 transients were 
acquired for each FID after acquiring 16 steady state scans at the beginning of the 2D-NMR 
experiment. A total of 2048 data points for the direct and 256 data points for the indirect time 
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domain were acquired. The spectral width was set to 7211 Hz (12 ppm) for both dimensions. 
The inter-scan relaxation delay was set to 2s. A hard pulse power of 25 kHz was used while 
the DIPSI-2 sequence was executed at a B1 field strength of 6250 Hz for a mixing time of 60 
ms.  
 
A detailed inspection of the 2D-TOCSY spectrum did not reveal any further resonances 
belonging to the 1H resonance at 2.737 ppm (Figure 57).   
 
Figure 57 Homonuclear 2D-1H,1H-TOCSY NMR spectrum with high concentration of 
Metabolite X 
158 
 
To exclude contamination following methanol chloroform extraction, a 1D spectrum was 
obtained from tissues extracted using phosphate buffer solution and extraction buffer. The 
peak was again visualized at 2.737 ppm, confirming the presence of this metabolite in tissue.  
 
This peak was also present in all plasma samples at 2.738 ppm (Figure 58). 
 
Figure 58 Level of Metabolite X in all plasma samples 
 
 
3.7.5 Unassigned resonance at 3.72 ppm (Metabolite Y) 
A peak at 3.72 ppm was observed to be highly elevated in non dysplastic Barrett’s mucosa in 
Tissue model 4 (Figure 59). The mean intensity of this peak in the dysplastic Barrett’s 
mucosa was much lower. Once again, an assignment for this peak could not be obtained by 
searching the available databases. 
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Figure 59 Level of Metabolite Y in non dysplastic and dysplastic Barrett’s mucosa on Model 
4 Tissue 
 
Following this a 2D 1H,13C-HSQC NMR spectrum with a very large number of data points 
for the indirect dimension was obtained in order to ascertain the carbon shift for this 
metabolite with very high precision. It was confirmed to be 1H 3.72 ppm and 13C as 72.3 ppm 
(Figure 60). 
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Figure 60 2D 1H,13C-HSQC NMR of a tissue sample with high concentration of Metabolite Y 
The proton and carbon shifts for this molecule were determined as 1H 3.72 ppm and 13C 72.3 
ppm respectively. 
 
 
For further exploration of this molecule a homonuclear 2D-1H,1H-TOCSY NMR spectrum 
was acquired. However, a detailed inspection of the 2D-TOCSY spectrum didn’t reveal any 
further resonances belonging to the 1H resonance at 3.72 ppm (Figure 61).   
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Figure 61 Homonuclear 2D-1H,1H-TOCSY NMR spectrum with high concentration of 
Metabolite Y 
 
 
Due to lack of an identity for this metabolite, it was again postulated that this might be the 
result of contamination during the methanol chloroform extraction. While considered 
unlikely on the basis that the quantity of metabolite Y should have been proportional to the 
weight of the tissue extracted (as the methanol and chloroform were added in proportion to 
the weight), and this was not the case, to completely exclude this as possibility, a 2D 13C-
HSQC was obtained from tissue extracted using phosphate buffer solution. The resulting 
spectrum was overlaid with the high resolution 2D 1H,13C-HSQC spectrum that was acquired 
earlier (Figure 62). The overlay confirmed the presence of this metabolite at the same 
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resonance in the tissue extracted using phosphate buffer solution. It was concluded that this 
was a metabolite found in the tissue, although it could not be further defined. 
 
Figure 62 Overlay 2D 1H,13C-HSQC 
 
2D 13C-HSQC was obtained from tissue extracted using phosphate buffer solution 
(represented in red) overlaid with 1H,13C-HSQC NMR of a tissue sample with high 
concentration of Metabolite Y (represented in blue). 
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DISCUSSION 
Numerous biomarkers that identify disease, cancer stage and prognosis have been described 
in the last 20 years. Some of these reflect exciting discoveries at the genome level. A few are 
currently used in standard clinical practice. These include CA 19.9 and CA 125 for diagnosis 
of pancreatic and ovarian malignancies,  prostate specific antigen for diagnosis, stage and 
prognostication in prostate cancer and carcino-embroyonic antigen (CEA) for monitoring 
colonic cancer as a means of identifying recurrence [177]. 
 
There have been major advances in treatments tailored to a specific predictor or gene 
signature. Markers have been described that can predict how a disease might respond to a 
particular treatment. In breast cancer, human epidermal growth factor receptor 2 (Her-2) 
overexpression predicts response to trastuzumab, the monoclonal antibody that blocks this 
receptor [178] and oestrogen receptor positivity predicts tamoxifen response [179]. In chronic 
myeloid leukaemia, a breakpoint cluster region–Abelson murine leukaemia oncogene (BCR–
ABL) translocation predicts response to imatinib mesylate [180]. Similarly for colonic 
cancer, mutations in KRAS predict response to epidermal growth factor receptor (EGFR) 
specific antibody therapy [181]. In lung cancer EGFR kinase domain mutations predict 
response to erlotinib or geftinib) [182] and in brain tumours EGFR mutations in the 
extracellular domain dictate response EGFR inhibitors [183]. Similar predictors that can be 
used to direct treatment for oesophageal adenocarcinoma have yet to be described. 
 
Despite these advances, genomic and more recently proteomic technologies, have failed to 
provide satisfactory information describing the aetiology, pathogenesis and outcome for 
many conditions.  Oesophageal adenocarcinoma has received relatively little attention, 
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relative to its importance as a cause of cancer death in the UK. The aim of the present study 
was to see if plasma and tissue metabolomics could shed any light on various aspects of this 
disease, its development from its precursor condition Barrett’s oesophagus and subsequent 
treatment. 
 
During this study, a number of metabolites were seen to be statistically significant on 
multivariate (PLS-DA) analysis or univariate (integrations). 3-hydroxybutyrate was 
significant both in plasma (multivariate and univariate) and tissue and has been discussed in a 
subsequent section. Other interesting metabolites identified in plasma included formate, 
glycerophosphocholine, lysine, pyruvate and valine.  
 
Formate has a distinctive chemical shift so preliminary identification was easy. However, it is 
only a singlet and therefore there was no definite assignment using 1D NMR spectras only. 
The only way to be certain was perform spiking experiments; however these were limited 
only to a few metabolites due to paucity of sample volumes. Lysine and valine are essential 
amino acids and as such differences could have been due to differences in protein degradation 
or transport processes into the cell and therefore changes wouldn't necessarily be metabolism 
related. The levels of pyruvate again can depend on actual nutritional state of person. 
Measurements of nutritional state were not performed for any of the patients in thus study so 
it would be difficult to comment on the levels of pyruvate. 
 
Hypoxanthine was noticed to be significant in tissue and has been discussed subsequently. 
After exclusion of model 1 (since it was not a clinically relevant model), only lactate and 
choline containing metabolites were significant in more than one model (two models each).   
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Lactate was statistically different in tissue models 2 and 4 on univariate analysis. A higher 
level was seen in normal tissue as compared to cancer mucosa (model 2) and in dysplastic 
Barrett’s as compared to non-dysplastic Barrett’s. It is difficult in the context of this study to 
comment on the differences in the levels of lactate. This is because of factors like variability 
from the time from biopsy to extraction and the warm ischaemia of the tissues, especially for 
the resectional specimens. During the warm ischaemia and to a lesser extent during the cold 
ischaemia, glycolysis is carrying on and thus levels of lactate may not accurately represent 
the presampling conditions. Lactate increases rapidly during hypoxia and ischaemia. Thus 
poorly vascularized tumours have a low intracellular pH as a result of increased lactate 
production. Increased rates of lactate production have been associated with a variety of 
neoplasms [143]. 
 
Choline containing metabolites were statistically different in models 2 and 4 of tissue. In 
model 2, a higher level of choline was seen in cancer mucosa as compared to normal mucosa 
and in dysplastic Barrett’s as compared to non-dysplastic Barrett’s in model 4. The term 
choline containing metabolites refers to choline, phosphocholine, phosphatidylcholine and 
glycerophosphocholine. These are key constituents of cell membranes.  Their levels are 
known to change during apoptosis and necrosis. 
 
Choline containing metabolites have been previously identified in numerous studies. 
Phospholipid metabolism has been investigated in breast cancer cells during exposure to the 
antimitotic drugs paclitaxel, vincristine, colchicine, nocodazole, methotrexate and 
doxorubicin using 31P NMR spectroscopy[184]. Phosphocholine to glutamate ratio has been 
shown to show the presence of oesophageal cancer in histologically-normal tissue [151]. 
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Choline and glycerophosphocholine have been identified in childhood brain tumours using 
both in vivo magnetic resonance spectroscopy (MRS) and ex vivo1H HR-MAS [185]. 
Thus the current project identified a number of metabolites that were either increased or 
reduced in a diseased state. Before making any conclusions about their use in clinical 
practice, the metabolism of the consistently observed metabolites needs to be discussed, so 
that any potential role in cancer can be appreciated. 
 
4.1 Hypoxanthine 
An elevated level of hypoxanthine was observed in cancer mucosa compared to control 
normal squamous mucosa from the same patients (Figure 31). More importantly, when a trio 
of samples were compared from patients with oesophageal adenocarcinoma who also had 
biopsies of their corresponding Barrett’s mucosa and normal squamous mucosa; the levels 
were lowest in the control mucosa and highest in the cancer mucosa (Figure 32). The findings 
of NMR were confirmed by similar observations from MS metabolomics of these samples. 
This finding was further supported by gene expression profiling of a limited number of 
tissues. These tissues were part of the larger sample group that was used for the NMR 
experiments. 
 
4.1.1 Hypoxanthine and its role in purine salvage 
Purine nucleotides are essential components of any cell comprising not just the raw material 
for the synthesis of DNA but also acting as vital cofactors for many different enzymatic 
reactions responsible for cell proliferation. Purine biosynthesis proceeds along two known 
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routes.  These include de novo synthesis and recycling of endogenous or exogenous purines 
through a salvage pathway (Figure 63). 
 
The de novo pathway for purine nucleotide synthesis leads to the formation of inosine 5’-
monophosphate (IMP) in ten metabolic steps. Hydrolysis of ATP is required to drive several 
reactions in this pathway. Overall, the de novo pathway for purine nucleotide synthesis is 
expensive in terms of moles of ATP utilized per mole of IMP synthesized. 
 
The salvage pathway involves the housekeeping protein hypoxanthine-guanine 
phosphoribosyl transferase (Hx-PRTase) which catalyses the addition of phosphoribosyl 
pyrophosphate to guanine or hypoxanthine to form guanosine monophosphate and inosine 
monophate respectively. In the absence of this pathway, hypoxanthine would proceed to form 
the waste product uric acid, through the formation of xanthine [186]. This is the congenital 
metabolic abnormality seen in Lesch-Nyhan syndrome where free purines (hypoxanthine and 
guanine) are oxidized by xanthine oxidase to uric acid which is sparingly soluble and causes 
gout [187]. 
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Figure 63 The purine Salvage pathway of purine synthesis 
This pathway involves the utilization of the housekeeping protein hypoxanthine-guanine 
phosphoribosyl transferase (Hx-PRTase) which catalyses the addition of phosphoribosyl 
pyrophosphate to guanine or hypoxanthine to form gaunosine and inosine respectively. 
 
The salvage pathways are used to recover bases and nucleosides that are formed during 
degradation of RNA and DNA, offsetting the potential waste of a vital resource. One of the 
other roles of purine salvage is that of enabling ingested purines or those synthesized in one 
tissue to be made available to other tissues [188].  Given its importance, it is not surprising 
that  the purine salvage pathway has been implicated in human cancer development [189]. In 
order to cope with rapid cell replication tumour cells use the more efficient purine salvage 
pathway for energy production and nucleic acid synthesis [190].  
169 
 
One important aspect of the salvage pathway would appear to lie in its ability to confer 
resistance to inhibitors of de novo nucleotide biosynthesis by salvage of extracellular 
nucleotides and nucleosides [191]. In a study by Natsumeda et al., it was noted that the 
activities of salvage enzymes of hypoxanthine and adenine (adenine 
phosphoribosyltransferase) were between 2 and 32 fold higher than that of 
amidophosphoribosyltransferase (a strictly de novo enzyme) in hepatomas, regenerating and 
differentiating livers [192]. It has long been known that inhibition of de novo synthesis leads 
to increased accumulation of substrates of the salvage pathway [193, 194]. The ability of cells 
to overcome the cytotoxicity of these  metabolites also appears to increase in parallel with 
malignancy [195]. One study suggested an important role for the salvage pathways of purine 
and pyrimidine biosynthesis in the increased resistance of the more tumourigenic cell lines 
[195]. In addition, circumvention of the inhibition of de novo pathway by an efficient salvage 
process may also confer a survival advantage to the cells by reducing or abolishing the effects 
of an anti metabolite [196]. The greater capacity of the purine salvage pathway than the de 
novo pathway, along with further rises in its activity in response to the drugs targeted against 
the de novo pathway highlights its likely importance [197]. Inhibition of purine nucleoside 
and base salvage could thus increase the anti proliferative effects of an antipurine 
chemotherapeutic agent.  
 
4.1.2 Activity of enzymes and metabolites of the salvage pathway in various cancers 
An increased level of hypoxanthine in plasma and a reduced level in urine has been 
previously demonstrated in patients with gastric and colonic carcinomas [198]. Recent 
metabolic profiling in colorectal cancer reveals the purine salvage pathway substitutes de 
novo synthesis in the progression of the disease [190] while earlier work by Rubie et al. has 
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demonstrated the overexpression of the Hx-PRTase gene in colorectal and other tumours 
[199]. 
 
In plasma from children with acute lymphoblastic leukaemia or non Hodgkin lymphoma, 
hypoxanthine levels have been reported to be higher than in healthy controls and these levels 
decreased after methotrexate administration [200]. An increased level of hypoxanthine in the 
urine has been noticed in mesothelioma transplanted nude mice. Moreover, the level of this  
metabolite was reduced following response to chemotherapy [201]. 
 
On the other hand, a reduced level of urinary hypoxanthine was reported by Yoo et al. in 
patients with non Hodgkin lymphoma. They reasoned that the level of hypoxanthine might be 
decreased due to consumption by tumour cells [202].  
 
Higher  levels of hypoxanthine-guanine phosphoribosyltransferase activity have been 
documented in tumours compared to peritumoural tissues [203]. Similarly, increased levels of 
adenosine deaminase and xanthine oxidase have been noticed in cancerous tissues compared 
to adjacent non-malignant tissues in human colorectal cancer [204]. A similar trend has been 
noticed in bladder cancer where xanthine oxidase activity is increased in patients with 
papillary and multiple tumours compared to the tumour free group. Adenosine deaminase 
activity was increased in patients with multiple and invasive tumours compared to patients 
with single and superficial tumours [205]. Elevated levels of  purine salvage pathway 
enzymes have also been reported in human osteosarcoma [206]. 
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4.1.3 Cancer drugs acting on purine metabolism 
5-FU belongs to a class of drugs known as anti metabolites. Chemotherapeutic 
antimetabolites are used to target key enzymes in the de novo purine and pyrimidine 
pathways [191]. The original hypothesis for the use of these drugs was that rapidly 
proliferating cells, i.e. tumour cells, would be more sensitive to these agents than normally 
dividing cells. However, it is now accepted that both acquired and inherent resistance to these 
drugs is more common in cancer cells compared to normal cells. 
 
The efficacy of 5-FU is limited by a lack of response achieving response rates of only 10-
20%  when used as a single agent [207, 208]. Attempts at biomodultaion of 5-FU to improve 
its efficacy led to the observation  that an excess of intracellular folate was necessary for the 
optimal inhibition of thymidylate synthatase and for an increased cytotoxic effect of 
fluorinated pyrimidines [209]. This observation led to the first clinical trial of 5-FU in 
combination with folinic acid in 1982 [210]. A subsequent meta-analysis confirmed that the 
response rate following this combination was statistically higher that after 5-FU alone [211].  
Methotrexate augments the actions of 5-FU by inhibiting dihyrofolate reductase and 
decreasing the folate pool required for pyrimidine biosynthesis [212]. A study by Fernandes 
et al. revealed a 25 fold increase in the inhibiton of soft agar colony formation of murine 
tumour cells when methotrexate preceded 5-FU [213].  
 
Over the years, it has become increasingly obvious that in order to attain reliable response 
rates for anti-metabolites, drugs need to target not only against the key enzymes of de novo 
pathways but also the salvage pathways that can otherwise circumvent the inhibition of a de 
novo pathway [191, 195, 214, 215]. 
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Dipyridamole is a reversible competitive nucleoside transport inhibitor. During experiments 
by Kinsella and Haran [195], it was noticed that dipyridamole could enhance 5-FU 
cytotoxicity by inhibiting thymidine salvage in cells in which the DNA-directed effects of 5-
FU predominated [209]. This was subsequently confirmed in human colon carcinoma cell 
lines in which inhibition of TS has been shown to be growth limiting at relatively low 
concentrations of 5-FU [216, 217]. Potentiation of the effect of 5-FU by dipyridamole has 
been shown in human colon cancer cell lines [218] where its addition increased toxicity of 5-
FU 3-fold. It was suggested that dipyridamole enhanced 5-FU toxicity by blocking salvage of 
thymidine. 
 
Encouraged by these results, Budd et al. conducted a phase 1 trial to evaluate the combination 
of dipyridamole, 5-FU and folinic acid patients with advanced refractory malignancy. The 
authors reported objective tumour responses in five  of 13 patients with breast cancer, and 
concluded that phase 2 trials of this combination were justified [219]. However, the results of 
a subsequent phase 2 trial were disappointing [220]. 
 
Most studies have mainly focussed on the inhibition of pyrimidine salvage by dipyridamole 
although a small number of studies have investigated the role of dipyridamole in the 
inhibition of purine salvage. Turner et al., looked at a novel antifolate, lometrexol (5,10-
dideazatetrahydrofolate) that  inhibits de novo purine biosynthesis. The authors noticed that 
co-incubation of lometrexol with hypoxanthine abolished its cytotoxicity. The addition of 
dipyridamole to this prevented hypoxanthine rescue and as a result, growth was inhibited by 
the combination of lometrexol, dipyridamole and hypoxanthine [221].  
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Chen et al., in a study to elucidate the role of dipyridamole induced methotrexate toxicity in 
an ovarian carcinoma cell line, concluded that dipyridamole potentiated the activity of 
methotrexate by inhibiting the salvage of hypoxanthine, and to a lesser extent, that of 
thymidine [222]. Thus there is some evidence to support the inhibition of hypoxanthine 
salvage by dipyridamole. 
 
However, even if the redeployment of existing inhibitors of the salvage pathway is 
unsuccessful, this research provides good evidence for further work in this direction. 
Effective inhibitors of a salvage pathway that works in epithelial tumours would represent a 
useful alternative to current chemotherapeutic regimens. 
 
4.2 Succinate and fumarate 
Fumarate was elevated in non dysplatic Barrett’s mucosa and succinate elevated in dysplastic 
Barrett’s mucosa. This finding was further investigated by performing a STOCSY on each of 
the classes in this model (Tissue model 4). This technique allows identification of highly 
correlated peak intensities. It was noticed that although for non dysplastic Barrett’s there was 
a positive correlation between succinate and fumarate (0.6615); this correlation was negative 
for dysplastic Barrett’s mucosa (-0.4594) (Figure 49; Figure 50). 
 
To further examine this finding, a STOCSY was performed on the more complex model 3 for 
tissue (normal squamous mucosa vs. Barrett’s mucosa in the presence of cancer vs. cancer 
mucosa) on each of the three subclasses. Similar results were obtained as for model 4. There 
was no correlation between succinate and fumarate for normal squamous mucosa (0.1368) 
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and cancer mucosa (-0.1325). However, this correlation was stronger and negative for 
dysplastic Barrett’s mucosa (-0.4678) (Figure 51; Figure 52; Figure 53). 
 
4.2.1 Succinate and its role in carcinogenesis. 
Succinate plays an important biochemical role within the energy generating mitochondria as a 
component of the citric acid cycle and its capability of donating electrons to the electron 
transport chain by the reaction: succinate + FAD → fumarate + FADH2.  This is catalysed by 
complex II of the mitochondrial Electron Transport Chain, also called Succinate 
Dehydrogenase (SDH).  In recent years, it has also been implicated in carcinogenesis. 
 
SDH is a housekeeping gene with a key bioenergetic role. However mutations in the gene 
encoding for SDH can cause cancer: mutations in subunits B, C or D of SDH specifically can 
lead to the development of human paraganglioma (HPGL) or phaeochromocytoma [223-225].  
 
Paragangliomas are typically benign tumours derived from neuronal ectoderm cells along the 
sympathetic or parasympathetic nervous systems [226]. In 2000, Baysal et al. discovered that 
the gene mutated in a particular HPGL syndrome associated with the 11q23locus (PGL1) was 
in fact SDHD (succinate-ubiquinone oxidoreductase subunit D) [223]. Following this initial 
discovery, it did not take long to identify the genes of two other HPGL-associated loci, PGL4 
(1p36) and PGL3 (1q21), to be SDHB (succinate-ubiquinone oxidoreductase subunit B) and 
SDHC (succinate-ubiquinone oxidoreductase subunit C), respectively [224, 225].  
 
Mutations in the SDH genes are associated not only with familial syndromes but are also 
observed in sporadic paraganglioma and in phaeochromocytoma, a subtype of paraganglioma 
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derived from catecholamine-secreting chromaffin cells, usually in the adrenal medulla [227]. 
The observation that loss of function of the SDH complex is mostly associated with 
paraganglioma, regardless of the SDH subunit involved, suggests that tumourigenesis 
because of these mutations stems from a common biochemical pathway. This is supported by 
the observation that mutations in either SDHB or SDHD result in the disintegration of the 
SDH complex and a complete loss of SDH enzymatic activity [228-230] 
 
A biochemical explanation of how SDH functions as  a tumour suppressor  was put forward 
in 2005 by Selak et al. who demonstrated how succinate that accumulates as a result of SDH 
inhibition, inhibits HIF-α prolyl hydroxylases in the cytosol [227].  This would in turn  lead 
to the stabilization and activation of the important transcriptions factor,  HIF-1α which would 
activate glycolysis [231]. 
 
A recent study examined the expression of SDH in colorectal cancer and analyzed the 
relationship among its expression, clinicopathological characteristics and prognosis. It also 
analyzed the relationship between SDH and HIF-1α. Some 336 colorectal tissue cores were 
examined using tissue microarray analysis by immunohistochemical analysis. It was noted 
that expression levels of SDHB in colorectal cancer were reduced compared with normal 
mucosa adjacent to the primary tumour. However there were no significant differences in the 
expression level of SDHA, SDHC and SDHD in colorectal cancer and normal mucosa.  Only 
expression levels of the subunit B were reduced in the cancer mucosa. The authors did find a 
close association between SDHB expression and tumour differentiation grade [232]. 
 
A recent report using 2-D DIGE and MS with the pH range of 4–7 found that in colon cancer 
some proteins such as succinate dehydrogenase subunit A, were down-regulated [233]. 
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4.2.2 Succinate and fumarate in the Tricarboxylic acid cycle (TCA) 
In the TCA cycle, succinate is oxidized to fumarate by succinate dehydrogenase. Fumarate is 
then hydrated to form L-malate by fumarase. The final reaction in the TCA cycle is catalyzed 
by malate dehydrogenase, converting L-malate to oxaloacetate. Thus the concentrations of 
succinate and fumarate are proportional assuming the activity of SDH is normal. 
 
4.2.3 Further research into SDH 
In this study, a negative correlation was noticed between succinate and fumarate in the pre 
neoplastic tissue which was not apparent in normal tissue or frankly neoplastic tissue. This 
observation may be important as it may indicate dysfunction of SDH as previously noted in 
other neoplastic tissues.  
 
If this finding can be confirmed in future studies, it may be a useful tool in the risk 
stratification of patients with Barrett’s oesophagus. Quantification of succinate and fumarate 
in these tissues might enable prediction of an identifiable biochemical response that exists in 
the absence of histologic change. That this change might reflect an unstable epithelium, 
seems an attractive hypothesis, which in turn might lead to the identification of a metabolic 
marker in non-dysplastic Barrett’s patients capable of identifying the high risk group likely to 
progress to adenocarcinoma. 
 
4.3 3-hydroxybutyrate  
In the current study, the level of 3-HB was increased in cancer mucosa compared to the 
adjacent normal mucosa. This difference although visualized on inspection of paired spectra 
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(Figure 41), was much more apparent on the loadings plot (Figure 24). This observation was 
confirmed by obtaining a 2D Hadamard 1H,1H-TOCSY-NMR spectrum for 3-HB and further 
by selective spiking of samples with high levels of 3-hydroxybutyrate with exogenous 3-HB. 
An elevated level of 3-HB was also noticed in the pre treatment plasma samples from patients 
with oesophageal adenocarcinoma (type 1,2) compared to plasma from control patients. To 
add to this, elevated levels of 3-HB were noticed for pre treatment plasma samples from non 
responders vs. pre treatment plasma samples from responders, supporting other observations 
that 3-HB might indeed be a marker of aggressive disease. 3- HB levels were also noted to be 
higher in plasma from patients with node positive disease compared to those with node 
negative disease and in plasma from patients with the more advanced T stages (T3, T4 vs. T1, 
T2). It is unlikely that these  differences were due to a difference in the fasting status of the 
patients as all patients had fasted overnight at the time of tissue sampling (during endoscopy 
or during surgery) and most plasma sampling was performed at the same time. 
 
Both advanced stage and non–response to chemotherapy are associated with poor prognosis. 
While measuring 3-HB levels in the former situation may be of limited value in decision-
making, it might have a role in assessing disease response and this seems worthy of 
prospective evaluation. 
 
4.3.1 Metabolism of 3-hydroxybutyrate  
3-hydroxybutyrate (3-HB) is one of the two main ketone bodies (along with aceto-acetate) 
that represent the end product of beta-oxidation of fatty acids.   Beta-oxidation allows the 
production of vital acetyl CoA and provides a route whereby fatty acids can be utilized to 
provide energy via the TCA cycle (Figure 64). 
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Figure 64 Metabolism of 3-hydroxybutyrate 
3-Hydroxybutyrate, a ketone formed as a break down product of fatty acid beta oxidation can 
reform acetyl groups for use in the Krebs cycle.  This proceeds via the formation of 
acetoacetate. 
 
Although acetyl groups that are not metabolized in the TCA cycle will ultimately form 3-HB 
(as well as acetoacetate and acetone), the reverse process is possible within the cell.  At a 
systemic level, 3 HB is mostly synthesized in the liver from acetyl-CoA after beta oxidation 
of fatty acids and can be used as an energy source by other tissue such as the brain when 
blood glucose is low. It is both secreted and taken up by the same monocarboxylate 
transporters (MCTs). After uptake by MCTs, it can re-enter the TCA cycle as acetyl-CoA and 
undergo oxidative metabolism, resulting in the production of high levels of ATP. High levels 
of this metabolite are seen in patients with diabetic ketoacidosis and alcoholic ketoacidosis. 
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Ketone bodies can also be produced from some amino acids (leucine, isoleucine, lysine, 
phenylalanine, tyrosine and tryptophan).  
 
4.3.2 Role of 3-HB and ketone bodies in carcinogenesis 
Numerous reports have implicated ketone bodies in carcinogenesis. Elevated levels of 3-HB 
have been detected in the serum of patients with colorectal malignancy [234]. Tiziani et al. 
observed elevated levels of 2- and  3-HB in patients with late stage head and neck cancer 
compared to early stage disease [235]. On the other hand, lower levels of 3-hydroxybutyrate 
have been reported from serum of patients with pancreatic cancer compared to healthy 
controls [236].  
 
Recently Bonuccelli et al.. provided conclusive evidence that ketone bodies and lactate fuel 
tumour growth and metastasis [237]. The administration of 3-HB in a xenograft model 
increased tumour growth 2.5-fold, without any measurable increases in tumour 
vascularization/ angiogenesis. 3-HB can also act as a chemo-attractant, stimulating the 
migration of epithelial cancer cells [237]. It has been suggested that 3-HB might be useful as 
a marker to identify high-risk cancer patients at diagnosis, for treatment stratification and/or 
for evaluating therapeutic efficacy during anticancer therapy [238]. 
 
The view that 3-hydroxybutyrate may be fuelling cancer is in part supported by the finding of 
increased breast cancer risk in a cohort of Mexican women who obtained a high percentage 
of calories from carbohydrate but not from fat [239].  
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Levels of 3-HB are however, profoundly affected by starvation. Blood glucose and insulin 
concentrations fall acutely during the first three days of fasting followed by a rise in the 
concentration of free fatty acids and ketone bodies that continues to increase and does not 
reach a plateau for more than two weeks [240]. Plasma levels of ketone bodies, rise 
significantly during  starvation as a result of accelerated catabolism of fatty acids [241]. All 
tissue samples and most of the plasma samples in this study had been collected from patients 
who had fasted overnight. This fasting was probably further compounded by long term 
starvation in patients with advanced gastro-oesophageal malignancy. It would thus be 
difficult to completely eliminate starvation as one of the possible causes for the increased 
levels of 3-HB in cancer mucosa. However, since starvation should equally effect both types 
of tissues (i.e normal mucosa and cancer mucosa), it would be unreasonable to completely 
ascribe these findings to starvation. Furthermore, it would be difficult to ascertain from the 
results of this study if the 3-HB was consumed or produced by the cancer cells.  
 
4.4 Comparison of results to proteomic data [242] 
The aims of the proteomics part of the study were similar to that of metabolomic analysis. 
Models were constructed in a similar fashion. During proteomic experiments it was noticed 
that normal oesophageal, normal gastric tissue and tumour tissues generated distinctly 
different MALDI spectra.  MALDI spectra of polypeptides and lipids discriminated between 
oesophageal adenocarcinoma and Barrett's and normal oesophagus, and between gastric 
cancer and normal stomach. However, the MALDI approach profiles the most abundant 
lipids (structural lipids) and low molecular weight proteins to generate a 'tissue fingerprint' 
and therefore does not provide in-depth biological information.  Thus, although some 
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comparisons can be made between the two studies in terms of how different tissue types are, 
there is little direct overlap in terms of disease mechanism. 
 
Firstly, the construction of the models was successful i.e. models which differentiated well on 
NMR metabolomics also differentiated well on MALDI proteomics. The primary method of 
extraction for tissues i.e. methanol chloroform extraction, worked well for both the analyses 
although tissues for proteomics were further processed before being submitted for analysis. 
However, this is where the commonalities between the two modalities end. Since both the 
studies were conducted synchronously, no attempts were made to specifically look for 
markers in proteomics that could identify involvement of particular pathways in light of the 
metabolomics results. Although this may be possible in future in-depth proteomic studies, 
what this study has demonstrated with great conviction is that the plasma and tissue 
processing protocols that we had developed were adequate to identify differences in between 
various types of histological tissues. The next step from here would be a combined 
proteomics/ metabolomics study specifically looking for pathways that were shown to be 
involved in this study. 
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4.5 NMR metabolomics in biomarker discovery  
The human genome project which was completed in 2003 identified approximately 23,000 
genes. “The post-genomic era was heralded by a greater awareness of functional genomic 
technologies. There was also a greater availability of technologies for global transcriptional 
and proteomic profiling” [243]. This paved the way for numerous biomarker studies utilizing 
genomics, transcriptomics and proteomics. One of the main disadvantages of this approach is 
that not all genes are under transcriptional control. Thus the information obtained from 
functional genomics is limited, especially due to post-transcriptional and post-translational 
modifications [104]. The possibilities with proteomics continue to be limited as the proteome 
of an organism remains an immense technical challenge. “There is thus an increased need to 
further define the phenotype resultant from a genetic modification to understand how the 
transcriptional or proteomic network may conspire to alter the expected phenotype” (Julian L. 
Griffin in Metabolic profiles to define the genome: can we hear the phenotypes? ) [243]. 
 
The metabolome is therefore most predictive of phenotype [115, 116]. Comprehensive and 
quantitative study of metabolites, or metabolomics, is best placed for diagnosing disease and 
to evaluate the role of novel treatment strategies. Metabolic profiles can be acquired using 
technologies like nuclear magnetic resonance (NMR) spectroscopy, direct infusion 
electrospray mass spectrometry (ESI-MS) and gas chromatography mass spectrometry (GC-
MS). 
 
4.5.1 Strengths of the study 
One of the main challenges is this study was to test of the feasibility of conducting a large 
biomarker profiling study using blood and tissue. Although, blood (plasma or serum) has 
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been previously used for biomarker profiling in metabolomics; this is probably the largest 
patient series examining tissue profiles utilising NMR.  
 
The first step towards achieving this goal was to optimise a tissue extraction protocol that 
could yield high quality specimens not only for NMR metabolomics, but also MS 
metabolomics and proteomics. It was also important that the variability in the mass of 
individual tissue specimens was accounted for to avoid differences due to the size of the 
biopsy. Protocols were successfully developed to achieve this. 
 
Once such protocols had been established, the next challenge was to optimise a method of 
tissue transport and storage that was not only reproducible but also feasible. Although, most 
studies in the past have utilised snap frozen tissues, we instead chose to utilise the concept of 
slow freezing for this study. This firstly helped us to equalise the warm ischaemia time of 
post resectional specimens to endoscopically obtained biopsies. More importantly it enabled 
us to formulate a protocol that was practical and obviated the use of liquid nitrogen. Thus this 
protocol could be used in facilities where the availability of liquid nitrogen is limited or the 
restrictions on its use limit large studies. However, it has to be conceded that the results of 
this study may reflect the profiles from our tissue extraction protocols only and might not be 
generalisable to other protocols. 
 
4.5.2 Advantages and disadvantages of using NMR for metabolomics 
NMR was used in the present study to acquire metabolite profiles in this study. Although one 
of the disadvantages of NMR over MS is its limited sensitivity; ease of sample preparation, 
reproducibility and quantitativity of NMR are unsurpassed. NMR data were acquired for 724 
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samples. The acquisition time for some of these samples extended to 16 hours with a total 
period of NMR experiments spanning three months. Instrument reproducibility was thus 
important for such a large study. Although MS metabolomics was also used as part of this 
study, it was used as a validation tool rather than in the discovery phase. 
 
Though most conditions can be controlled, there are still obstacles that had to be overcome 
with NMR. While spectral variation due to temperature changes can be avoided by stringent 
control of sample temperature, controlling spectral shifts due to varying pH is much more 
difficult as even really small pH variations will lead to visible shifts in NMR spectra. These 
small pH dependent variations in chemical shift were further reduced by adding several data 
points together into singe bins. A disadvantage of this processing technique is that it can lead 
to artifacts due to signals potentially belonging to two adjacent bins. A manual inspection 
was therefore necessary, compressing several bins into a single bin if necessary to avoid these 
artefacts. 
 
4.5.3 Advantages and disadvantages of using metabolomics for tissue profiling 
Metabolomics is the most downstream of all the ‘omic’ sciences so it should explain most of 
the variations in the phenotype. However, one of the disadvantages of using metabolomics is 
that it only represents a snapshot of the metabolic profile. As a result it fails to indicate the 
processes or pathways that are dysregulated that might be causing these effects. Moreover, an 
increased quantity of a metabolite may indicate overproduction or underusage, a dilemma 
that metabolomics fails to address. Some of these weaknesses can be compensated for by 
using a combination of approaches that may indicate the pathways of interest, although this 
may not always be possible. 
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4.6 Future studies 
This study has identified a large number of metabolic changes in oesophageal 
adenocarcinoma. Although, the findings from this study are quite substantial; it probably 
forms only the first step towards the successful discovery and validation of a biomarker. A 
variety of studies need to be performed before any concrete conclusions can be drawn out.  
 
One of the future studies would consist of a validation study on a separate cohort of patients 
examining the metabolites of interest. Other studies would include enzyme based assays for 
specific metabolites validate and estimate accurate concentrations of these metabolites. Cell 
based studies would help further elucidate the proposed pathways for these effects. They 
would also allow testing of inhibitors of these pathways (e.g. dipyrimadole) in cell lines 
treated with various chemotherapeutic regimens. A population based cross sectional study 
would enable quantification of normal levels of these metabolites. One of the final steps 
would then be to produce and validate a diagnostic test assessing for the diseased state.  
 
Another direction for future studies could be exploring modalities such as in vivo MRS and 
ex vivo1H HR-MAS. Both of these techniques have shown good promise in the last decade. 
On the subject of oesophageal cancer, 1H magic angle spinning – nuclear magnetic resonance 
spectroscopy has been recently utilised to generate metabolic profiles of tumour tissue, 
proximal histologically normal mucosa from cancer patients  and proximal histologically 
normal mucosa from a control group [151]. The authors of this study were able to identify 
metabolites in tissue that could identify the presence of oesophageal cancer. Thus a 
combination of these techniques is likely to yield further data towards the understanding of 
oesophageal carcinogenesis. In vivo MRS, although has been used for some malignancies 
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(primarily brain tumors) [185], it’s use in oesophageal cancer has not yet been documented . 
One of the greatest advantages of this tool is that it obviates the need for tissue biopsies. 
However, the oesophagus and stomach and quite accessible to endoscopy and biopsy 
continues to be the mainstay of diagnosis. Perhaps further use of this technology would be 
seen in the coming years for lesions that are hard to biopsy. 
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CONCLUSION 
Some important milestones were achieved during this study. A tissue extraction protocol was 
optimised that could yield high quality specimens not only for NMR metabolomics, but also 
MS metabolomics and proteomics. Moreover, this protocol was developed without the need 
for liquid nitrogen, thus adding to the simplicity of the protocol. 
 
Using NMR metabolomics, it was possible to differentiate successfully between two normal 
tissue types from a large number of patients with gastro oesophageal malignancy. This was a 
necessary first step since before commenting on differences in between cancer and normal. It 
was important to explore the capability of NMR metabolomics in doing the same with normal 
tissue types. Besides this, NMR metabolomics was also able to distinguish between normal, 
pre-neoplastic stages and cancer. 
 
This study identified alterations in a metabolite (hypoxanthine) that may point towards the 
possibility of identifying a cohort of patients with Barrett’s oesophagus who were at a high 
risk of malignant transformation. This is quite important for Barrett’s surveillance 
programmes and may eventually reduce the need for repeated endoscopies and biopsies in a 
sub group of patients. However, these conclusions have to be guarded since the number of 
patients with non dysplastic Barrett’s and Barrett’s in the presence of cancer were limited. 
Moreover, a successful validation of this hypothesis would require longitudinal follow up of 
patients with Barrett’s oesophagus and this was beyond the scope of the present study. 
 
3-hydroxybutyrate was identified as a marker in tissue and plasma that may indicate 
advanced or unresectable disease. The place for such markers in the current staging of 
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oesophago-gastric malignancies needs to be established following their successful validation. 
This study also identified a potential dysregulation of succinate dehydrogenase and 
emphasied its importance in oesophageal carcinogenesis. However, these results were 
obtained from a very small cohort of patients and further work is required to explain and 
validate the significance of such changes.  
 
The natural progression from this study would be a validation study followed by cell based 
studies to actually understand the pathways involved. A successful conclusion of such studies 
may pave the way for new biomarkers and treatments in the management of gastro-
oesophageal malignancy.
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Metabolite Mean Std. Deviation 
2-aminobutyrate .024353 .0071546 
2-hydroxy iso valerate .006647 .0074908 
2-hydroxybutyrate .008692 .0064992 
3-hydroxybutyrate .011039 .1270739 
Acetate .042426 .0445935 
Acetoacetate .067231 .1093225 
Acetone .087114 .1311031 
Acetyl amino acid .015647 .0054581 
Alanine .378017 .1138357 
Choline .010403 .0053265 
Citrate .057453 .0236251 
Creatine .020796 .0174333 
Creatine phosphate .011646 .0038897 
Creatinine .063032 .0220004 
Dimethylglycine .006198 .0032916 
Ethanol .017162 .0511004 
Formate .003991 .0023409 
Glutamate .037824 .0126958 
Glutamine .114068 .0348504 
Glutathione .001007 .0126733 
Glycerol .028757 .0120554 
G-phosphocholine -.015137 .0182915 
Hypoxanthine .000384 .0005470 
Isoleucine .047963 .0156006 
Isopropanol .015552 .1035024 
Keto iso valerate .009650 .0033401 
Lactate 1.770996 .6719760 
Leucine .192808 .0576260 
Lysine .258454 .0615606 
O-phosphocholine .017204 .0068388 
Phenylalanine .029661 .0073930 
Pyruvate .033200 .0256216 
Threonine .020343 .0063527 
Tyrosine .032894 .0111381 
Valine .223737 .0565852 
Metabolite integrations for plasma 
Metabolite p value (Mann Whitney U test) 
Formate 0.00005106440632984040 
Pyruvate 0.00006400452968875750 
Hypoxanthine 0.00018893424196922500 
Dimethylglycine 0.00039802607111595400 
Acetyl amino acid 0.00584657806660471000 
3-hydroxybutyrate 0.00847444991898300000 
Isopropanol 0.01105007819702430000 
Ethanol 0.01290584831592470000 
Glutamate 0.01768895824647080000 
Significant metabolites in model 1 plasma 
 
Metabolite p value (Mann Whitney U test) 
Formate 0.01168524053145980000 
Glutathione 0.01610264007719110000 
Pyruvate 0.04858648391825310000 
Significant metabolites in model 2 plasma 
 
Metabolite p value (Mann Whitney U test) 
Isoleucine 0.02343481218857220000 
Dimethylglycine 0.03443122146081490000 
Tyrosine 0.03729508449041750000 
Significant metabolites in model 3 plasma 
 
Metabolite p value (Mann Whitney U test) 
G-phosphocholine 0.00556404350217377000 
Valine 0.02334220201289080000 
Creatinine 0.03220968567371050000 
Lysine 0.03763531378731430000 
Significant metabolites in model 4 plasma 
 
  
Metabolite p value (Mann Whitney U test) 
G-phosphocholine 0.00675510459297715000 
Threonine 0.00811802832829044000 
O-phosphocholine 0.00974012240527190000 
Valine 0.01382302382037670000 
Lysine 0.01382302382037670000 
Leucine 0.01382302382037670000 
Glycerol 0.01638235277370590000 
Dimethylglycine 0.02277472785404030000 
Keto iso valerate 0.04867667180111600000 
Significant metabolites in model 5 plasma 
  
Metabolite Mean Std. Deviation 
4-hydroxy phenyl lactate .018215 .0345528 
Acetate .119616 .0820797 
α-keto iso valerate .005753 .0127742 
Alanine .286643 .1306737 
AMP .004013 .0037977 
Aspartate .006169 .0034534 
ATP .025864 .0149452 
Choline .084977 .0457011 
Creatine .199382 .0850647 
Creatinine .025959 .0301362 
Formate .058906 .0587258 
Fumarate .004351 .0021874 
Glucose .005892 .0048112 
Glutamate .222381 .0715619 
Glutamine .148623 .0739374 
Glutathione .022378 .0105691 
Glycogen .030431 .0430747 
G-phosphocholine .164114 .1554231 
Hydroxy iso valerate .000207 .0001928 
Hypoxanthine .008627 .0061983 
Inosine .008277 .0063262 
Inositol .095442 .0435443 
Iso leucine .004962 .0025601 
Lactate 2.031453 .9644534 
Leucine .017673 .0093018 
O-phosphocholine .300370 .2682802 
Phenylalanine .009980 .0047249 
Succinate .031898 .0287288 
Taurine .085309 .0322215 
Tyrosine .010881 .0058323 
Uracil .000889 .0010912 
Valine .019401 .0071317 
Metabolite integrations for tissue 
  
Metabolite p value (Mann Whitney U test) 
G-phosphocholine 0.00000000000000000783 
O-phosphocholine 0.00000000000000003487 
Glutamine 0.00000000000000025264 
Alanine 0.00000000000000404783 
Creatinine 0.00000000000000894615 
Choline 0.00000000000008294786 
Glycogen 0.00000000000454229413 
Glutathione 0.00000000000796944585 
ATP 0.00000000003448514800 
Valine 0.00000000006757361607 
Glutamate 0.00000000029092553732 
Acetate 0.00000000135033067310 
Hypoxanthine 0.00000001114204629791 
Inosine 0.00000003231716628324 
Glucose 0.00000034593623024716 
Creatine 0.00000096180980364916 
Taurine 0.00000575888759804659 
Fumarate 0.00002171090580425370 
Phenylalanine 0.00002176838237348080 
Lactate 0.00008104621804410970 
AMP 0.00010601210048534400 
Inositol 0.00011034186855826800 
Aspartate 0.00025810564781414200 
Tyrosine 0.00304201600067409000 
α-keto iso valerate 0.00401715346647147000 
4-hydroxy phenyl lactate 0.01152722517356030000 
Significant metabolites in model 1 tissue 
  
Metabolite p value (Mann Whitney U test) 
Glutamine 0.00000000000007739282 
ATP 0.00000000000050670429 
Alanine 0.00000000000443959995 
Creatine 0.00000000001706646402 
Creatinine 0.00000000003485538814 
Hypoxanthine 0.00000000009798046121 
Choline 0.00000000089376757203 
Uracil 0.00000000263763364523 
Fumarate 0.00000000292720659715 
O-phosphocholine 0.00000000399947185098 
G-phosphocholine 0.00000028492311608275 
Glutathione 0.00000958354679895991 
Glycogen 0.00002221336919832280 
Inosine 0.00002634051216311610 
Acetate 0.00286219695558342000 
Taurine 0.00836440680389192000 
Valine 0.01006364892583440000 
Glutamate 0.01006810993498070000 
Glucose 0.01273950619676460000 
Iso leucine 0.03143098977002870000 
Leucine 0.03992567174334220000 
Lactate 0.04074856500688650000 
Significant metabolites in model 2 tissue 
 
Metabolite p value (Mann Whitney U test) 
Succinate 0.00625929392305007000 
O-phosphocholine 0.02391934824795000000 
Lactate 0.02931834791715420000 
Inositol 0.03573443118569690000 
Aspartate 0.04307557946267690000 
Significant metabolites in model 4 tissue 
 
Metabolite p value (Mann Whitney U test) 
Tyrosine 0.04125988432522410000 
Significant metabolites in model 5 tissue 
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PROTOCOL  
[VERSION 2, 15th April 2008] 
 
 
Metabolomic analysis of peripheral blood to predict the response to neoadjuvant 
chemotherapy in oesophageal and gastric cancer 
 
Background 
Oesophageal cancer is a highly aggressive malignancy with approximately 7,500 new cases 
diagnosed in United Kingdom every year. It is the 9th leading cause of cancer1; and 5th 
leading cause of death due to cancer in the United Kingdom. More than 50% of oesophageal 
cancer patients present with unresectable disease, contributing to its dismal overall 5-year 
survival rate of between 9 and 40%, even in resectable stages.  
 
While a meta-analysis of neoadjuvant chemotherapy trials in oesophageal cancer did not show 
an overall survival benefit, most studies were dominated by squamous cell cancer. The 
subgroup however, who respond to this treatment has been consistently shown to have a 
survival benefit and this was particularly evident in the largest and most recent trial conducted 
by the Medical Research Council which was dominated by patients with adenocarcinoma. 
These patients need to be identified from non responders either before, or at an early stage of 
this potentially toxic treatment.  
 
Aims 
We aim to prospectively evaluate the role of plasma metabolites in prediction of response to 
neoadjuvant chemotherapy by application of the principles of proteomics.  
 
Inclusion Criteria 
All patients considered medically fit for neoadjuvant chemotherapy and belong to one of the 
following groups 
1. Have potentially surgically resectable disease 
• Adenocarcinoma of the oesophagus 
• Afdenocarcinoma of the gastro oesophageal junction (Siewert types 1,2,or 3) 
• Gastric carcinoma 
and have not received any prior treatment for their cancer. 
2. Are receiving palliative chemotherapy. 
  
 
 - 2 -  
Project Title: Metabolomics in prediction of response to neoadjuvant chemotherapy in oesophageal and gastric cancer 
  
 
Exclusion Criteria 
1. Patients who are considered medically unfit for chemotherapy. 
2. Patients who are unable to complete their neoadjuvant therapy during the course of 
treatment. 
 
Staging investigations 
All patients should have a  
1. Spiral/ Multi-slice CT with oral contrast or water of chest and abdomen (pelvis is 
optional). Maximum slice width 5mm. IV contrast/venous phase. 
2. Endoscopic ultrasound (EUS) for all Type III gastro-oesophageal junctional tumours 
and according to local practice for other tumours. For obstructing tumours, the use of 
an oesophago-probe is preferable, but dilatation to facilitate complete scanning is 
permissible. 
The results of an EUS should take precedence over other imaging modalities when 
staging tumour and nodes, whereas CT should take precedence when staging distal 
disease. 
3. Diagnostic Laparoscopy with intraperitoneal wash +/- laparoscopic ultrasound. 
4. PET scan for assessment of hepatic/ extra hepatic disease. 
5. MRI or bone scans if clinically indicated. 
 
Histological confirmation of diagnosis and baseline staging investigations must be 
reviewed by a Multidisciplinary Team (MDT). 
 
Assessment of Response to neoadjuvant chemotherapy 
Spiral/multi-slice CT, with oral contrast or water including chest, abdomen (pelvis optional) 
within 2 weeks of completion of chemotherapy. This is part of routine practice and is not being 
carried out solely for purposes of research. Maximum slice width 5mm. IV contrast/venous 
phase. Volumetric assessments would be made to access the reduction in total volume of the 
tumour. 
Final assessment of response will be made after examination of the hisopathological specimen. 
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Recruitment 
Paients who fit the inclusion criteria would be provided with the patient information sheet 
once they have been informed of the diagnosis. These patients would have upto 1 week to 
decide whether they would like to participate in the study. 
At the same time healthy volunteer controls suffering with reflux disease would be recruited 
into the study. They would be supplied with information sheet for volunteer controls. General 
practitioners for both patients and controls would be subsequently informed. The recruitment 
process is expected to last 6 – 12 months.  
 
Sample size calculation 
For a test with a sensitivity of 80%, we want the sample size to estimate its sensitivity to 
within 5%. This amounts to saying that the confidence interval for sensitivity should have a 
width of 10% (2*5%=10%). Because 0.8 lies near the extreme of the range of sensitivity (0-
1) it is better to use a confidence interval based on a score test rather than the usual Wald 
statistic. (Wilson (1927) discussed in Agresti and Coull, Am. Stat. May 1998; 52, 2 (equation 
2)). For a 95% confidence interval to have a total width of 10%, we require approximately 
132 patients. 
 
Methodology 
Patients will be divided into 2 groups i.e. responders and non responders based on the post 
chemotherapy investigations and examination of the histopathological specimen obtained 
after oesophagectomy.   
Blood samples will be collected from all patients who fit the inclusion criteria. These samples 
will be divided into ‘responders’ and ‘non responders’ and will be collected at serial time 
intervals; before, during and after treatment with neoadjuvant chemotherapy. At the same 
time they will be also collected from healthy patients with benign oesophageal disease 
confirmed on endoscopy. These would serve as ‘controls’. 
 
Metabolomic analysis of plasma will involve -  
1. Sample Collection and processing: Blood samples will be collected, placed on ice and 
processed within 20 minutes. They are subsequently centrifuged to remove red blood cells. 
Plasma samples will be deproteinized by filtration or addition of acetonitrile, followed by 
centrifugation and replacement of solvent to yield 600 µL ultrafiltrate/sample in 
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90%H2O/10%D2O for NMR analysis. (The D2O is added for frequency locking during the 
acquisition of the NMR spectrum) Pooled samples will be used in the first instance i.e. the 
ultrafiltrate from responders is pooled and compared with the pooled ultrafiltrate from non 
responders. This should identify major areas of difference. Tissues will either be analysed by 
MAS-NMR (magic angle spinning) to reduce the line widths in the spectrum or by extracting 
tissue samples using a MEOH/EtOH mixture followed by lyophilisation. 
 
2. NMR fingerprinting: The ultrafiltrate will be analyzed by 600 and 800 MHz spectrometers 
using cryogenically cooled probes. 1D spectra or 2D J-resolved spectra will be recorded to to 
identify changes in metabolite concentrations. Spectra will be processed using software 
written by researchers at HWB-NMR in Birmingham, PLS-toolbox for PCA/PLS and the 
Chenomx software for signal identification. Relevant metabolites will be identified from 
loadings plots in PCA or PLS analysis. 
 
3. Validation: Once resonances are identified, we will confirm the identity of signals by 
adding metabolites to the sample. An enhanced peak confirms the metabolite initially 
identified using the reference software.  To identify unknown metabolites 2D COSY and 
HSQC spectra will be recorded.  
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PATIENT INFORMATION SHEET  
[VERSION 2, 15th April 2008] 
 
 
Metabolomic analysis of peripheral blood to predict the response to neoadjuvant 
chemotherapy in oesophageal and gastric cancer 
 
Invitation 
 You are being invited to take part in a research study. Before you decide whether to take part it is 
important for you to understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there 
is anything that is not clear or if you would like more information. Take time to decide whether or not you wish 
to take part.  
 Your hospital doctor will have explained that you have developed cancer of the oesophagus (the tube 
leading from your throat to your stomach) or stomach. As you know the treatment of these cancers may involve 
chemotherapy, radiotherapy and surgery. We are currently investigating the best way to identify patients who 
would respond to chemotherapy so as to tailor treatment for individual patients and reduce the potential for side 
effects. We would like to invite you to take part in a research study being conducted by the University Hospital 
Birmingham Upper Gastrointestinal surgery unit. 
 
Why have I been chosen? 
You have been chosen for this study because you have cancer of the oesophagus/ stomach of a type considered 
suitable for chemotherapy (drug treatment).  
 
Why is the research being done? 
Recent research has shown that only a proportion of patients are likely to respond to chemotherapy. Our aim is 
potentially seperate responders from non responders preferably at an early stage of this treatment to avoid 
unnecessary chemotherapy and its side effects. 
 
Do I have to take part? 
No. Taking part in the study is entirely voluntary. If you decide not to take part this will not affect your 
relationship with your doctor in any way or the treatment you are offered in the future. When you have read this 
information sheet and the consent form, we would encourage you to discuss the study with others if you wish, to 
help you decide whether to take part. No effective treatment will be withheld if you take part in this research.  
 
At any time you may withdraw your consent without giving a reason and without affecting your future care, but 
data on your progress will continue to be collected unless you specifically request this to stop. If you do not 
wish to take part in this study, you will be offered whatever treatment your hospital doctor thinks is best for you. 
 
What will happen to me if I take part? 
This research does not alter the treatment you receive in the hospital in any way. You will continue to receive 
the treatment that was best suited for your type of cancer. We will take blood samples coinciding with the times 
of your routine blood tests. We will also analyse tiny pieces of samples (about the size of a pin head) from the 
oesophagus/ stomach removed at the time of endoscopy and surgery. We will not take any samples that will 
interfere with how the Doctors treat you. We will not ask the Surgeons to take any extra tissue for us and the 
surgery would be the same whether your take part or not.  
 
 
How is the research done? 
We intend to use state of the art metabolomic analysis (an investigation into the activity of cancer cells) to 
identify predictors of response from your blood and tissue specimens.  
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Who is organising and funding the research? 
Professor Derek Alderson is the overall lead of the research group. The research will be funded in part with the 
funds available with the Upper Gastrointestinal surgery unit at the University Hospitals Birmingham Foundation 
trust and other government funding bodies. 
 
What do I have to do? 
If you agree to take part in the study there is nothing extra that you need to do. 
 
What medical tests are involved? 
None over and above that were initially planned for your treatment.   
 
What are the side effects of any treatment received when taking part? 
There are no additional side effects or complications beyond those associated with the standard treatment.  
 
What are the possible disadvantages and risks of taking part? 
As we are not undertaking additional procedures there are no disadvantages to taking part. 
 
What are the possible benefits of taking part? 
There is no intended benefit to you personally from taking part in this study.  The information we get from this 
study will help us to treat future patients with cancer of the oesophagus/ stomach better. 
 
What if something goes wrong? 
As we only take blood samples and tissue samples during endoscopy and from the oesophagus/ gastric that has 
been surgically removed, no risks are anticipated from your participation in the study. 
 
Will my taking part in this study be kept confidential? 
If you consent to take part in the research any of your medical records may be inspected by the professionals 
involved in the research. Your details however are anonymous and any tissue or data from the study will be 
anonymous. It will not be possible to trace these back to you. 
All information which is collected about you during the course of the research will be kept strictly confidential.  
Any information about you which leaves the hospital will have your name and address removed so that you 
cannot be recognised from it. 
 
What will happen to the results of the research study? 
The results of the study will be published in a suitable medical journal. Patients taking part will not be identified 
in any published report. You will be able to obtain a summary of the findings from patient support groups, or 
your study doctor.  
 
How many patients would be required for the study? 
Although it is difficult to predict exact numbers before preliminary results of the study are available, we 
estimate not more than 150 participants would be required. The recruitment process is expected to last 6 – 12 
months. 
 
Who has reviewed the study? 
 
The South Birmingham Ethics Committee and the University Hospital Birmingham Research and Development 
Committee have reviewed and approved this study. 
 
Contact for Further Information 
If you have any concerns or further questions about the study you can telephone Dr Rishi Singhal on 0121 627 
2276, University of Birmingham. If you have any concerns about the study and wish to contact someone 
independent, you may telephone the Research and Development office at the Queen Elizabeth hospital. 
 
You will be provided with a copy of this form for your records.  
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PATIENT CONSENT FORM  
[VERSION 2, 15th April 2008] 
 
 
Metabolomic analysis of peripheral blood to predict the response to neoadjuvant 
chemotherapy in oesophageal and gastric cancer 
 
Patient Identification Number for this trial: 
Name of Researcher: Mr Rishi Singhal 0121 6272276 
        
1. I confirm that I have read and understand the patient information sheet (Version 2, 15th April 2008]) for the 
above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time,  ?
 without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible ? 
 individuals from the research group or from regulatory authorities where it is relevant to my 
 taking part in research.  I give permission for these individuals to have access to my  
 records. 
 
4.  I agree that my GP be informed of my involvement with this research study ? 
 
5. I agree to take part in the above study.   ? 
 
 
 
 
 
 
 
 
 
 
 
________________________ ________________ ____________________ 
Name of Patient   Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date  Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher   Date  Signature 
 
 
 
 1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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GP LETTER  
[VERSION 2, 15th April 2008] 
 
 
Metabolomic analysis of peripheral blood to predict the response to neoadjuvant 
chemotherapy in oesophageal and gastric cancer 
 
 
 
 
Dear Dr  
 
 
Your Patient:     (DOB:  / / ) 
 
has been found to have oesophageal/ gastric cancer. This patient has kindly agreed to take part in a research 
aimed to identify predictors of response to neoadjuvant chemotherapy in oesophageal/ gastric cancer. The 
participation in this research would not in any way alter the treatment appropriate for the type of cancer. 
 
Please find enclosed a copy of the patient information sheet for this trial. You will be kept up to date with your 
patient’s progress but if you have any concerns or questions regarding this study please contact the responsible 
physician:  
 
 
 
 
Professor/Mr    at University Hospital Birmingham Foundation Trust 
 
Tel:  
 
 
 
 
 
 
 
 
Metabolomics in prediction of response to neoadjuvant chemotherapy in patients with 
oesophageal adenocarcinoma  
 
Data collection proforma – Rishi Singhal      Date:  
 
Hospital Number: 
Study Number: 
Patient name:  
Sex: 
Weight: 
Height: 
BMI: 
Ethnicity:  Caucasian  Asian   Chinese  Other 
Contact No.: 
Smoking status: Non smoker  Ex smoker  Smoker 
Alcohol status: Non drinker  Mild drinker  Moderate  Severe 
 
 
Cancer 
Oesophageal/Gastric 
Adeno/Squamous 
Siewert type 
OGD location: Distance -   Length -  
 
Staging 
TNM 
EUS     Date: 
CT   
 Date Findings  
1st CT    
2nd CT    
    
PET 
 Date Findings  
1st PET    
2nd PET    
 
Staging laparoscopy 
 Date Findings  
1st staging lap    
2nd staging lap    
    
Histopathology   Date:    TRG: 
 
 
 
Chemotherapy 
 
5FU/ ECX/ ECX+B  
 
 Start End Complete (Y/N) Complications 
Cycle 1     
Cycle 2     
Cycle 3     
 
 
Dates 
Date of diagnosis: 
Date of Chemotherapy start: 
Date of Chemotherapy finish:  
Date of Surgery: 
Date of Discharge: 
 
Medical Comorbidities 
 
 
 
 
 
Drug History 
 
 
 
 
 
 
Blood sample collection 
 
 Sample No. Date  Sample time Fasting status Time in centrifuge Time in freezer 
1st sample       
2nd sample       
3rd sample       
 
 
Tissue sample collection 
 
 Sample No. Date  Sample time Fasting status Time in freezer Number of specis 
1st sample       
2nd sample       
3rd sample       
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INFORMATION SHEET FOR VOLUNTEER CONTROLS 
[VERSION 2, 15th April 2008] 
 
 
Metabolomic analysis of peripheral blood to predict the response to neoadjuvant 
chemotherapy in oesophageal and gastric cancer 
 
Invitation 
 You are being invited to take part in a research study. The first thing we would like to inform you is 
that you do not have the disease that we are investigating (ie Oesophageal or gastric cancer). Before you decide 
whether to take part it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with friends, relatives and 
your GP if you wish. Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
  
Why have I been chosen? 
Although you do not have the disease we are investigating, we require a number of patients with other 
conditions to act as a control for our experiments. Your participation will help us to standardize our research and 
obtain meaningful results. 
 
Why is the research being done? 
Recent research has shown that only a proportion of patients with cancer of the oesophagus/ stomach are likely 
to respond to chemotherapy. Our aim is potentially separate responders from non responders preferably at an 
early stage of this treatment to avoid unnecessary chemotherapy and its side effects. 
 
Do I have to take part? 
No. Taking part in the study is entirely voluntary. If you decide not to take part this will not affect your 
relationship with your doctor in any way or the treatment you are offered in the future. When you have read this 
information sheet and the consent form, we would encourage you to discuss the study with others if you wish, to 
help you decide whether to take part. No effective treatment will be withheld if you take part in this research.  
 
At any time you may withdraw your consent without giving a reason and without affecting your future care, but 
data on your progress will continue to be collected unless you specifically request this to stop. If you do not 
wish to take part in this study, you will be offered whatever treatment your hospital doctor thinks is best for you. 
 
What will happen to me if I take part? 
This research does not alter the treatment you receive in the hospital in any way. We will take blood samples 
and also analyse tiny pieces of samples (about the size of a pin head) from the oesophagus/ stomach that were 
removed at the time of endoscopy. We will not take any samples that will interfere with how the Doctors treat 
you.  
 
How is the research done? 
We intend to use state of the art metabolomic analysis (an investigation into the activity of cancer cells)  to 
identify predictors of response from your blood and tissue specimens.  
 
Who is organising and funding the research? 
Professor Derek Alderson is the overall lead of the research group. The research will be funded in part with the 
funds available with the Upper Gastrointestinal surgery unit at the University Hospitals Birmingham Foundation 
trust and other government funding bodies. 
 
What do I have to do? 
If you agree to take part in the study there is nothing extra that you need to do. 
 
What medical tests are involved? 
None over and above that were initially planned for your treatment.   
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What are the side effects of any treatment received when taking part? 
There are no additional side effects or complications beyond those associated with the standard treatment.  
 
What are the possible disadvantages and risks of taking part? 
As we are not undertaking additional procedures there are no disadvantages to taking part. 
 
What are the possible benefits of taking part? 
There is no intended benefit to you personally from taking part in this study.  The information we get from this 
study will help us to treat future patients with cancer of the oesophagus/ stomach better. 
 
What if something goes wrong? 
As we only take blood samples and tissue samples during endoscopy from the oesophagus/ stomach, no risks are 
anticipated from your participation in the study. 
 
Will my taking part in this study be kept confidential? 
If you consent to take part in the research any of your medical records may be inspected by the professionals 
involved in the research. Your details however are anonymous and any tissue or data from the study will be 
anonymous. It will not be possible to trace these back to you. 
All information which is collected about you during the course of the research will be kept strictly confidential.  
Any information about you which leaves the hospital will have your name and address removed so that you 
cannot be recognised from it. 
 
What will happen to the results of the research study? 
The results of the study will be published in a suitable medical journal. Patients taking part will not be identified 
in any published report. You will be able to obtain a summary of the findings from patient support groups, or 
your study doctor.  
 
How many healthy volunteers would be required for the study? 
Although it is difficult to predict exact numbers before preliminary results of the study are available, we 
estimate not more than 150 participants would be required. The recruitment process is expected to last 6 – 12 
months. 
 
Who has reviewed the study? 
The South Birmingham Ethics Committee and the University Hospital Birmingham Research and Development 
Committee have reviewed and approved this study. 
 
Contact for Further Information 
If you have any concerns or further questions about the study you can telephone Dr Rishi Singhal on 0121 627 
2276, University of Birmingham. If you have any concerns about the study and wish to contact someone 
independent, you may telephone the Research and Development office at the Queen Elizabeth hospital. 
 
You will be provided with a copy of this form for your records.  
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 VOULENTEER CONTROLS CONSENT FORM  
[VERSION 2, 15th April 2008] 
 
 
Metabolomic analysis of peripheral blood to predict the response to neoadjuvant 
chemotherapy in oesophageal and gastric cancer 
 
Patient Identification Number for this trial: 
Name of Researcher: Mr Rishi Singhal 0121 6272276 
        
1. I confirm that I have read and understand the information sheet for volunteer controls (Version 2, 15th April 
2008) for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time,  ?
 without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible ? 
 individuals from the research group or from regulatory authorities where it is relevant to my 
 taking part in research.  I give permission for these individuals to have access to my  
 records. 
 
4.  I agree that my GP be informed of my involvement with this research study ? 
 
5. I agree to take part in the above study.   ? 
 
 
 
 
 
 
 
 
 
 
 
________________________ ________________ ____________________ 
Name of Patient   Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date  Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher   Date  Signature 
 
 
 
 1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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GP LETTER (GP information for volunteer controls) 
[VERSION 2, 15th April 2008] 
 
 
Metabolomic analysis of peripheral blood to predict the response to neoadjuvant 
chemotherapy in oesophageal and gastric cancer 
 
 
 
 
Dear Dr  
 
 
Your Patient:     (DOB:  / / ) 
 
has kindly agreed to take part in a research aimed to identify predictors of response to neoadjuvant 
chemotherapy in oesophageal/ gastric cancer. The tissue and blood specimens obtained from your patient would 
be used as a control in our experiments. The participation in this research would not in any way alter his/ her 
treatment. 
 
Please find enclosed a copy of the patient information sheet for this trial. You will be kept up to date with your 
patient’s progress but if you have any concerns or questions regarding this study please contact the responsible 
physician:  
 
 
 
 
Professor/Mr    at University Hospital Birmingham Foundation Trust 
 
Tel:  
 
 
 
 
 
 
 
 
Metabolomics in prediction of response to neoadjuvant chemotherapy in patients with 
oesophageal adenocarcinoma : Controls 
 
Data collection proforma – Rishi Singhal      Date:  
 
Hospital Number: 
Study Number: 
Patient name:  
Sex: 
Weight: 
Height: 
BMI: 
Ethnicity:  Caucasian  Asian   Chinese  Other 
Contact No.: 
Smoking status: Non smoker  Ex smoker  Smoker 
Alcohol status: Non drinker  Mild drinker  Moderate  Severe 
 
Symptoms 
 
 
Medical Comorbidities 
 
 
Drug History 
 
 
OGD date/ findings 
 
 
 
 
Blood sample collection 
 
 Sample No. Date  Sample time Fasting status Time in centrifuge Time in freezer 
1st sample       
2nd sample       
 
 
Tissue sample collection 
 
 Sample No. Date  Sample time Fasting status Time in freezer Number of 
specis 
Site 
1st sample        
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Keywords:
Oesophageal adenocarcinomaAim: To identify a reliable MALDI ‘cancer fingerprint’ to aid in the rapid detection and
characterisation of malignant upper GI-tract disease from endoscopic biopsies.
Methods: A total of 183 tissue biopsies were collected from 126 patients with or without
oesophago-gastric malignancy and proteins and lipids separated by methanol/chloroform
extraction. Peak intensities in the lipid and protein MALDI spectra from five types of
samples (normal oesophageal mucosa from controls, normal oesophageal mucosa
from patients with oesophageal adenocarcinoma, nondysplastic Barrett's oesophagus,
oesophageal adenocarcinoma, normal gastric mucosa and gastric adenocarcinoma)
were compared using non-parametric statistical tests and ROC analyses.
Results: Normal oesophageal and gastric tissue generated distinctMALDI spectra characterised
by higher levels of calgranulins in oesophageal tissue. MALDI spectra of polypeptides and
lipids discriminated between oesophageal adenocarcinoma and Barrett's and normal
oesophagus, and between gastric cancer and normal stomach. Many down-regulations were
unique to each cancer type whilst some up-regulations, most notably increased HNPs 1–3,
were common.
Conclusions: MALDI spectra of small tissue biopsies generated with this straightforward
method can be used to rapidly detect numerous cancer-associated biochemical changes.
These can be used to identify upper GI-tract cancers regardless of tumour location.
© 2013 Elsevier B.V. All rights reserved.Gastric adenocarcinoma
Endoscopy
Biopsy
MALDI
HNPs 1–31. Introduction
Oesophageal cancer is a highly aggressive malignancy with
some 8000 new patients diagnosed in the United Kingdomeach
year, making it the ninth most common cancer and fifth most
common cause of death from cancer [1]. The incidence of
adenocarcinoma of the oesophagus has risen dramatically
since the mid-1970s accounting for nearly three quarters of allnces, College ofMedical an
G. Ward).
r B.V. All rights reserved.oesophageal cancers in most Western countries [2]. Adenocar-
cinoma is strongly linked to the rising incidence of gastro-
oesophageal reflux disease and specifically within that condi-
tion, to the development of Barrett's metaplasia where the
normal squamous epithelium is replaced by a columnar lining.
Changes in the epidemiology of oesophageal adenocarcinoma
have been accompanied by changes in gastric cancer in the
West. Whilst less than 10% of gastric cancers were located at ordDental Sciences, University of Birmingham, Edgbaston, Birmingham,
